New benzazepine derivatives, drugs containing these and use of the same for producing drugs

Abstract

New derivatives of benzazepine, particularly of benzofuro[3a,3,2,ef][2]benzazepin of the general formula (I) 1

Description

[0001] The invention relates to new compounds and drugs containing the new compounds as active, pharmaceutical ingredients.

[0002] Likewise, the invention relates to the use of the new compounds for the preparation of drugs for the treatment of Alzheimer's disease and related dementia conditions, as well as for the treatment of Langdon-Down Syndrome (mongolism, trisomy 21).

[0003] The acid addition salt of galanthamine, which has the chemical structure 3

[0004] as well as some of its analog, are known as active pharmaceutical ingredients having an inhibitory effect on the synaptic enzyme, acetylcholine esterase. Galanthamine is therefore used pharmacologically for paralysis symptoms resulting from polio mellitus and for different diseases of the nervous system.

[0005] Galanthamine and some of its derivatives are also used for the symptomatic treatment of Alzheimer's disease and related dementia conditions (EP 236 684 B1).

[0006] Chemically, galanthamine is an alkaloid of the morphine group, which can be obtained from snowdrops (Galanthus woronowii, G. nivalis etc.) and other Amaryllidaceae.

[0007] Aside from obtaining galanthamine from plant sources, chemical methods of synthesizing galanthamine and its analogs, including its acid addition salts, have also become known (WO 95/27715).

[0008] The Down syndrome is attributed to a tripling of chromosome 21, that is, the patients have a set of 47 chromosomes instead of 46. This can be demonstrated relatively simply cytologically. Trisomy 21 is associated with moderate to severe mental impairment and a series of symptoms of physical dysmorphism. A causative treatment is not possible at the present time. The existing impairment can be influenced by selective therapeutic measures. However, a distress usually remains.

[0009] The new inventive compounds are new benzazepine derivatives, particularly derivatives of benzofuro[3a, 3, 2,ef][2] benzazepine.

[0010] They are compounds of the general formula (I) 4

[0011] in which

[0012] R1, R2 either are the same or different and represent

[0013] hydrogen, F, Cl, Br, I, CN, NC, OH, SH, NO2, SO3H, NH2, CF3 or

[0014] a lower (C1-C6), optionally branched, optionally substituted (Ar) alkyl or (Ar) alkoxy group or

[0015] an amino group, which is substituted by one or two or different lower (C1-C6), optionally branched, optionally substituted (Ar) alkyl or (Ar) alkyl carbonyl or (Ar) alkoxy carbonyl or

[0016] a COOH, COO(Ar) alkyl, CONH, CON(Ar) alkyl group or

[0017] represents —(CH2)n—Cl, —(CH2)n—Br, —(CH2)n—OH, —(CH2)n—COOH, —(CH2)n—CN, —(CH2)n—NC, in which

[0018] it is also possible to define R1-R2 jointly as —CH═CH—CH═CH—, —O—(CH2)n—O—, with n=1 to 3.

[0019] R3═R1, particularly OH and OCH3 and furthermore

[0020] R2-R3 can jointly form: —O—(CH2)n—O—, with n=1 to 3

[0021] R4, R5: either are both hydrogen or, alternatively, any combination of hydrogen or an (Ar) alkyl, (Ar) alkenyl, (Ar) alkinyl with

[0022] S—R8, wherein R8 is hydrogen or a lower (C1-C10), optionally branched, optionally substituted (Ar) alkyl group

[0023] SO—R8, SO2R8

[0024] OH, O-protective group (such as TMS, TBDMS)

[0025] O—CS—N—R8 (thiourethanes)

[0026] O—CO—N—R9, wherein R9 has the following meaning: 5

[0027] O—CO—R5 (ester, R8 see above), in particular, also esters with the substitution pattern of amino acids such as 6

[0028] Furthermore: R4, R5=jointly hydrazone (═N—NH—R10, ═N—N(R10, R11), Oximines (═N—O—R11), wherein R10 is hydrogen, a lower (C1-C6), optionally branched, optionally substituted (Ar)-alkyl or (Ar)-alkyl carbonyl or (Ar)-alkyl carbonyloxy group as well as a sulfonic acid group, such as a tosyl and mesyl group and R11 is hydrogen, a lower (C1-C6), optionally branched, optionally substituted (Ar)-alkyl or (Ar)-alkyl carbonyl group, as well as a sulfonic acid group, such as a tosyl and mesyl group.

[0029] as well as substituents of the type 7

[0030] Y1, Y2═O, S, NH or N—R10 (excess valences in each case are —H)

[0031] wherein, in the event that R4═H, R5 can also be OH and, in the event that R5═H, R4 can also be OH.

[0032] G1, G2: jointly or separately have the meaning:

[0033] —C(R13, R14)—, wherein R13, R14 can be hydrogen, OH, a lower, optionally branched, optionally substituted (Ar)-alkyl, aryl, (Ar)-alkoxy or aryloxy group or jointly an alkyl spiro group (C3 to C7 spiro ring).

[0034] Furthermore, G1 and G2 jointly represent 8

[0035] with m=1 to 7

[0036] G3: represents CH2 or ═CO

[0037] R6 represents a group -(G4)p-(G5)q-G6 with p, q=0 to 1, in which G4 satisfies the following definition

[0038] —(CH2)r—, —C(R15,R16)(CH2)—, with R=1 to 6 and R15, R16=hydrogen, lower, optionally branched or optionally substituted (Ar)-alkyl, cycloalkyl, aryl groups

[0039] —O— or —NR15 9

[0040] with s=1 to 4, t=0 to 4 10

[0041] that is an ortho, meta or para disubstituted aromatic 11

[0042] wherein G7=NR15, O or S,

[0043] G5 can be identical with or different from G4 and, in the event that P=1, additionally represents —S—,

[0044] G6 fulfills the following definition: 12

[0045] with

[0046] R17, R18, R19 and R20 individually or jointly are the same or different, hydrogen, lower, optionally branched, optionally substituted (Ar)-alkyl, cycloalkyl or aryl groups, wherein R17 and R18 and R19 and R20 can jointly form a cycloalkyl group (with a ring size of 3-8)

[0047] G8=O, S, NH, NR21—(CH2)n—,

[0048] R21═CHO, COOR17 or a heteroaryl group, which is unsubstituted or substituted identically or differently by one or several F, Cl, Br, I, NO2, NH2, OH, alkyl, alkyloxy, CN, NC or CF3, CHO, COOH, COOalkyl, SO3H, SH or S-alkyl groups, (heteroaryl being, in particular, 2-pyridyl, 4-pyridyl, 2-pyrimidinyl) or,

[0049] a methyl group, which is substituted by 1-3 phenyl groups, which are unsubstituted or substituted identically or differently by one or more F, Cl, Br, I, NO2, NH2, alkyl, alkyloxy, CN, NC or CF3 groups,

[0050] Furthermore, G6 can be: 13

[0051] a lower, optionally branched, optionally substituted (Ar)-alkyl, (Ar)-alkenyl, (Ar)-alkinyl, cycloalkyl or aryl groups,

[0052] —O—R17, —NR17R18, phthalamido, —CN or —NC.

[0053] R7 is identical with R6 or represents —O—(−) (N-oxide) or a free electron pair (e-pair), wherein R6 and R7 can also form a common ring, 3 to 8 carbon atoms in size and

[0054] [X] exists only if, and represents an ion of a pharmacologically usable inorganic or organic acid, when R5 and R6 are present and the nitrogen atoms thus carries a positive charge.

[0055] Z═N or N+ in the event that R6 and R7 are present jointly and R7 is not O−.

[0056] A special case of the new compounds of the general formula (I) are the compounds of the general formula (II) 14

[0057] wherein the groups have the meanings described for formula (I). This formula arises formally out of formula (I), in that the bond from C1 to the furan oxygen is broken and, instead, a bond between C1 and Z is formed directly.

[0058] Furthermore, the invention comprises the new, substituted, bridged bases of the general formula (III) and their synthesis, and particularly to 2,5-diazabicyclo[2.2.1]heptane: 15

[0059] wherein R22

[0060] is a (hetero) aryl group, which is unsubstituted or substituted identically or differently by one or several F, Cl, Br, I, NO2, NH2, OH, alkyl, alkoxy, CN, NC or CF3, CHO, COOH, COOalkyl, SO3H, SH or S-alkyl groups or

[0061] a methyl group, which is substituted by two phenyl groups, which are substituted identically or differently by one or more F, Cl, Br, I, NO2, NH2, OH, alkyl, alkoxy, CN, NC or CF3, CHO, COOH, COOalkyl, SO3H, SH or S-alkyl groups,

[0062] R17, R18, n, s having tie meanings given for the general formula (I) and

[0063] R23 -(G5)q-(G4)p-G9

[0064] wherein G4 and G5 have the meanings given for the general formula (I) and G9 is defined as:

[0065] Hydrogen, F, Cl, Br, I, OH, O-ts, 0-ms, O-triflate, COOH, COCl CHO, —O—R17, —NR17R18, phthalimido, —CN or —NC or by other groups suitable for nucleophilic substitutions, addition reactions, condensation reactions, etc.

[0066] Examples of these types of compounds are: 16

[0067] These compounds of the general formula (III) represent not only a pharmaceutically interesting class of compounds, but also find use as substitutents in a plurality of basic compounds. The compound 105 to 109 represent the compounds.

[0068] The inventive drugs can be used successfully for the treatment of Alzheimer's disease and related dementia conditions, as well as for the treatment of Langdon-Downs syndrome.

[0069] The invention likewise relates to the use of the compounds used above for the preparation of drugs for the treatment of Alzheimer's disease and related dementias, as well as for the treatment of Langdon-Downs syndrome.

[0070] Particularly preferred pursuant to the invention are the compounds named in the survey below. In the survey, the ACHE inhibition values (IC50, that is, the 50% inhibition concentration) of the inventive compounds, which are one of the factors, which determine the effectiveness, are also given.

[0071] The inhibition of acetylcholine esterase was determined by a modified method of Ellmann (reference 44), human serum from a pool of 10 test subjects being used as serum.

[0072] Method: 520 μL of solution of the test substance (concentrations of 10−4 to 10−7 and, in exceptional cases, up to 10−9 moles/liter were used) in 0.02 M tris(hydroxymethyl)aminomethane solution, buffered with HCl to a pH of 7.8 and 400 μL of m-nitrophenol solution (Sigma Diagnostics, Art. 420-2) were incubated in the semi-micro cuvette at 37° C. with 40 μL of cholinesterase solution (Sigma Diagnostics, Art. 420-MC, diluted 1:15 with water) and 160 μL of serum and the change in the absorption was measured over 5 minutes against a comparison sample in a Beckmann DU-50 spectrophotometer with a kinetics program. The values were given as a percentage of the comparison sample and the inhibiting concentration (IC50) was calculated from the course of the curve.

[0073] Survey of the New Compounds of the Type of the General Formula:

17

[X]

Subst. Nr.

Chir.

R1

R2

R3

R4

R5

R6

R7

Z

[X]

G3

IC50 in μMol

Gal

(−)

H

H

CH3

OH

H

CH3

H

N−

Br−

CH2

6

*HBr

(+)

1

(+/−)

Br

H

CH3

OH

H

CH3

—

N

—

CH2

10

2

(+/−)

Br

H

CH3

H

OH

CH3

—

N

—

CH2

3

(−)

Br

H

CH3

OH

H

CH3

—

N

—

CH2

4

4

(+/−)

Br

H

CH3

OH

H

H

—

N

—

CH2

5

5

(−)

Br

H

CH3

OH

H

H

—

N

—

CH2

3

6

(+)

Br

H

CH3

OH

H

H

—

N

—

CH2

>150

7

(+/−)

br

H

CH3

H

OH

H

—

N

—

CH2

8

(+/−)

Br

H

CH3

—O—CH2—CH(CH3)—O—

CHO

—

N

—

CH2

9

(+/−)

H

H

CH3

—O—CH2—CH(CH3)—O—

CH3

—

N

—

CH2

10

(+/−)

Br

H

CH3

—O—CH2—CH2—O—

CHO

—

N

—

CH2

11

(+/−)

H

H

CH3

—O—CH2—CH2—O—

CH3

—

N

—

CH2

12

(+/−)

H

H

CH3

—O—CH2—CH2—O—

H

CH3

—

N

—

CH2

13

(+/−)

Br

H

CH3

—O—CH2—CH2—O—

—

N

—

CH2

14

(+/−)

Br

H

CH3

—O—CH2—CH2—O—

CH2—Ph

—

N

CH2

15

(+/−)

Br

H

CH3

═O

H

—

N

—

CH2

16

(+/−)

Br

H

CH3

═O

CH3

—

N

—

CH2

52

17

(−)

H

H

CH3

18

H

CH3

—

N

—

CH2

70

18

(+)

H

H

CH3

19

H

CH3

—

N

—

CH2

85

19

(−)

H

H

CH3

20

H

CH3

—

N

—

CH2

75

20

(+)

H

H

CH3

21

H

CH3

—

N

—

CH2

120

21

(−)

H

H

CH3

22

CH3

—

N

—

CH2

55

22

(+)

H

H

CH3

23

CH3

—

N

—

CH2

35

23

(−)

H

H

CH3

24

CH3

—

N

—

CH2

25

24

(+)

H

H

CH3

25

CH3

—

N

—

CH2

85

25

(−)

H

H

CH3

H

26

CH3

—

N

—

CH2

45

26

(−)

H

H

CH3

H

27

CH3

—

N

—

CH2

27

(+)

H

H

CH3

H

28

CH3

—

N

—

CH2

28

(−)

H

H

CH3

H

29

CH3

—

N

—

CH2

29

(−)

H

H

CH3

H

30

CH3

—

N

—

CH2

>150

30

(+)

H

H

CH3

H

31

CH3

—

N

—

CH2

120

31

(−)

H

H

CH3

H

32

CH3

—

N

—

CH2

>>150

32

(−)

H

H

CH3

H

33

CH3

100

33

(+/−)

Br

H

CH3

34

H

CH3

—

N

—

CH2

34

(+/−)

Br

H

CH3

35

H

CH3

—

N

—

CH2

35

(+/−)

Br

H

CH3

OH

H

n-Pentyl

—

N

—

CH2

36

(+/−)

Br

H

CH3

O-TBDMS

H

H

—

N

—

CH2

37

(+/−)

Br

H

CH3

O-TMS

H

CH3

—

N

—

CH2

38

(+/−)

Br

H

CH3

O-TBDMS

H

CH3

—

N

—

CH2

39

(+/−)

H

H

CH3

O-TBDMS

H

CH3

—

N

—

CH2

40

(+/−)

Br

H

CH3

Ethlenglykolketyl

CH2—Ph

—

N

—

CH2

41

(+/−)

Br

H

CH3

═O

Allyl

—

N

—

CH2

42

(+/−)

Br

H

CH3

OH

H

Allyl

—

N

—

CH2

43

(+/−)

H

H

CH3

OH

H

allyl

—

N

—

CH2

44

(+/−)

Br

H

CH3

═O

CH2—Ph

—

N

—

CH2

45

(+/−)

Br

H

CH3

OH

H

CH2—Ph

—

N

—

CH2

46

(+/−)

H

H

CH3

OH

H

CH2—Ph

—

N

—

CH2

47

(+/−)

H

H

CH3

═O

CH2—Ph

—

N

—

CH2

48

(+/−)

Br

H

CH3

O—COCH3

H

COCH3

—

N

—

CH2

49

(+/−)

Br

H

CH3

OH

H

n-Hexyl

—

N

—

CH2

insol.

50

(+/−)

Br

H

CH3

OH

H

Propargyl

—

N

—

CH2

insol.

51

(+/−)

Br

H

CH3

OH

H

CH2COOEt

—

N

—

CH2

20

52

(+/−)

Br

H

CH3

OH

H

CH2CN

—

N

—

CH2

insol.

53

(+/−)

Br

H

CH3

OH

H

CH2CONH2

—

N

—

CH2

54

(+/−)

Br

H

CH3

OH

H

36

—

N

—

CH2

3

55

(+/−)

Br

H

CH3

OH

H

37

—

N

—

CH2

56

(+/−)

Br

H

CH3

OH

H

38

—

N

—

CH2

57

(+/−)

Br

H

CH3

OH

H

39

—

N

—

CH2

58

(+/−)

Br

H

CH3

OH

H

40

—

N

—

CH2

0, 2

59

(+/−)

Br

H

CH3

OH

H

CO—CH3

—

N

—

CH2

60

(+/−)

Br

H

CH3

OH

H

CO—COOEt

—

N

—

CH2

61

(+/−)

Br

H

CH3

OH

H

CO—(CH2)2—COOCH3

—

N

—

CH2

insol.

62

(+/−)

Br

H

CH3

OH

H

COOCH3

—

N

—

CH2

insol.

63

(+/−)

Br

H

CH3

OH

H

t-BOC

—

N

—

CH2

64

(+/−)

Br

H

CH3

OH

H

CO—C15H31

—

N

—

CH2

65

(+/−)

Br

H

CH3

OH

H

Ethyl

—

N

—

CH2

66

(+/−)

Br

H

CH3

OH

H

CO—(CH2)2COOH

—

N

—

CH2

>150

67

(+/−)

Br

H

CH3

OH

H

CO—COOH

—

N

—

CH2

68

(+/−)

Br

H

CH3

OH

H

CH2—CH2—OH

—

N

—

CH2

69

(+/−)

H

H

CH3

OH

H

CH2—CH2—OH

—

N

—

CH2

70

(+/−)

Br

H

CH3

OH

H

CH2—CH2—OH

—

N

—

CH2

71

(+/−)

Br

H

CH3

OH

H

CH2—COOH

—

N

—

CH2

72

(+/−)

H

H

CH3

OH

H

CO—C15H31

—

N

—

CH2

73

(+/−)

H

H

CH3

OH

H

CH2CN

—

N

—

CH2

74

(+/−)

H

H

CH3

OH

H

41

—

N

—

CH2

75

(+/−)

H

H

CH3

═N—OTs

CH3

—

N

—

CH2

76

(+)

H

H

CH3

═N—OH

CH3

—

N

—

CH2

insol.

77

(−)

H

H

CH3

═N—OH

CH3

—

N

—

CH2

insol.

78

(+)

H

H

CH3

═N—OCH3

CH3

—

N

—

CH2

insol.

79

(−)

H

H

CH3

═N—OCH3

CH3

—

N

—

CH2

>150

80

(+/−)

H

H

CH3

═NH

CH3

—

N

—

CH2

81

(−)

H

H

CH3

═N—NH—CH3

CH3

—

N

—

CH2

>150

82

(+/−)

H

H

CH3

═N—N(CH3)2

CH3

—

N

—

CH2

insol.

83

(+/−)

H

H

CH3

═N—HN—(CH2)2OH

CH3

—

N

—

CH2

>150

84

(+/−)

H

H

CH3

═N—NH—CHO

CH3

—

N

—

CH2

>150

85

(+/−)

H

H

CH3

═N—NH-tBOC

CH3

—

N

—

CH2

>150

86

(+/−)

H

H

CH3

═N—NH-pTs

CH3

—

N

—

CH2

87

(+/−)

H

H

CH3

42

CH3

—

N

—

CH2

insol.

88

(+/−)

H

H

CH3

43

CH3

—

N

—

CH2

>150

89

(+/−)

H

H

CH3

44

CH3

—

N

—

CH2

>150

90

(+/−)

H

H

CH3

═N—NH2

CH3

—

N

—

CH2

40

91

(−)

H

H

CH3

OH

H

45

CH3

N−

BR−

CH2

8

92

(−)

H

H

CH3

OH

H

46

CH3

N−

Cl−

CH2

2

93

(−)

H

H

CH3

OH

H

47

CH3

N+

Cl−

CH2

5

94

(−)

H

H

CH3

OH

H

48

CH3

N+

BR−

CH2

4

95

(−)

H

H

CH3

OH

H

49

CH3

N+

Cl−

CH2

6

96

(+)

H

H

CH3

OH

H

50

CH3

N+

Cl−

CH2

97

(+)

H

H

CH3

OH

H

51

CH3

N+

Cl−

CH2

98

(−)

H

H

CH3

OH

H

—O−CH3

N+

—

CH2

insol.

99

(−)

H

H

CH3

OH

H

Propargyl

CH3

N+

BR−

CH2

100

(−)

H

H

CH3

OH

H

CH2—CONH2

CH3

N+

Hal−

CH2

101

(+/−)

Br

H

CH3

═O

CH3

—

N

—

C═O

102

(+/−)

Br

H

CH3

OH

H

CH3

—

N

—

C═O

103

(+/−)

Br

H

CH3

O-TBDMS

H

CH3

—

N

—

C═O

104

(−)

H

H

CH3

OH

H

CH3

—

N

—

CH2

105

(+/−)

Br

H

CH3

OH

H

52

—

N

—

CH2

106

(+/−)

H

H

CH3

OH

H

53

—

N

—

CH2

107

(+/−)

Br

H

CH3

OH

H

54

—

N

—

CH2

108

(+/−)

Br

H

CH3

OH

H

55

—

N

—

CH2

109

(+/−)

Br

H

CH3

OH

H

56

—

N

—

110

(+/−)

Br

H

CH3

—O—CH2CH2—O—

CH3

—

N

—

CH2

111

(+)

Br

H

CH3

OH

H

CH3

—

N

—

CH2

>150

112

(+/−)

H

H

CH3

OH

H

H

—

N

—

CH2

7

117

(−)

NO2

H

CH3

OH

H

CH3

—

N

—

CH2

118

(−)

NH2

H

CH3

OH

H

CH3

—

N

—

CH2

[0074] The general formula (II) is a special case of the general formula (I)

57	formula (II)
PAT II
Nr.	Chiral	R1	R2	R3	R4	R5	G3	DB*	IC50
113	(+/−)	Br	H	CH3	═O		CH2	yes	5
114	(+/−)	Br	H	CH3	OH	H	CH2	yes
115	(+/−)	H	H	CH3	OH	H	CH2	yes	>150
116	(+/−)	Br	H	CH3	OH	H	CH2	no	50
DB = double bond
Please note:
“Chiral” refers in the whole of the Table to the plurality of the respective
educt. The values of the rotation of the products are determined in the
experimental part.

[0075] The compounds, contained in drugs pursuant to the invention, can be administered in any suitable chemical or physical form, such as an acid addition salt. For example, they can be administered as hydrobromide, hydrochloride, methyl sulfate or methyl iodide.

[0076] The inventive drugs can be administered to patients orally or by subcutaneous or intravenous injection or intracerebroventricularly by means of an implanted container.

[0077] It may be necessary to start with doses lower than effective ones.

[0078] Typical dosing rates when administering drugs containing the active ingredients proposed pursuant to the invention depend on the nature of the compound used and on the condition of the patient. Typically, dosage rates lie in the range of 0.01 to 1.0 mg per day per kg of body weight, depending on the age, the mental condition and other medication of the patient.

[0079] The inventive drugs may be present in the following specific formulations:

[0080] tablets or capsules containing 0.5 to 50 mg

[0081] parenteral solution containing 0.1 to 30 mg/mL

[0082] liquid formulation for oral administration in a concentration of 0.1 to 15 mg/mL.

[0083] The inventive compounds can also be a transdermal system, in which 0.1 to 10 mg are released per day.

[0084] A transdermal dosing system consists of a reservoir layer, which contains 0.1-30 mg of the active substance as free base or salts, if necessary, together with a penetration accelerator, such as dimethyl sulfoxide, or a carboxylic acid, such as octanoic acid, and a skin-neutral polyacrylate, such as hexyl acrylate/vinyl acetate/acrylic acid copolymer together with a plasticizer, such as isopropyl myristate. The covering is an outer layer, which is impermeable to the active ingredient, such as metal-coated, siliconized polyethylene Band-Aid with a thickness of, for example, 0.35 mm. A dimethylaminomethyl acrylate/methyl acrylate copolymer in an organic solvent, for example, is used to produce an adhesive layer.

[0085] Some examples of methods, by means of which inventive compounds can be synthesized, are given below.

EXPERIMENTAL SECTION

[0086] General Instructions

[0087] Thin-layer chromatography with silica gel 60 F254 (Merck, Art. No. 5554).

[0088] Abbreviations used:

[0089] NH4OH concentrated aqueous ammonia

[0090] PE petroleum ether or naptha (40°-60° C.)

[0091] p-Ts=p-Tos=p-toluene sulfamide

[0092] CE=capillary electrophoresis

[0093] Rotations are generally recorded at a concentration of C=0.1.

[0094] The melting points are determined by the Kofler method using a microscope with a hot stage; the values are not corrected.

[0095] The glass autoclave comes from Büchi (TinyClave, MiniClave).

[0096] The water content of the solvent where given is determined by the Karl Fischer method.

[0097] The element microanalysis were carried out in the Microanalytical Laboratory at the Institute for Physical Chemistry of the University of Vienna under the direction of Mag. J. Theiner.

[0098] NMR spectra were recorded on a Büchi 200 FS FT-NMR spectrometer, CDCl3 or DMSO-d6 being used as solvent.

[0099] 1 H-NMR: measurement frequency 200.13 MHz, internal standard: CDCl3 (δ=7.26 ppm)

[0100] or

[0101] DMSO-d6 (δ=2.50 ppm)

[0102] 13 C-NMR: measurement frequency 50.32 MHz, internal standard: CDCl3 (δ=77.0 ppm)

[0103] or

[0104] DMSO-d6 (δ=39.5 ppm)

[0105] The splittings in the NMR spectroscopy are labeled as follows:

[0106] s=singlet d=doublet t=triplet

[0107] q=quartet m=multiplet

[0108] Where necessary, the multiplicities of the 13C spectra were determined by DEPT experiments, the assignments of the 1H spectra optionally by COSY experiments. Uncertain assignments were marked with an asterisk.

[0109] Experimental Section

[0110] (±) 8-Bromogalanthamine (1), (±) 8-Bromo-epigalanthamine (2)

[0111] To a suspension of 4.0 g (10.5 mmoles) of bromo-N-formyl narwedine in 60 mL of toluene, 24 mL (36 mmoles) of 1M DIBAL-H solution in toluene is added dropwise at 0° C. The reaction is stirred for one hour at room temperature, the remaining reducing agent is decomposed with water and 20 mL of ammonia are subsequently added. After stirring for 20 minutes at room temperature, the precipitated material is filtered off, the organic phase is separated and the aqueous phase washed with 50 mL of toluene. The combined organic phases are dried over sodium sulfate, filtered and the solvent is removed under vacuum. The residue is separated by means of column chromatography. Yield: 0.9 g (23.3%) of one and 0.8 g (20.7%) of two.

[0112] Bromogalanthamine (1) data:

[0113] molecular weight C17H19BrNO3: 365.23

[0114] IR(KBr): 689,03 m; 778,57 m; 839,37 m; 989,86 m; 1050,66 s; 1212,43 s; 1279,87 s; 1434,08 s; 14,72 s; 16113,99 s; 2667,39 m; 3370-3778 br.

[0115] 1 H-NMR (CDCl3): 6,9 (s, 1 H); 6.06 (m, 2 H); 4,60 (d, 1 H); 4,15, (t, 1 H); 3,92 (d, 1 H); 3,82 (s, 3 H); 3,24 (m, 1 H); 2,98 (dt, 1 H); 2,68 (dd, 1 H); 2,42 (s, 3 H); 2,05 (m, 2 H); 1,60 (dt, 1 H).

[0116] 13 C-NMR (CDCl3): 145,32 s; 144,00 s 133,96 s; 127,95 d; 127,68 s; 126,51 d; 115,61 d; 114,22 s; 88,56 d; 61,58 d; 58,56 t; 55,95 q; 53,26 t; 48,56 s; 42,06 q; 33,47 t; 29,69 t.

[0117] Epi-bromogalanthamine (2) data:

[0118] molecular weight C17H19BrNO3: 365.23

[0119] IR(KBr): 667,95 w; 752 m; 836,68 m; 1040,31 s; 1208,39 s; 12,82 m; 1435,25 m; 1485,72 m; 1512,94 w; 1558,27 w; 1615,19 m; 1667,14 w; 2943,24 w; 3360-3575 br.

[0120] 1 H-NMR (CDCl3): 6,85 (s, 1 H); 5,96 (AB, 22); 4,69 (m, 2 H); 4,28 (d, 1 H); 3,90 (d, 1 H); 3,83 (s, 1H; 3,25 (m, 1 H); 2,95 (m) 1 H); 2,85 (dt, 1 H); 2,36 (s 3 H); 2,15 (td, 1 H), 1,69 (m, 2 H).

[0121] 13 C-NMR (CDCl3+DMSO-d6): 145,84 s; 143,49 s; 133,89 s; 133,14 d; 126,12 s; 124,35 d; 115,04 s; 113,01 s; 88,26 d; 61,10 d; 57,44 t; 55,58 q; 52,84 t; 47,86 s; 41,20 q; 33,35 t; 31,43 t.

[0122] (±) Bromogalanthamine (1)

[0123] Method 1:

[0124] To a solution of 2.0 g (5.6 mmoles) of (4) in 20 mL of water, 5 mL of 89% HCOOH and 5 mL of 37% formaldehyde are added and boiled under reflux. After being boiled for 15 minutes, the reaction mixture is diluted with water, the pH is adjusted with 25% ammonia to a value of 9 and the solution is extracted three times with 20 mL of methylene chloride. The combined organic phases arc dried with sodium sulfate, filtered and the solvent is evaporated under vacuum. Chromatographic purification of the residue (150 mg of silica gel) CHCl3: MeOH=97:→95:5) results in a colorless foam. Yield: 2.0 g (96.4%)

[0125] Method 2:

[0126] To a suspension of 10 g (26.4 mmoles) of bromo-N-formyl narwedine in 200 mL of THF, 100 mL (100 mmoles) of a 1 M solution of L-selectride is added dropwise at 0° C. during a period of 30 minutes. After stirring for 30 minutes at 0° C., the reagent is decomposed with water and the reaction mixture treated with 100 mL of a 25% ammonia solution. After 30 minutes of stirring at room temperature, the solvent is concentrated under vacuum to half its volume, transferred to a separating funnel, treated with 100 mL of 25% ammonia and extracted three times with 200 mL of methylene chloride. The combined organic phases are dried over sodium sulfate, filtered and the solvent is evaporated under vacuum. To the residue, 50 mL of water, 30 mL of 98% HCOOH and 30 mL of a 37% formaldehyde solution are added and the reaction mixture is boiled under reflux. After 15 minutes of boiling, the reaction is neutralized with ammonia and extracted three times with 200 mL of methylene chloride. The combined organic phases are dried over sodium sulfate, filtered and the solvent is evaporated under vacuum. Chromatographic purification of the residue (600 mg of silica gel) CHCl3: MeOH=9:1:→8:2) results in a colorless foam. Yield: 6.4 g (66.2%).

[0127] Method of Synthesizing rac., (−) or (+) Bromogalanthamine (1,3, III):

[0128] Method A:

[0129] To a solution of 4.00 g (10.8 mmoles) of nivaline in 40 mL of 30% fonnic acid, 40 mL of 30% hydrogen peroxide solution are added and the reaction mixture is heated rapidly to 100° C. After 20 minutes, the reaction mixture is cooled rapidly to room temperature, made alkaline with concentrated aqueous ammonia and extracted three times with 50 mL of ethyl acetate. The organic phase is washed once with saturated, aqueous sodium chloride solution, dried (sodium sulfate), filtered and evaporated, 2.55 g (64% of the theoretical yield) of colorless crystals with a melting point of 76°-77° C. and a rotation of αD20[CHCl3]=−93° of 3 being obtained.

[0130] TLC: CHCl3: MeOH=9:1

[0131] Method B:

[0132] A solution of 1.0 g (2.84 mmoles) of rac. N-demethylbromogalanthamine (4) in 1 mL of 37% of formaldehyde, 2 mL of formic acid and 5 mL of water are stirred for 3 hours at 70° C. The solution is allowed to cool, made alkaline with concentrated aqueous ammonia and left to crystallize for 20 hours at 4° C. The precipitate is filtered off, dried at 50° C./20 mm, 0.85 g (82% of the theoretical yield) of colorless crystals of 1, melting at 76° to 77° C. being obtained.

[0133] TLC: CHCl3: MeOH=9:1

[0134] Method C:

[0135] See the general procedure for the reduction with L-selectride.

[0136] NMR data of (1,3, III)

[0137] 1 H-NMR (CDCl3; δ (ppm)): 1.60 (ddd, 1H, H-9, J(9,9′)=14.2 Hz); 1.90-2.15 (m, 2H, H-9′/5, J(5,5′)=15.1 Hz); 2.20 (b, 1H tauscht D2O, OH); 2.45 (s, 3H, NCH3); 2.65 (ddd, 1H, H-5′, J(5,5′)=15.1 Hz); 2.95 (ddd, 1H, H-10, J(10,10′)=15.6 Hz); 3.25 (ddd, 1H, H-10′, J(10,10′)=15.6 Hz); 3.80 (s, 3H, OCH3); 3.95 (d, 1H, H-12, J(12,12′)=16.0 Hz); 4.15 (dd, 1H, H-6); 4.30 (d, 1H, H-12′, J(12,12′)=16.0 Hz); 4.60 (b, 1H, H-4a); 5.95-6.10 (m, 2H, H-7/8); 6.90 (s, 1H, H-2)

[0138] 3 C-NMR (CDCl3; δ (ppm)): 29.7 (t, C-5); 33.5 (t, C-9); 42.1 (q, NCH3); 48.6 (s, C-8a); 53.3 (t, C-10); 55.9 (q, OCH3); 58.7 (t, C-12); 61.6 (d, C-6); 88.6 (d, C-4a); 114.2 (s, C-1); 115.6 (d, C-8); 126.5 (t, C-2); 127.6 (s, C-12a); 127.9 (t, C-7); 134.0 (s, C-12b); 144.0 (s, C-3a); 145.3 (s, C-3)

[0139] N-Demethylbromogalanthamine (4):

[0140] Method A

[0141] N-formyl bromonarwedine (50.0 g, 132 mmoles) is suspended in 250 mL of absolute tetrahydrofuran and treated at −25° to −20° C. with 430 mL (430 mmoles) of a 1N solution of L-selectride in tetrahydrofuran. After 3 hours, the reaction mixture is hydrolyzed with a 1:1 solution of ethanol in tetrahydrofuran, concentrated to about 200 mL, treated with 400 mL of ethanol and once again concentrated to 200 mL, in order to remove the borate ester. The residue is taken up in 500 mL of ethanol, treated with 62% aqueous hydrobromic acid until a pH of 1 is reached and stirred for 24 hours at room temperature. The resulting precipitate is filtered off with suction and washed with a little ethanol. After being dried, the precipitate is dissolved in 500 mL of water. The aqueous phase is slowly made alkaline with concentrated aqueous ammonia while being cooled and stirred well, so that the product precipitates. The precipitate is left to crystallize in the refrigerator and then filtered off with suction. By extraction of the filtrate with ethyl acetate, a second fraction of the product is obtained, the total yield being 33.5 g (72% of the theoretical yield) of colorless crystals of 4.

[0142] TLC: CHCl3: MeOH−95:5

[0143] Method B

[0144] See general procedure for reducing with L-selectride.

[0145] 1 H-NMR (CDCl3; δ (ppm)): 1.65-1.85 (m, 2H, H-9/9′), 1.98 (ddd, 1H, H-5); 2.25 (b, 2H tauschen D2O, NE/OH); 2.62 (ddd, 1H, H-5′); 3.05-3.35 (m, 2H, H-10/10′); 3.80 (s, 3H, OCH3); 3.85 (d, 1H, H-12, J(12,12′)=14.7 Hz); 4.10 (dd, 1H, H-6); 4.48 (d, 1H, H-12′, J(12,12′)=14.7 Hz); 4.56 (b, 1H, H-4a); 5.90-6.05 (m, 2H, H-7/8); 6.85 (s, 1H, H-2)

[0146] 13 C-NMR (CDCl3; δ (ppm)): 29.7 (t, C-5); 39.8 (t, C-9); 46.6 (t, C-10); 49.3 (s, C-8a); 52.7 (t, C-12); 56.0 (q, OCH3); 61.7 (d, C-6); 88.4 (d, C-4a); 113.0 (s, C-1); 115.5 (d, C-8); 126.8 (d, C-2); 127.9 (d, C-7); 131.6 (s, C-12a); 134.1 (s, C-12b); 144.0 (s, C-3a); 145.8 (s, C-3)

[0147] (±) N-Dimethyl-bromogalanthamine (4), (±) N-Demethyl-epibromo-galanthamine (7)

[0148] To a suspension of 1.0 g (2.6 mmoles) of bromo-N-formyl narwedine in 5 mL of THF, 3.0 g (11.8 mmoles) of LiAlH(t-BuO)3 in 15 mL of THF is added dropwise at 0° C. over a period of 30 minutes. After being stirred at 0° C. for 30 minutes, the reaction mixture is refluxed. After 22 hours of refluxing, the complex, formed with the reagent, is decomposed with water and the reaction mixture treated with 10 mL of 25% ammonia solution. After 30 minutes of stirring at room temperature, 50% of the solvent is evaporated under vacuum, the remainder is transferred to a separating funnel, mixed with 10 mL of 25% ammonia solution and extracted three times with 20 mL of methylene chloride. The combined organic phases are extracted with sodium sulfate and filtered and the solvent is evaporated under vacuum. Chromatographic purification of the residue (60 g of silica gel) CHCl3: MeOH=95:5→9:1→8:2) results in two products: 300.0 mg (32.2%) of N-demethyl-bromogalanthamine (4) as a colorless foam and 270 mg (29.0%) of N-demethyl-epibromoalanthamine (7) as a colorless foam.

[0149] N-demethyl-epibromogalanthamine (7) data:

[0150] Molecule: C16H18BrNO3: 352,21

[0151] IR(KBr): 781,60 w; 834,28 w; 976,63 w; 1050,28 m; 1179,73 m; 1211,87 m; 1280,07 m; 1435,24 m; 1486,10 m; 1616,37 m; 2923,54 w; 3700-2900 mbr.

[0152] 1 H-NMR (CDCl3): 6,86 (s, 1); 5;92 (AB, 2H); 4,56 (m, 2H); 4,50 und 3,82 (AB, 2H); 3,80 (s, 3H); 3,28, (m, 2H); 2,52, (m, 1H); 2,20-1,70 (m, 3H).

[0153] 13 C-NMR (CDCl3): 146,73 s; 143,91 s; 134,10 s; 132,17 s; 132,17 d; 131,48 d; 126,34 d; 115,34 d; 112,44 s; 88,51 d; 62,81 d; 56,10 q; 52,34 t; 49,25 s; 46,82 t; 40,52 t; 32,07 t.

[0154] (−)-N-Demethylbromogalanthamine (5) and (−)-N-Demethylbromogalanthamine (6)

[0155] (−)-N-Demethylbromogalanthamine (5)

[0156] To a solution of 10.0 g (28.4 mmoles) of rac. N-demethylbromogalanthamine (4) in 30 mL of methanol, a solution of 4.4 g (11.4 mmoles) of (−)-O,O-di-p-toluoyl tartaric acid in 5 mL of methanol is added dropwise and subsequently rinsed with 1 mL of ethanol. The solution is seeded (without seeding, crystal formation can take several weeks) and allow to stand for 2 days at 4° C. After scratching with a glass rod, the solution is left standing for a further 2 to 5 days at 4° C., scratching with a glass rod being repeated several times. Subsequently, the precipitate itself is filtered off with suction, washed three times with ice cold methanol and taken up in 100 mL of water. The aqueous phase is made alkaline with aqueous ammonia and extracted three times with 60 mL of ethyl acetate. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (sodium sulfate, activated charcoal), filtered and evaporated, 1.90 g (38% of the theoretical yield) of colorless crystals with a rotation of αD20 [CHCl3]=−104° (after CE: >99.9%) of 5 being obtained. The methanol mother liquor is evaporated, the residue taken up in 100 mL of water and treated in the same way as the pure salt above, 7.13 g (88% of the theoretical yield) of crude product being recovered, which is used for obtaining 6.

[0157] (−)-N-Demethylbromogalanthamine (6)

[0158] To a solution of 7.13 g (20.2 mmoles) of recovered (from 5) N-demethylbromogalanthamine (this slightly concentrated product forms crystals more rapidly than racemic (4)) in 10 mL of methanol, a solution of 3.12 g (8.1 mmoles) of (+)-O,O-di-p-toluoyl tartaric acid in 4 mL of methanol is added dropwise, a further 1 mL of methanol being used for rinsing. The solution is seeded with a crystal (without seeding, crystal formation can take several weeks) and treated as in the recovery of 5, 2.02 g (57% of the theoretical yield) of colorless crystals with a rotation of αD20 [CHCl3]=+102° (after CE: >99.9%) of 6.

[0159] C16H18BrNO3 * 1.05 C20H18O8 * 1.01 H2O (JOS 1500) 776.11 g/mol

[0160] calculated: C57.26 H5.05 N1.80

[0161] found : C57.28 H5.12 N1.82

[0162] (±) Bromo-N-formyl narwedine propylene glycol ketal (8)

[0163] Bromo-N-formyl narwedine (100 g), 100 g of propylene glycol and 0.5 g of sulfuric acid in 800 mL of toluene (two phases at room temperature) are refluxed with vigorous mechanical stirring (above about 90° C., homogeneous) for 14 hours with removal of water. After cooling, the phases were separated (the toluene phase being the upper phase) the propylene glycol phase was extracted twice with 100 mL of toluene, the combined toluene phases were shaken twice with 200 mL of saturated NaHCO3 solution, dried over sodium sulfate and evaporated: Yield: 115.3 g of a yellowish foam (8) (100% of the theoretical yield, crude), which crystallized overnight. Column chromatography of 1.0 g (60 g of silica gel 60, CHCl3/1-2% MeOH) resulted in 0.80 g of a colorless foam, which crystallized from ethyl acetate. Melting point: 170°-171° C.

[0164] Molecule C20H22BrNO5: 436.28

[0165] 1 H-NMR (CDCl3): 8.12 (d, H), 6.88 (s, H), 5.96-6.17 (m, H), 5.75 (dd, H), 5.68 (d, H/2), 5.10 (d, H/2), 4.53 (b, H), 4.48 (d, H/2), 4.31 (d, H/2),3.12-4.38 (m, 5H), 3.82 (s, 3H), 2.56-2.80 (m, H), 2.05-2.35 (dd, H), 1.83-2.05 (m, 2H), 1.22-1.47 (m, 3H).

[0166] 13 C-NMR (CDCl3): 162.48, 161.72, 147.17, 144.89, 144.64, 132.16, 129.04, 128.51, 129.57, 127.82, 127.70, 127.61, 115.70, 115.48, 127.09, 126.77, 126.5, 113.20, 111.66, 102.38, 102.22, 87.25, 87.07, 73.38, 72.46, 71.67, 71.41, 71.23, 70.55, 70.28, 55.92, 51.52, 46.18, 48.43, 40.77, 39.29, 36.07, 35.97, 34.58, 33.68, 33.44, 33.13, 18.68, 17.59, 17.45.

[0167] Comment—NMR, diastereoisomers: Because of the additionally introduced chiral center by means of the (±) propylene group, diastereoisomers are formed, which cause signal splitting in addition to that caused by the formyl group.

[0168] (±) Narwedine-propylene Glycol Ketal (9)

[0169] LiAlH4 (37.5 g) is added under argon into a previously dried, 4 L multi-neck flask, into which 800 mL of THF are then run from a dropping funnel. The temperature rises with vigorous foaming to about 45° C. (depends on the water content of the THF and of the reaction flask).

[0170] A suspension of 114 g of (8) (crude) in THF was added dropwise over 15 minutes, the temperature increasing to the refluxing temperature (65°-68° C.). Refluxing with mechanical stirring was now continued for 10 hours, after which the reaction mixture was cooled. 100 mL of water in 100 mL of THF were then added dropwise with cooling.

[0171] Removal of 10 mL, making alkaline with ammonia, extraction with ethyl acetate (3×20 mL) and evaporation yielded an oily product (9). Column chromatography (5 g of silica gel 60, CHCl3/3-5% MeOH) of 0.17 g resulted in 0.1 g of colorless foam.

[0172] Molecule: (C20H25NO4): 343.42

[0173] 1 H-NMR (CDCl3): 6.60 (dd, 2H), 6.16 (dt, H), 5.68 (dd, H)) 4.55 (m, H), 4.38-4.00 (m, 3H), 3.80 (s, 3H), 3.68-2.95 (m, 4H), 2.78-2.60 (m, H), 2.35 (s, 3H), 2.24-2,02 (m, 2H), 1.62 (bd, H) 1.28 (t, 3H).

[0174] 13 C-NMR (CDCl3): 146.59, 143.92, 132.04, 131.90, 129.57, 129.16, 128.86, 128.76, 128.39, 127.44, 126.92, 126.12, 126.02, 121.16, 111.05, 110.90, 110.77, 102.87, 102.73, 87.23, 73.15, 72.24, 71.43, 71.12, 70.44, 70.17, 60.28, 55.59, 55.53, 55.45, 53.83, 47.87, 47.80, 47.75, 41.80, 41.70, 34.84, 33.95, 33.66, 33.37, 18.66, 17.62, 17.43.

[0175] Comment—NMR, diastereoisomers: Because of the additionally introduced chiral center by means of the (±) propylene group, diastereoisomers are formed, which cause signal splitting in addition to that caused by the formyl group.

[0176] N-formyl Bromonarwedine Ethylene Glycol Ketal (10):

[0177] N-formyl bromonarwedine (10.0 g, 26.5 mmoles) in 20 g of ethylene glycol and 200 mL of toluene are refluxed with 0.1 mL of concentrated sulfuric acid using a water separator. After 24 hours, the toluene phase is decanted off and the ethylene glycol phase boiled out once with toluene. The combined toluene phases are washed twice with saturated, aqueous, sodium hydrogen carbonate solution and evaporated, colorless crystals of 10, melting at 192°-193° C. being obtained quantitatively. EtOAc: MeOH=99:1

[0178] 1 H-NMR (CDCl3; δ (ppm)): 1.75-2.10 (m, 2H, H-9/9′); 2.15 (dd, 1H, H-5, J(5,5′)=16.5 Hz); 2.65 (dd, 1H, H-5′, J(5,5′)=16.5 Hz); 3.60 (ddd, 1H, H-10); 3.80 (s, 3H, OCH3); 3.90-4.10 (m, 5H, H-10′, O—CH2—CH2—O); 4.30 (d, 1H, H-12Conformer A, J(12,12′)=17.8 Hz); 4.50 (d, 1H-12Conformer B); 4.55 (b, 1H, H-4a); 5.10 (d, 1H, H-12′Conformer A, J(12,12′)=17.8 Hz); 5.65 (d, 1H, H-12′Conformer B); 5.70 (d, 1H, H-8); 6.10 (t, 1H, H-7); 6.85 (s, 1H, H-2); 8.10, 8.15 (2*s, 1H, CHOConformer A/B)

[0179] 13 C-NMR (CDCl3; δ (ppm)): 32.9 (t, C-5); 36.0 (t, C-9); 39.3, 40.7 (2* t, C-10Conformer A/B); 48.4 (s, C-8a); 46.1, 51.4 (2* t, C-12Conformer A/B); 55.9 (q, OCH3); 64.2, 65.1 (2* t, O—CH2—CH2—O); 86.9, 87.1 (2* s, C-4aConformer A/B); 102.0 (s, C-6); 111.6 (d, C-2); 115.4, 115.7 (2* d, C-8Conformer A/B); 126.4 (s, C-12a); 126.7 (s, C-1); 127.5, 127.7 (2* t, C-7Conformer A/B); 132.0, 132.1 (2* s, C-12bConformer A/B); 144.6, 144.8 (2* s, C-3aConformer A/B); 147.1 (s, C-3); 161.6, 162.4 (2* s, CHOConformer A/B)

[0180] Narwedine ethylene glycol ketal (11):

[0181] Method A:

[0182] To a suspension of 2.0 g (4.74 mmoles) of 10 in 50 mL of absolute tetrahydrofuran, 20 mL of a 0.9 molar lithium aluminum hydride solution in diethyl ether are added dropwise at 0° C. The reaction mixture is subsequently allowed to warm up to room temperature and finally refluxed (boiling point: 52° C.). After 50 hours, the reaction mixture is cooled and hydrolyzed with 3 mL of a 2:1 mixture of tetrahydrofuran and water. After that, 50 mL of water and 50 mL of concentrated aqueous ammonia are added and the aqueous is extracted three times with 50 mL of ethyl acetate. The combined organic phases are washed once with saturated sodium chloride solution, dried (sodium sulfate) and evaporated. By purification with MPLC using EtOAc:MeOH=8:2, 820 mg (52% of the theoretical yield) of colorless crystals of 11, melting at 109°-110° C. are obtained.

[0183] TLC: CHCl3:MeOH=9:1

[0184] Method B:

[0185] (−) Narwedine (1.0 g, 3.5 mmoles) in 2.0 g of ethylene glycol and 20 mL of toluene are refluxed with 0.05 mL of concentrated sulfuric acid using a water separator. After 24 hours, the toluene phase is decanted off and the ethylene glycol phase boiled out once with toluene. The combined toluene phases are washed twice with saturated, aqueous sodium hydrogen carbonate solution and evaporated, colorless crystals of 11 being obtained quantitatively.

[0186] TLC: CHCl3:MeOH=9:1

[0187] 1 H-NMR (CDCl3; δ (ppm)): 1.65 (ddd, 1H, H-9, J(9,9′)=13.4 Hz); 2.10 (ddd, 1H, H-9′, J(9,9′)=13.4 Hz); 2.15 (dd, 1H, H-5, J(5,5′)=14.2 Hz); 2.40 (s, 3H, NCH3); 2.65 (dd, 1H, H-5′, J(5,5′)=14.2 Hz); 3.05 (ddd, 1H, H-10); 3.20 (ddd, 1H, H-10′); 3.60 (d, 1H, H-12, J(12,12′)=16.0 Hz); 3.80 (s, 3H, OCH3); 3.90-4.05 (m, 4H, O—CH2—CH2—O); 4.10 (d, 1H, H-12′, J(12,12′)=16.0 Hz); 4.55 (dd, 1H, H-4a); 5.65 (d, 1H. H-8, J(7-8)=9.8 Hz); 6.15 (d, 1H, H-7, J(7,8)=9.8 Hz); 6.55, 6.60 (AB, 2H, H-1/2)

[0188] 13 C-NMR (CDCl3; δ ppm)): 33.2 (t, C-5); 33.8 (t, C-9); 41.7 (q, N—CH3); 47.8 (t, C-10); 53.8 (s, C-8a); 55.5 (q, OCH3); 60.2 (t, C-12); 64.0, 65.0 (2* t, O—CH2—CH2—O); 87.1 (d, C-4a); 102.5 (s, C-6); 110.9 (d, C-8); 121.1 (d, C-2); 125.9 (d, C-7); 128.7 (s, C-12a); 128.9 (s, C-12b); 131.8 (d, C-1); 143.8 (s, C-3a); 146.5 (s, C-3)

[0189] (±) Galanthamine-2-hydroxyethyl ether (12)

[0190] To the educt (10) (1.0 g), dissolved in 25 mL of THF and cooled to 0° C., 9 mL of a 1M solution of lithium aluminum hydride in THF were added dropwise over a period of 5 minutes and stirring was continued at 0° C. for 30 minutes. Subsequently, the reaction mixture was refluxed for 48 hours and cooled and 25 mL (25%) ammonia were added dropwise, after which 4 mL of the reaction mixture were extracted with 20 mL of ethyl acetate. The organic phases were dried over sodium sulfate and evaporated. Yield: 0.76 g of a yellowish oil (12)(92.9% of the theoretical yield). Colunmn chromatography (40 g of silica gel 60, CHCl3/2-7% of MeOH) resulted in 0.62 g of colorless foam.

[0191] Molecular weight (C19H24NO4): 330.40

[0192] N-Demethylbromonarwedine ethylene glycol ketyl (13)

[0193] N-formylbromonarwedine ethylene glycol ketal (9.0 g, 21.3 mmoles) (10) is suspended in 100 mL of absolute tetrahydrofuran, treated at −15° to at most −10° C. with 28.4 mL (25.6 mmoles) of a 0.9 N solution of lithium aluminum hydride in diethyl ether and stirred at this temperature. After 20 minutes, a further 10 mL of a 0.9 N lithium aluminum hydride solution in diethyl ether are added dropwise and stirred for a further 20 minutes at −15° to −10° C. Subsequently, the reaction mixture is hydrolyzed with 15 mL of 2:1 mixture of tetrahydrofuran and water, the solution is concentrated in a rotary evaporator and the residue taken up in 200 mL of water and extracted three times with 100 mL portions of ethyl acetate. The combined organic phases are washed with a saturated, aqueous sodium chloride solution, dried (sodium sulfate) and evaporated, 6.53 g (78% of the theoretical yield) of colorless crystals of 13 being obtained.

[0194] DC:

[0195] CHCl3:MeOH=95:5

[0196] EtOAc:MeOH=9:1

[0197] 1 H-NMR (CDCl3; δ (ppm)): 1.70-1.85 (b, 1H tauscht D2O, NH); 1.80 (dd, 1H, H-9); 1.90 (dd, 1H, H-9′); 2.15 (dd, 1H, H-5, J(5,5′)=16.0 Hz); 2.65 (dd, 1H, H-5′, J(5,5′)=16.0 Hz); 3.20 (ddd, 1H, H-10); 3.80 (s, 3H, OCH3); 3.85-4.10 (m, 6H, H-10′/12, HO—CH2—CH2—O); 4.50 (d, 1H, H-12′, J(12,12′)=14.2 Hz); 4.60 (dd, 1H, H-4a); 5.65 (dd, 1H, H-8, J(7,8)=9.8 Hz); 6.15 (dd, 1H, H-7, J(7,8)=9.8 Hz); 6.85 (s, 1H, H-2)

[0198] N-Benzyl-bromonarwedine ethylene glycol ketal (14)

[0199] N-demethylbromonarwedine ethylene glycol ketal (250 mg, 0.63 mmoles) (13) is mixed with 63 mg (0.63 mmoles) of triethylamine in 15 mL of absolute tetrahydrofuran and 108 mL (0.63 mmoles) of benzyl bromide are added at room temperature and the mixture is subsequently stirred for 24 hours. The reaction mixture is treated with 50 mL of water and the aqueous phase extracted three times with 20 mL portions of ethyl acetate. The combined organic phases are washed once with saturated, aqueous sodium chloride solution, dried (sodium sulfate) and evaporated, 260 mg (85% of the theoretical yield) of colorless crystals having a melting point of 118°-119° C. of 14 being obtained. TLC: EtOAc:MeOH=9:1

[0200] 1 H-NMR (CDCl3; δ (ppm)): 1.65 (ddd, 1H-9, J(9,9)=14.2 Hz); 2.05-2.30 (m, 2H, H-5, H-9′); 2.65 (dd, 1H, H-5′, J(5,5′)=13.4 Hz); 3.00-3.30 (m, 2H, H-10/10′); 3.70 (s, 2H, CH2—Ph); 3.80 (s, 3H, OCH3); 3.90-4.20 (m, 5H, H-12, O—CH2—CH2—O); 4.35 (dd, 1H, H-12′, J(12,12′)=15.1 Hz); 4.60 (ddd, 1H, H-4a); 5.70 (d, 1H, H-8, J(7,8)=9.8 Hz); 6.25 (d, 1H, H-7, J(7,8)=9.8 Hz); 6.85 (s, 1H, H-2); 7.25-7.30 (m, 5H, Ph)

[0201] 13 C-NMR (CDCl3; δ (ppm)): 33.1 (t, C-5); 33.4 (t, C-9); 48.5 (s, C-8a); 50.7 (t, C-10); 55.8 (q, OCH3); 56.4 (t, C-12); 56.9 (t, CH2—Ph); 64.2, 65.1 (2* t, O—CH2—CH2—O); 87.4 (d, C-4a); 102.3 (s, C-6); 113.6 (s, C-1); 115.6 (d, C-8); 126.6 (s, Ph-1); 127.1 (d, C-7); 128.2, 128.9 (6* d, Ph-2-6, C-2); 133.1 (s, C-12a); 137.9 (s, C-12b); 144.2 (s, C-3a); 146.3 (s, C-2)

[0202] N-Demethylbromonarwedine (15):

[0203] Method A:

[0204] See general procedure for splitting the ethylene glycol protective group.

[0205] Method B:

[0206] N-formyl bromonarwedine ketal (10) (9.0 g, 21.3 mmoles) are suspended in 100 mL of absolute tetrahydrofuran, treated at −25° to not more than −20° C. with 28.4 mL (25.6 mmoles) of a 0.9N lithium aluminum hydride solution in diethyl ether and stirred at this temperature. After 20 minutes, a further 10 mL (9.0 mmoles) of a 0.9N lithium aluminum hydride solution in diethyl ether are added dropwise and stirred for a further 20 minutes at −25° to −20° C. Subsequently, the reaction mixture is hydrolyzed with 15 mL of a 2:1 mixture of tetrahydrofuran and water and evaporated in a rotary evaporator and the residue is taken up in 200 mL of 2N hydrochloric acid and stirred for 15 minutes. The aqueous phase is treated with 5.71 g (38.1 mmoles) of L-(+)-tartaric acid, made alkaline with concentrated aqueous ammonia and extracted three times with 100 mL of ethyl acetate. The combined organic phases are washed with saturated, aqueous sodium chloride solution, dried (sodium sulfate) and evaporated, 6.53 g (78% of the theoretical yield) of colorless crystals of 15 being obtained.

[0207] DC:

[0208] CHCl3:MeOH =95:5

[0209] EtOAc:MeOH=9:1

[0210] 1 H-NMR (CDCl3; δ (ppm)): 1.90-2.15 (m, 2H, H-9/9′); 2.75, 2.95 (AB, 2H, H-5/5′, J(5,5′)=16.0 Hz); 3.10-3.35 (m, 2H, H-10/10′); 3.75 (s, 3H, O—CH3); 3.90 (d, 1H, H-12, J(12,12′)=16.4 Hz); 4.40 (d, 1H, H-12′, J(12,12′)=16.4 Hz); 4.55 (dd, 1H, H-4a); 5.90 (d, 1H, H-8, J(7,8)=10.7 Hz); 6.90 (s, 1H, H-2); 7.05 (d, 1H, H-7, J(7,8)=10.7 Hz)

[0211] 13 C-NMR (CDCl3; δ (ppm)): 36.3 (t, C-5); 37.0 (t, C-9); 45.6 (s, C-8a); 49.5 (t, C-10); 51.3 (t, C-12); 55.9 (q, OCH3); 87.9 (d, C-4a); 112.5 (s, C-1); 116.0 (d, C-8); 126.6 (d, C-7); 129.6 (s, C-12a); 132.0 (s, C-12b); 143.7 (s, C-3a); 144.8 (d, C-2); 146.6 (s, C-3)

[0212] Bromonarwedine (16):

[0213] Method A:

[0214] See general procedure for splitting the ethylene glycol protective group.

[0215] Method B:

[0216] N-formyl bromonarwedine ketal (10) (9.0 g, 21.3 mmoles) are suspended in 100 mL of absolute tetrahydrofuran, treated at −5° to not higher than 0° C. with 10.0 mL (26.0 mmoles) of a 2.6N lithium aluminum hydride solution in tetrahydrofuran and stirred at this temperature. After 20 minutes, a further 5 mL (13.0 mmoles) of a 2.6N solution of lithium aluminum hydride in tetrahydrofuran are added dropwise and stirred for a further 20 minutes at −5° to 0° C. The solution is subsequently hydrolyzed with 15 mL of a 2:1 mixture of tetrahydrofuran and water and evaporated in a rotary evaporator and the residue is taken up in 200 mL of 2N hydrochloric acid and stirred for 15 minutes. The aqueous phase is treated with 6.4 g (42.9 mmoles) of L-(+)-tartaric acid, made alkaline with concentrated aqueous ammonia and extracted three times with 100 mL of ethyl acetate. The combined organic phases are washed with saturated, aqueous sodium chloride solution, dried (sodium sulfate) and evaporated, 6.21 g (80% of the theoretical yield) of colorless crystals of 16 being obtained.

[0217] DC:

[0218] CHCl3:MeOH=95:5

[0219] EtOAc:MeOH 9:1

[0220] 1 H-NMR (CDCl3; δ (ppm)): 1.90 (ddd, 1H, H-9, J(9,9′)=12.5 Hz); 2.25 (ddd, 1H, H-9′, J(9,9′)=12.5 Hz); 2.45 (s, 3H, NCH3); 2.75 (dd, 1H, H-5, J(5,5′)=17.8 Hz); 2.95-3.25 (m, 3H, H-5′/10/10′); 3.85 (s, 3H, OCH3); 3.95 (d, 1H, H-12, J(12,12′)=16.9 Hz); 4.25 (d, 1H, H-12′, J(12,12′)=16.9 Hz); 4.70 (dd, 1H, H-4a); 6.05 (d, 1H, H—S, J(7,8)=9.8 Hz); 6.95 (s, 1H, H-2); 7.00 (d, 1H, H-7, J(7,8)=9.8 Hz)

[0221] 13 C-NMR (CDCl3; δ (ppm)): 33.0 (t, C-5); 36.9 (t, C-9); 42.9 (q, NCH3); 49.2 (s, C-8a); 53.5 (t, C-10); 56.1 (q, OCH3); 58.9 (t, C-12); 88.0 (C-4a); 114.0 (s, C-1); 116.3 (d, C-2); 127.2 (d, C-8); 127.9 (s, C-12a); 131.6 (s, C-12b); 143.9 (s, C-3a); 144.4 (d, C-7); 146.5 (s, C-3); 193.9 (s, C-6)

Splitting Off of The Ethylene Glycol Protective Group
(15, 16, Narwedine)
				empirical weight,
Substance No.	Educt No.	R1	R6	molecular weight
15	13	Br	H
Narwedin	11	H	CH3	C17H19NO3 [285.35]
16	110	Br	CH3	C17H18BrNO3 [364.25]

[0222] Educt (5 g) is dissolved in 100 mL of 2N hydrochloric acid and heated to 100° C. for 30 minutes. After cooling, the solution is made alkaline with concentrated aqueous ammonia and the product filtered off with suction and dried at 50° C./20 mm, or extracted with ethyl acetate, dried (sodium sulfate) and evaporated.

[0223] TLC: CHCl3: MeOH=9:1

Substance No	Name	Yield	Melting Point
15		91% colorless crystals	173-174° C.
Narwedin	Narwedin	quantitative colorless
		crystals
16	Bromnarwedin	quantitative colorless	75-77° C.
		crystals

[0224] Narwedin:

[0225] H-NMR (CDCl3; δ (ppm)): 1.85 (ddd, 1H, H-9, J(9,9′)=14.2 Hz); 2.25 (ddd, 1H, H-9′, J(9,9′)=14.2 Hz); 2.75 (ddd, 1H, H-5, J(5,5′)=17.8 Hz); 3.05-3.30 (m, 3H; H-5′/10/10′); 3.70 (d, 1H, H-12, J(12,12′)=12.5 Hz); 3.80 (s, 3H, OCH3); 4.10 (d, 1H, H-12′, J(12,12′)=12.5 Hz); 4.70 (b, 1H, H-4a); 6.00 (d, 1H, H-8, J(7,8)=9.8 Hz); 6.60-6.70 (m, 2H, H-1/2); 6.95 (d, 1H, H-7, J(7,8)=9.8 Hz)

[0226] 13 C-NMR (CDCl3; δ (ppm)): 33.3 (t, C-5); 37.3 (t, C-9); 42.5 (q, NCH3); 49.0 (s, C-8a); 54.1 (t, C-10); 56.0 (q, OCH3); 60.7 (t, C-12); 88.0 (d, C-4a); 111.9 (d, C-2); 122.0 (d, C-8); 127.1(d, C-1); 129.4 (s, C-12a); 130.6 (s, C-12b); 144.0 (d, C-7); 144.4 (s, C-3a); 147.0 (s, C-2); 194.4 (s, C-6)

General Procedure for Reduction with L-Selectide
				empirical
				formula,
Substance				molecular
No.	Educt No.	R1	R6	weight
4	Bromformyl narwedin	Br	58	C16BrNO3[352.24]
3	Bromnarwedin	Br	59	C17H20BrNO3[366.26]
42	41	Br	60	C19H22BrNO3[392.30]
45	44	Br	61	C22H24BrNO3[442.36]
46	47	H	62	C23H25 NO3[363.46]

[0227] Educt (100 mg) is suspended in 5 mL of absolute tetrahydrofuran and treated at −5° to 0° C. with 1.2 equivalents of a 1N solution of L-selectide in tetrahydrofuran. After 30 minutes, the reaction mixture is hydrolyzed with a 1:1 mixture of tetrahydrofuran and water and evaporated to dryness in a rotary evaporator, the residue being taken up in 50 mL of 2N hydrochloric acid and stirred overnight at room temperature. The aqueous phase is washed with 20 mL of diethyl ether and made alkaline slowly with cooling and good stirring with concentrated aqueous ammonia, so that the product precipitates. The precipitate is permitted to crystallize for several days in the refrigerator and then filtered off with suction. By extracting the filtrate with ethyl acetate, a second fraction of product is recovered. The crude product is purified by column chromatography (15 g silica gel, solvent: 9:1 mixture of chloroform and ethanol).

[0228] TLC: CHCl3:MeOH=9:1

Substance			Melting
No.	Name	Yield	Point
4	(6R)-4a,5,9,10,11,12-Hexahydro-	90% color-
	1-brom-3-methoxy-6H-	less crys-
	benzofuro[3a,3,2-ef][2]benzazepin-	tals
	6-ol
3	(6R)-4a,5,9,10,11,12-Hexahydro-	quanti-	76-77° C.
	1-brom-3-methoxy-11-methyl-6H-	tative
	benzofuro[3a,3,2-ef][2]benzazepin-	colorless
	6-ol	crystals
42	(6R)-4a,5,9,10,11,12-Hexahydro-	30%
	1-brom-3-methoxy-11-(2-
	propenyl)-6H-benzo-
	furo[3a,3,2ef][2]-benzazepin-
	6-ol
45	(6R)-4a,5,9,10,11,12-Hexahydro-	50%
	1-brom-3-methoxy-11-(phenyl-
	methyl)-6H-benzofuro[3a,3,2-
	ef][2]-benzazepin-6-ol
46	(6R)-4a,5,9,10,11,12-Hexahydro-	80%
	3-methoxy-11-(phenylmethyl)-6H-
	benzofuro[3a,3,2-ef][2]benzazepin-
	6-ol

[0229]

(−)-Galanthamine Carbamates and Thiocarbamates
	Empirical
Product	Formula	R	Method	R
	C24H26N2O4[406.48]	(−)-Galanthamin-phenylcarbarnate	A	63
17	C26H29N2O4[433.53]	(−)-Galanthamin-R-α-methyl- benzylcarbamate	A	64
19	C26H29N2O4[433.53]	(−)-Galanthamin-S-α-methyl- benxylcarbamate	A	65
	C23H23N2O4[456.54]	(−)-Galanthamin-α-naphtylcarbarnate	B	66
	C22H30N2O4[386.49]	(−)-Galanthamin-n-butylcarbamate	A	67
21	C24H26N2O3S [422.55]	(−)-Galanthamin-phenylthiocarbamate	B	68
23	C22H30N2O3S [402.56]	(−)-Galanthamin-n-butylthiocarbamate	B	69

[0230] Method A:

[0231] Isothionate or thioisothianate (1.2 equivalents) is added under argon to a solution of 500 mg (1.74 mmoles) of (−)-galanthamine in 50 mL of absolute tetrahydrofuran and stirred for 24 hours under reflux. The reaction mixture was evaporated and the residue purified by column chromatography (acetone=methanol=9:1), colorless crystals being obtained.

[0232] Method B:

[0233] Sodium hydride (95%, 68 mg, 2.62 mmoles) was added under argon to a solution of 500 mg (1.74 mmoles) of (−)-galanthamine in 15 mL of absolute dimethylformamide and stirred for 30 minutes at room temperature. Subsequently, 1.2 equivalents of isocyanate or thioisocyanate were added dropwise and stirring was continued for a further 3 hours. The reaction mixture was poured into 150 mL of water and extracted twice with 150 mL of ethyl acetate. The organic phases were washed once with 100 ii of water, dried over sodium sulfate and evaporated. The residue was purified by column chromatography (acetone:methanol=9:1), colorless crystals being obtained.

[0234] TLC: Toluene:MeOH=4:1

		*αD(25° C.,
Product	Yield [% d. Th.]	c = 1)	melting point. [° C.]
	94 (Lit.|15|: 80%)	−43.6°	85-86 (Lit.|15|: 85-87)
	58 (Lit.|15|: 60%)	−56.0°	199-203 (Lit.|15|: 203-204)
	93 (Lit.|15|: 100%)	−57.0°	48-51 (Lit.|15|: 47-49)
17	96	−45.5°	74-77
19	99	−48.1°	135-136
21	97	−22.5°	175-176
23	71	−48.5°	165-167

[0235]

1 H-NMR [CDCl3; δ (ppm)]:
Proton	17
H-5	1.60; m	1.60; m	1.58; m	1.60; m
H-1	2.10; m	2.10; m	2.10; m	1.90; m
Hb-5	2.20; m	2.18; m	2.15; m	2.10; m
CH3—N—	2.40; s	2.4; s	2.40; s	2.38; s
Hb-1	2.75; br.d	2.80; br.d	2.65; br.d	2.68; br.d
Hb-6	3.10; m	3.08; m	3.05; m	3.05; m
Ha-6	3.30; m	3.30; m	3.15; m	3.25; m
Hb-8	3.70; br.d	3.68; br.d	3.65; br.d	3.65; br.d
CH3—O—	3.85; s	3.85; s	3.85; s	3.80; s
Ha-8	4.15; br.d	4.15; br.d	4.10; br.d	4.10; br.d
H-12a	4.55; t	4.59; m	4.50; t	4.55; t
H-2	5.40; t	5.45; t	5.23; t	5.25; t
H-3	5.95; dd	6.00; dd	5.90; dd	5.85; dd
H-4	6.30; d	6.35; d	6.20; d	6.25; d
H-9	6.60; d	6.60; d	6.55; d	6.55; d
H-10	6.65; d	6.70; d	6.60; d	6.65; d
diverse H	6.95 (s, 1H, —NH—)	7.35 (s, 1H, —NH—)	0.9 (t, 3H, CH3—)	1.45 (m, 3H, CH3—)
	7.0-7.3 (m, 5H, Ph)	7.5-7.9 (m, 7H, Naph)	1.30 (m, 2H, CH3—CH2—)	4.48 (m, 1H, —CH—)
			1.42 (m, 2H, (—CH2—CH2—)	5.20 (s, 1H, —NH—)
			3.15 (m. 2H, (—NH—CH2—)	7.28 (m, 5H, Ar—H)
			4.85 (s, 1H, —NH—)
Proton	19	21	23
Ha-5	1.55; m	1.60; m	1.65; m
Ha-1	2.10; dd	2.00; m	2.00; m
Hb-5	1.90; m	2.15; m	2.10; m
CH3—N—	2.40; s	2.35; s	2.38; s
Hb-1	2.70; br.d	2.60; m	2.75; m
Hb-6	3.02; m	3.00; m	3.05; m
Ha-6	3.25; m	3.25; m	3.50; m
Hb-8	3.65; br.d	3.60; br.d	3.70; br.d
CH3—O—	3.80; s	3.70; s	3.80; s
Ha-8	4.10; br.d	4.05; br.d	4.10; br.d
H-12a	4.55; t	4.50; t	4.55; t
H-2	5.28; t	5.90; m	6.30; t
H-3	5.90; dd	6.00; dd	5.95; dd
H-4	6.20; d	6.25; d	6.05; d
H-9	6.55; d	6.50; d	6.55; d
H-10	6.65; d	6.10; d	6.65; d
diverse H	1.50 (d. 3H. CH3—)	6.9-7.25 (d. 5H, Ph—H)	0.90 (t. 3H. CH3—)
	4.80 (m, 1H, —NH—CH—CH3)	8.40 (s, 1H, —NH—)	1.30 (m, 2H, CH3—CH2—)
	5.20 (s. 1H. —NH—)		1.60 (m. 2H, —CH2—CH2—CH2—)
			3.25 (m. 2H. —NH—CH2—)

[0236]

13 C-NMR [CDCl3; δ (ppm)]:
C-Atom	17
C-1	27.8; t	27.9; t	29.1; t	27.9; t
C-5	34.1; t	34.3; t	34.2; t	34.2; t
CH3—N—	41.7; q	41.9; q	40.5; q	41.7; q
C-4a	47.8; s	47.9; s	47.7; s	47.8; s
C-6	53.6; t	53.7; t	53.8; t	53.6; t
CH3—O	55.6; q	55.7; q	55.5; s	55.6; s
C-8	60.3; t	60.4; t	60.3; t	60.3; t
C-2	63.6; d	64.0; d	62.9; d	63.2; d
C-12a	86.3; d	86.3; d	86.3; d	86.3; d
C-3	110.9; d	111.0; d	110.9; d	111;0; d
C-4	118.6; d	119.0; d	121.2; d	121.2; d
C-9	121.4; d	120.7; d	123.4; d	123.3; d
C-10	130.4; d	128.5; d	129.8; d	128.3; d
C-8a	132.0; s	129.2; s	129.1; s	129.2; s
C-11b	138.0; s	132.1; s	132.1; s	132.1; s
C-11a	143.7; s	143.8; s	143.7; s	143.6; s
C-11	146.3; s	146.4; s	146.3; s	146.3; s
diverse C	122.8 (d, Ar—C)	120.7; 121.4; 123.0; 125.7;	13.5 (q. CH3—CH2—)	22.4 (q, CH3—)
	123.0 (d, Ar—C)	125.9; 130.6 (d, 6 naphth.C)	19.7 (t, CH3—CH2—)	50.6 (d, —NH—CH—)
	128.7 (d, 3 Ar—C)	126.7 (s, naphth.C-8a)	27.9 (t, —CH2—CH2—)	125.8; 127; 129.9;
	129.0 (s, Ar—C)	132.7 (s, naphth.C-4a)	40.5 (t, —NH—CH2—)	(d, 5 Ar—C)
		134.0 (s, naphth.C-1)	156.1 (s, —OC—NH—)	143.7 (s, Ar—C)
	C-Atom	19	21	23
	C-1	27.9; t	27.5; t	30.9; t
	C-5	34.3; t	34.1; t	34.1; t
	CH3—N—	41.8; q	41.8; q	41.8; q
	C-4a	47.8; s	47.9; s	48.0; t
	C-6	53.6; t	53.6; t	53.6; t
	CH3—O—	55.5; q	55.0; q	55.5; q
	C-8	60.3; t	60.3; t	60.3; t
	C-2	63.1; d	71.2; d	69.7; d
	C-12a	86.3; d	86.1; d	86.3; d
	C-3	110.9; d	110.9; d	110.8; d
	C-4	121.2; d	120.8; d	121.3; d
	C-9	123.3; d	121.5; d	122.7; d
	C-10	128.3; d	128.7; d	129.2; d
	C-8a	132.1; s	130.0; s	131.0; s
	C-11b	143.7; s	131.3; s	132.0; s
	C-11a	143.9; s	137.7; s	143.7; s
	C-11	146.3; s	143.7; s	146.3; s
	diverse C	22.4 (q. —CH3)	100.8-128.7 (d. 5 Ar—C)	13.6 (. —CH3)
		50.6 (d. —NH—CH—CH3)	129.1 (s, Ar—C)	19.9 (t. —CH2—CH3)
		155.3 (s. —OOC—NH—)	146.3 (s. OSC—NH—)	27.8 (t. —CH2—CH2—CH2—)
				44.9 (. —NH—CH2—CH2—)
				189.1 (s. —OSC—NH—)

[0237]

(+)-Galanthamine Carbamates and Thiocarbamates
	Empirical
Product	Formula	Name	R
	C24H26N2O4[406.48]	(+)-Galanthamine-phenylcarbamate	70
18	C26H29N2O4[433.53]	(+)-Galanthamin-R-α-methylbenzylcarbamate	71
20	C26H29N2O4[433.53]	(+)-Galanthamin-S-α-methylbenzylcarbarnate	72
22	C24H26N2O3S [422.55]	(+)-Galathamine-phenylthiocarbamate	73
24	C22H30N2O3S [402.56]	(+)-Galanthamin-n-butylthiocarbamate	74

[0238] General Procedure

[0239] Sodium hydride (95%, 68 mg, 2.62 mmoles) was added under argon to a solution of 500 mg (1.74 mmoles) of (+)-galanthamine in 15 mL of absolute dimethylformamide and stirred for 30 minutes at room temperature. Subsequently, 1.2 equivalents of isocyanate or thioisocyanate were added dropwise and stirring was continued for a further 3 hours. The reaction mixture was poured into 150 mL of water and extracted twice with 150 mL of ethyl acetate. The organic phases were washed once with 150 mL of water, dried over sodium sulfate and evaporated. The residue was purified by column chromatography (acetone:methanol=9:1), colorless crystals being obtained.

[0240] TLC: Toluene:MeOH=4:1

Product	Yield [% d. Th.]	*αD(25° C., c = 1)	Melting Point [° C.]
	84	+51.9°	77-80
18	42	+55.6°	58-60
20	47	+56.5°	55-57
	56	+43.5°	195-198
	91	+42.0°	52-55
22	61	+10.4°	75-78
24	73	+31.2°	122-125

[0241]

(−)-N-tert.-Boc-Amino Acid Epigalaanthamine Ester
	Empirical
Product	Formula	Name	R
25	C24H32N2O6[444,55]	(−)-N-t-Boc-Glycin-epigalanthaminester	75
26	C30H40N2O8[592,74]	(−)-N-t-Boc-L-Asparaginesaure-β-benzylester- epigalanthaminester	76
28	C33H40N2O8[592,74]	(−)-N-t-Boc-D-Asparaginesaure-β-benzylester- epigalanthaminester	77
29	C27H38N2O6S [518,65]	(−)-N-t-Boc-L-Methionin-epigalanthaminester	78
31	C27H38N2O8S [518.65]	(−)-N-t-Boc-D-Methionin-epigalanthaminester	79
32	C31H38N2O6[534.65]	(−)-N-t-Boc-L-Phenylalanin-epigalanthaminester	80

[0242] General Procedure

[0243] (−)-Galanthamine (800 mg, 2.78 mmoles), 1.2 equivalents of t-Boc-amino acid and 876.0 mg (3.34 mmoles) of triphenyl phosphine are added to 50 mL of absolute tetrahydrofuran. After the addition of 581.7 mg (3.34 mmoles) of diethyl azodicarboxylate (DEAD), the reaction mixture was stirred for 3 hours at room temperature. After the reaction, the solution was evaporated and the oily residue was purified by column chromatography, first in ethyl acetate, in order to separate the many by-products with a high Rf, and then in acetone. Upon drying in vacuum, the oily product expanded to a foam, from which it then hardened in air.

[0244] TLC: acetone:MeOH=9:1

Product	Yield [% d. Th.]	αD(25° C., c = 1)	melting point [° C.]
25	93	−187.3°	65-66
26	50	−146.6°	53-56
28	53	−140.0°	63-67
29	78	−181.7°	117-119
31	62	−140.6°	126-130
32	44	−159.1°	67-69

[0245]

1 H-NMR [CDCl3; δ (ppm)]:
Proton	25	26	28
Ha-5	1.65; m	1.65; m	1.60; m
H-1	1.85; m	1.80; m	1.70; m
Hb-5	2.18; m	2.20; m	2.15; m
CH3—N—	2.40; s	2.35; s	2.40; s
Hb-1	2.80; m	2.80; m	2.70; m
Hb-6	3.05; m	3.10; m	3.10; m
H-6	3.25; m	3.25; m	3.25; m
Hb-8	3.65; br.d	3.65; br.d	3.60; br.d
CH3—O—	3.80; s	3.85; s	3.85; s
Ha-8	4.05; br.d	4.05; br.d	4.05; br.d
H-12a	4.55; t	4.60; t	4.55; t
H-2	3.90; d	4.55; d	4.50; d
H-3	5.70; d	5.60; d	5.70; d
H-4	6.15; d	6.05; d	6.10; d
H-9	6.55; d	6.55; d	6.55; d
H-10	6.65; d	6.65; d	6.65; d
diverse H	1.45 (s, 9H, 3 × CH3—)	1.45 (s, 9H. 3 × CH3—)	1.45 (s. 9H, 3 × CH3—)
	1.80 (t, 2H, —OOC—CH2—)	2.90 (m, 1H, —OOC—CH—)	2.90 (m. 1H, —OOC—CH—)
	5.60 (s, 1H, —NH—COO—)	3.0 (d, 2H, —CH2—COOBn)	3.0 (d, 2H, —CH2—COOBn)
		5.10 (s, 2H, —OOC—CH2—Ph)	5.15 (s, 2H, —OOC—CH2—Ph)
		5.60 (s, 1H, —NH—COO—)	5.60 (s, 1H, —NH—COO)
		7.30 (m, 5H, Ph—H)	7.35 (m, 5H, Ph—H)
Proton	29	31	32
Ha-5	1.65; m	1.65; m	1.65; m
H-1	1.80; m	1.80; m	1.80; m
Hb-5	1.95; m	1.95; m	2.20; m
CH3—N—	2.10; s	2.40; s	2.40; s
Hb-1	2.85; m	2.75; m	2.80; m
Hb-6	3.05; m	3.05; m	3.00; m
H-6	3.25; m	3.25; m	3.25; m
Hb-8	3.65; br.d	3.60; br.d	3.60; br.d
CH3—O—	3.85; s	3.85; s	3.85; s
Ha-8	4.05; br.d	4.05; br.d	4.05; br.d
H-12a	4.60; t	4.60; t	4.55; t
H-2	4.40; m	4.40; m	4.50; m
H-3	5.70; d	5.70; t	5.50; t
H-4	6.15; d	6.15; d	6.10; d
H-9	6.55; d	6.55; d	6.55; d
H-10	6.65; d	6.65; d	6.65; d
diverse H	1.45 (s. 9H, 3 × CH3—)	1.40 (s. 9H. 3 × CH3—)	1.40 (s. 9H, 3 × CH3—)
	2.10 (s. 3H, CH3—S—)	2.10 (s, 3H. CH3—S—)	3.10 (m. 1H. —OOC—CH—)
	2.20 (m, 2H, —CH2—CH2—S—)	2.15 (m, 2H. —CH2—CH2—S—)	5.60 (m. 2H, —CH2—Ph)
	2.55 (m, 2H, —CH2—CH2—S—)	2.50 (m. 2H, —CH2—CH2—S—)	5.10 (s. 1H, —NH—COO—)
	2.60 (m. 1H. —OOC—CH—CH2—)	2.60 (m. 1H, —OOC—CH—CH2—)	6.10-6.30 (m, 5H, Ph—H)
	5.15 (s. 1H, —NH—COO—)	5.15 (s, 1H. —NH—COO—)

[0246]

13 C-NMR [CDCl3; δ (ppm)]:
C-Atom	25	26	28
C-1	28.1; t	29.1; t	28.9; t
C-5	33.9; t	33.9; t	34.1; t
CH3—N—	41.9; q	41.8; q	42.0; q
C-4a	47.9; s	47.9; s	48.0; s
C-6	53.8; t	53.8; t	53.9; t
CH3—O—	55.8; q	55.8; q	55.9; q
C-8	60.2; t	60.2; t	60.3; t
C-2	67.4; d	68.0; d	68.0; d
C-12a	87.4; d	87.4; d	87.5; d
C-3	111.1; d	111.1; d	111.2; d
C-4	121.5; d	121.4; d	121.5; d
C-9	126.6; d	126.5; d	126.6; d
C-10	127.4; d	128.1; d	128.3; d
C-8a	128.9; s	129.0; s	129.1; d
C-11b	132.3; s	132.3; s	132.4; s
C-11a	143.7; s	143.8; s	143.8; s
C-11	146.5; s	146.5; s	146.6; s
diverse C	28.1 (q, 3 × CH3—)	28.1 (q. 3 × CH3—)	28.2 (q, 3 × CH3—)
	42.4 (t, —OOC—CH2—NH—)	36.8 (t, —CH2—)	36.9 (t, —CH2—)
	79.7 (s, —O—C(CH3)3)	50.0 (d, —CH—)	50.1 (d, —CH—)
	155.6 (s, —OOC—CH2—NH—)	66.6 (t, —O—CH2—Ph)	66.7 (t, —O—CH2—Ph)
	169.6 (s, —NH—COO—)	79.9 (s, —O—C(CH3)3)	80.0 (s, —O—C(CH3)3)
		128.2-128.4 (d, 4 Ar—C)	128.3-128.5 (d, 5 Ar—C)
		131.8 (d, Ar—C)	135.4 (s, Ar—C)
		135.3 (s, Ar—C)	155.2 (s, —OOC—CH—)
		155.1 (s, —OOC—CH—)	170.2 (s, —NH—COO—
		170.2 (s, —NH—COO—)	170.5 (s, —COO-Bn)
		170.4 (s, —COOBn)
C-Atom	29	31	32
C-1	28.1; t	28.1; t	28.1; t
C-5	33.9; t	34.0; t	33.9; t
CH3—N—	41.8; q	41.9; q	41.9; q
C-4a	48.0; s	48.0; s	47.9; s
C-6	53.8; t	53.8; t	53.8; t
CH3—O—	55.8; q	55.8; q	55.8; q
C-8	60.2; t	60.2; t	60.2; t
C-2	67.4; d	67.7; d	67.5; d
C-12a	87.4; d	87.3; d	87.4; d
C-3	111.1; d	111.1; d	111.1; d
C-4	121.5; d	121.5; d	121.4; d
C-9	126.4; d	126.6; d	126.4; d
C-10	128.4; d	128.3; d	128.2; d
C-8a	129.0; s	129.0; s	131.7; s
C-11b	132.3; s	132.3; s	132.7; s
C-11a	143.8; s	143.7; s	143.8; s
C-11	146.5; s	146.5; s	146.5; s
diverse C	15.4 (q. —S—CH3)	15.4 (q, —S—CH3)	(28.1 (q, 3 × CH3—)
	28.1 (q, 3 × CH3—)	28.1 (q. 3 × CH3—)	38.4 (t, —CH2—Ph)
	29.6 (t, —CH2—CH2—S—)	29.8 (t, —CH2—CH2—S—)	54.5 (d, —CH—)
	32.1 (t, —CH2—CH2—S—)	32.1 (t, —CH2—CH2—S—)	79.7 (s, —O—C(CH3)3)
	52.8 (d, —CH—)	52.8 (d, —CH—)	126.8-131.8 (d, 5 Ar—C)
	79.9 (s, —O—C(CH3)3)	79.8 (s, —O—C(CH3)3)	136.9 (s, Ar—C)
	155.2 (s, —OOC—CH—)	155.1 (s, —OOC—CH—)	154.9 (s, —OOC—CH—)
	171.5 (s, —OOC—NH—)	171.5 (s, —OOC—NH—)	171.7 (s, —OOC—NH—)

[0247]

uz,11/33 (+)-N-tert.-Boc-Amino Acid-Epigalanthamine Ester
	Empirical
Product	Formula	Name	R
27	C33H40N2O2[592,74]	(+)-N-t-Boc-L-Asparaginsäure-β-benzyester-nl epigalanthaminester	81
30	C27H33N2O6S [515,65]	(+)-N-t-Boc-L-Methionin-epigalanthaminester	82

[0248] General Procedure

[0249] (+)-Galanthamine (800 mg, 2.78 mmoles), 1.2 equivalents of t-Boc-amino acid and 876.0 mg (3.34 mmoles) of triphenyl phosphine are added to 50 mL of absolute tetrahydrofuran. After the addition of 581.7 mg (3.34 mmoles) of diethyl azodicarboxylate (DEAD), the reaction mixture was stirred for 3 hours at room temperature. After the reaction, the solution was evaporated and the oily residue was purified by column chromatography, first in ethyl acetate, in order to separate the many by-products with a high Rf, and then in acetone. Upon drying in vacuum, the oily product expanded to a foam, from which it then hardened in air.

Product	Yield [% d. Th.]	αD(25° C., c = 1)	Melting Point [° C.]
27	75	÷121°	130-134
30	41	÷117°	112-115

[0250] (+)-Bromogalanthamine-Phenyl Carbamate (33)

[0251] Crude bromogalanthamine (400 mg, 1.09 mmoles) was dissolved in 50 mL of absolute tetrahydrofuran, treated in an argon atmosphere with 390 mg (3.28 mmoles) of phenyl isocyanate and stirred for 24 hours under reflux. The reaction mixture was evaporated and the residue purified by column chromatography (EE:MeOH=3:2), 450 mg (85% of the theoretical yield) of colorless crystals being obtained.

[0252] TLC: EE:MeOH—3:2

[0253] 1 H-NMR [CDCl3; δ (ppm)]: 1.60 (m, 1H, Ha-5); 2.10 (m, 1H, Hb-5); 2.35 (m, 1H, Ha-1); 2.40 (s, 3H, N—CH3); 2.70 (br, d, 1H, Hb-1); 3.0 (m, 1H, Hb-6); 3.20 (m, 1H, Ha-6); 3.80 (s, 3H, CH3O—); 3.95 (dd, 1H, H-3); 4.30 (br. d, 1H, Ha-8); 4.55 (t, 1H, H-12a); 5.35 (t, 1H, H-2); 5.95 (dd, 1H, H-3); 6.30 (d,1H, H-4); 6.90 (s, 1H, H-10); 7.0 (s, 1H, —OOC—NH—); 7.0-7.30 (m, 5H, Ar—H).

[0254] 13 C-NMR [CDCl3; δ(ppm)]: 27.7 (t, C-1); 34.2 (t, C-5); 42.0 (s, N—CH3); 48.5 (s, C-4a); 53.4 (t, C-6); 56.0 (q, CH3O—); 58.6 (t, C-8); 63.6 (d, C-2); 86.6 (d, C-12a); 113.9 (s, C-9); 115.7 (d, C-3); 118.7 (d, C-4); 123.2, 123.5 (d, 2 Ar—C); 127.9 (s, C-8a); 128.9 (d, C-10); 130.3 (s, 3 Ar—C); 133.3 (s, C-11b); 138.0 (s, Ar—C); 144.0 (s, C-11a); 146.1 (s, C-11); 153.3 (s, —OOC—NH—).

[0255] (+)-Bromogalanthamine-R-α-methylbenzyl Carbamate (34)

[0256] Crude bromogalanthamine (510 mg, 1.39 mmoles) was dissolved in 20 mL of absolute THF, treated in an argon atmosphere with 615 mg (4.18 mmoles) of R-(+)-α-methylbenzyl isocyanate and stirred for 2 days under reflux. The reaction mixture was evaporated and the residue purified by column chromatography (EE:MeOH=4:1), 600 mg (84% of the theoretical yield) of colorless crystals being obtained.

[0257] TLC: EE:MeOH—4:1

[0258] 1 H-NMR [(CDCl3); δ (ppm)]: 1.40 (s, 3H, CH3—); 1.55 (m, 1H, Ha-5); 2.0 (m, 1H, Ha-1); 2.05 (m,1H, Hb-5); 2.35 (s, 3H, N—CH3); 2.65 (m, 1H, Hb-1); 2.95 (m, 1H, Hb-6); 3.25 (m, 1H, Ha-6); 3.75 (s, 3H, CH3O—); 3.95 (d, 1H, Hb-8); 4.25 (d, 1H, Ha-8); 4.50 (t; 1H, H-12a); 4.80 (m, —NH—CH—); 5.20 (s, 1H, —NH—CH—); 5.22 (t, 1H, H-2); 5.88 (dd, 1H, H-3); 6.20 (d, 1H, H-4); 6.90 (s, 1H, H-10); 7.30 (m, 5H:, Ar—H).

[0259] 13 C-NMR [CDCl3); δ (ppm)]: 22.1 (q, —CH—CH3); 22.1 (s, —CH—CH3); 27.5 (t, C-1); 33.7 (t, C-5); 41.4 (q, N—CH3); 48.1 (s, C-4a); 52.8 (t, C-6); 55.6 (q, CH3O—); 58.0 (t, C-8); 62.7 (d, C-2); 86.2 (d, C-12a); 113.4 (s, C-9); 115.3 (d, C-4); 123.6; 125.6; 126.8 (d, 3 Ar—C); 127.3 (s, Ar—C); 128.1; 129.3 (d, 2 Ar—C); 132.9 (s, C-8a); 143.0 (s, C-11b); 143.7 (s, C-11a); 145.7 (s, C-11); 155.0 (s, —OOC—NH—).

[0260] (+)-N-Pentyl-demethylbromogalanthamine (35)

[0261] In an argon atmosphere at room temperature, 430 mg (2.84 mmoles) of n-pentyl bromide is added dropwise to a solution of 100 mg (2.84 mmoles) of crude demethylbromogalanthamine in 30 mL of absolute THF. Subsequently, the reaction mixture was stirred under reflux for 2 days. The reaction mixture was evaporated, the oily residue taken up hi 10 mL of water and adjusted with concentrated ammonium hydroxide to a pH of 10, a yellow precipitate being formed. The precipitate is filtered off with suction, washed with a little water and, after drying (became viscous in air), purified by column chromatography (chloroform:acetone=85:15), 510 mg (43% of the theoretical yield) of a brown oil being obtained.

[0262] TLC: chloroform:acetone=85:15

[0263] 1 H-NMR [CDCl3; δ (ppm)]: 0.90 (t, 3H, —CH3); 1.30 (m, 4H, —CH2—CH2—CH3); 1.50 (t, 2H, —N—CH2—); 1.55 (m, 1H, Ha-5); 1.98 (m, 1H, Ha-1); 2.15 (m, Hb-5); 2.30 (s, OH); 2.50 (sext., 2H, —CH2—CH2—CH3); 2.65 (dd, 1H, Hb-1); 3.05 (m, 1H, Hb-6); 3,28 (m, 1H, Ha-6); 3.80 (s, 3H, CH3O—); 3.95 (br. d, 1H, Hb-8); 4.10 (t, 1H, H-2); 4.35 (br. d, 1H, Ha-8); 4.55 (t, 1H, H-12a); 6.0 (dd, 1H, H-3); 6.10 (d, 1H, H-4); 6.85 (s, 1H, H-10).

[0264] 13 C-NMR [CDCl3; δ (ppm)]: 13.9 (q, —CH3); 22.4 (t, —CH2—CH2—CH3); 27.1 (t, —CH2—CH2—CH3); 29.4 (t, N—CH2—CH2—); 29.7 (t, C-1); 33.1 (t, N—CH2—CH2—); 48.8 (s, C-4a); 52.5 (t, C-5); 52.3(t, C-6); 56.0 (q, CH3O—); 56.0 (t, C-8); 61.7 (d, C-2); 88.7 (d, C-12a); 114.3 (s, C-9); 115.7 (d, C-3); 126.7 (d; C-4); 127.8 (d, C-10); 128.1 (s, C-8a); 134.1(s, C-11b); 144.0 (s, C-11a); 145.3 (s, C-11).

[0265] O-TBDMS-N-Demethylbromogalanthamine (36):

[0266] A solution of 200 mg (0.57 mmoles) of 4.63 mg (0.63 mmoles) of triethylamine, 38 mg (0.57 mmoles) of imidazole, 157 mg (1.14 mmoles) of potassium carbonate and 171 mg (1.14 mmoles) of t-butyldimethychlorosilane in 15 mL absolute tetrahydrofuran is refluxed for 12 hours. Subsequently, the tetrahydrofuran is removed in a rotary evaporator and the residue purified by column chromatography (15 g of silica gel, solvent:chloroform:MeOH=95:5), 30 mg (12% of the theoretical yield) of an oily substance (36) being obtained.

[0267] TLC: chloroform:MeOH=9:1

[0268] H-NMR (CDCl3; δ (ppm)): 0.09 (s, 9H, C(CH3)3); 0.85 (s, 6H, Si(CH3)2); 1.82 (dd, 1H, H-9); 1.96-2.14 (m, 2H, H-9′/5); 2.34 (ddd, 1H, H-5′); 3.31 (ddd, 1H, H-10); 3.51 (ddd, 1H, H-10′); 3.80 (s, 3H, OCH3); 3.86 (d, 1H, H-12); 4.46 (b, 1H, H-6); 4.60 (b, 1H, H-4a); 4.22 (d, 1H, H-12′); 5.98 (dd, 1H, H-8); 6.01 (d, 1H, H-7); 6.88 (s, 1H, H-2)

[0269] O-TMS-Bromogalanthamine (37):

[0270] A solution of 800 mg (2.19 mmoles) of rac. bromogalanthamine (1), 260 mg mmoles) of trimethylsilyl chloride and 243 mg (2.40 mmoles) of triethylamine in 30.1 absolute tetrahydrofuran is refluxed. After 2 hours, a further 130 mg (1.2 mmoles) of trimethylsilyl chloride are added dropwise and refluxed for one hour. Subsequently, the reaction mixture is evaporated, taken up in a little dichloromethane and purified over a filter column, bright yellow crystals of 37, melting at 228°-230° C., being obtained quantitatively.

[0271] TLC: chloroform:MeOH=9:1

[0272] 1 H-NMR (CDCl3; δ (ppm)): 0.10 (s, 9H, Si(CH3)3); 1.75 (broad d, 1H H-9); 2.00-2.20 (m, 2H, H-9′/5); 2.35-2.50 (broad d, 1H, H-5′); 2.50 (s, 3H, NCH3); 3.0-3.15 (m, 1H, H-10); 3.50 (ddd, 1H, H-10′); 3.85 (s, 3H, OCH3); 4.20 (d, 1H, H-12, J(12,12′)=16.0 Hz); 4.25 (b, 1H, H-6); 4.50 (d, 1H, H-12′, J(12,12′)=16.0 Hz); 4.60 (dd, 1H, H-4a); 5.90 (dd, 1H, H-8, J(7,8)=9.8 Hz); 6.00 (dd, 1H, H-7, J(7,8)=9.8 Hz); 6.90 (s, 1H, H-2)

[0273] (−)-O-TBDMS-Bromogalanthamine (38):

[0274] A solution of 2.0 g (5.46 mmoles) of (−)-bromogalanthamine (3), 1.23 g (8.20 mmoles) of t-butyldimethylchlorosilane and 0.61 g (6.00 mmoles) of triethylamine in 50 mL of tetrahydrofuran is heated for 4 hours at 50° C. Subsequently, the tetrahydrofuran is evaporated in a rotary evaporator, the residue taken up in a little dichloromethane and purified over a 1 cm silica gel column, 1.8 g (69% of the theoretical yield) of amorphous, viscous substance (38) with a rotation of an αD20 [CHCl3]=−66° being obtained.

[0275] TLC: chloroform:MeOH=9:1

[0276] 1 H-NMR (CDCl3; δ (ppm)): 0.05 (s, 6H, Si(CH3)2); 0.90 (s, 9H, SiC(CH3)3); 1.75-1.90 (m, 1H, H-9); 1.95-2.10 (m, 2H, H-5/9′, J(5,5′)=16.9 Hz); 2.55 (s, 3H, NCH3); 2.65 (dd, 1H, H-5′, J(5,5′)=16.9 Hz); 3.00-3.15 (m, 1H, H-10, J(10,10′)=12.5 Hz); 3.45 (ddd, 1H, H-10′, J(10,10′)=12.5 Hz); 3.85 (s, 3H, OCH3); 4.15 (dd, 1H, H-6); 4.20 (d, 1H, H-12, J(12,12′)=16.0 Hz); 4.45 (d, 1H, H-12′, J(12,12′)=16.0 Hz); 4.60 (b, 1H, H-4a); 5.59, 6.05 (AB, 2H, H-7/8, J(7,8)=10.7 Hz); 6.95 (s, 1H, H-2)

[0277] O-TBDMS-Galanthamine (39):

[0278] A solution of 500 mg (1.36 mmoles) of galanthamine hydrobromide, 1.37 mg (1.36 mmoles) of triethylamine, 224 mg (1.36 mmoles) of potassium carbonate and 244 mg (1.63 mmoles) of t-butyldimethylchlorosilane in 20 mL of absolute tetrahydrofuran and 5 mL of absolute N,N-dimethylformamide is stirred for 4 hours at 60° C. Subsequently, the reaction mixture is evaporated and purified over a silica gel column, 320 mg (59% of the theoretical yield) of a yellow, oily substance (39), being obtained.

[0279] TLC: chloroform:MeOH=9:1

[0280] 1 H-NMR (CDCl3; δ (ppm)): 0.05, 0.10 (2* s, 6H, Si(CH3)2); 0.85, 0.90 (2* s, 9H, SiC(CH3)3); 1.55 (ddd, 1H, H-9, J(9,9′)=14.2 Hz); 2.00-2.20 (m, 2H, H-5/9′, J(9,9′)=14.2 Hz); 2.25-2.45 (m, 1H, H-5′); 2.35 (s, 3H, NCH3); 3.00 (ddd, 1, H-10, J(10,10′)=11.6Hz); 3.30 (ddd, 1H, H-10′, J(10,10′)=11.6 Hz); 3.60 (d, 1H, H-12, J(12,12′)=14.2 Hz); 3.85 (s, 3H, OCH3); 4.15 (d, 1H, H-12′, J(12,12′)14.2 Hz); 4.25 (dd, 1H, H-6); 4.55 (dd, 1H) H-4a); 5.85 (dd, 1H, H-8, J(7,8)=9.8 Hz); 6.10 (d, 1H, H-7, J(7,8)=9.8 Hz); 6.50, 6.60 (AB, 2H, H-1/2, J(1,2)=8.0 Hz)

[0281] N-Allyl-N-demethyl-narwedine (41):

[0282] A solution of 100 mg (0.29 mmoles) of demethylbromonarwedine (15), 38 mg (0.31 mmoles) of allyl bromide, 46 mg (0.31 mmoles) of sodium iodide and 85 mg (0.62 mmoles) of potassium carbonate in 10 mL of absolute acetone is refluxed for 12 hours. Subsequently, the solution is evaporated, taken up in 2N hydrochloric acid, made alkaline with concentrated ammonia solution and extracted with chloroform. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (sodium sulfate), filtered and evaporated, 50 mg of crude product being obtained, which is purified by column chromatography (15 g of silica gel, solvent: chloroform:MeOH=9:1), 28 mg (25% of the theoretical yield) of colorless crystals (41) being obtained.

[0283] TLC: chloroform:MeOH=9:1

[0284] 1 H-NMR (CDCl3; δ (ppm)): 1.80-2.25 (m, 3H-599′); 2.75 (ddd, 1H, H-5′); 3.05-3.25 (m, 2H, H-10/10′); 3.78 (s, 2H, NCH2); 3.84 (s, 3H, OCH3); 4.00 (d, 1H, H-12); 4.55 (d, 1H, H-12′); 4.73 (b, 1H, H-4a); 5.18 (dd, 2H, ═CH2); 5.90 (dd, 1H, ═CH); 6.04 (d, 1H, H-8); 6.90 (s, 1H, H-2); 7.03 (d, 1H, H-7)

[0285] (6R)-4a,5,9,10,11,12-Hexahydro-1-bromo-3-methoxy-11-(phenylmethyl)-6H-benzofuro-[3a,3,2-ef][2]benzazepin-6-one (44):

[0286] A solution of 500 mg (1.43 mmoles) of demethylbromonarwedine (15), 244 mg (1.43 mmoles) of benzyl bromide, 214 mg (1.43 mmoles) of sodium iodide and 400 mg (2.90 mmoles) of potassium carbonate in 40 mL of absolute acetone is refluxed for 4 hours. Subsequently, the solution is evaporated, taken up in 2N hydrochloric acid, made alkaline with concentrated ammonia and extracted with trichloromethane. The combined organic phases are washed once with saturated, aqueous sodium chloride solution, dried (sodium sulfate), filtered and evaporated, 350 mg of crude product being obtained, which is purified by column chromatography (15 g of silica gel, solvent: EtOAc:PE=1:1), 280 mg (45% of the theoretical yield) colorless crystals of 44, with a melting point of 135°-138° C., being obtained.

[0287] TLC: chloroform:MeOH=9:1

[0288] 1 H-NMR (CDCl3; δ (ppm)): 1.88 (dd, 1H, H-9); 2.15 (ddd, 1H, H-9′); 2.55-2.80 (m, 2H, H-5/5′); 2.98-3.38 (m, 2H, H-10/10′); 3.77 (s, 2H, NCH2); 3.86 (s, 3H, OCH3); 4.03 (d, 1H, H-12); 4.31 (d, 1H, H-12′); 4.74 (b, 1H, H-4a); 6.04 (d, 1H, H-8); 6.93 (s, 1H, H-1H, H-7); 7.21-7.46 (m, 5H, Ph)

[0289] 13 C-NMR (CDCl3; δ (ppm)): 31.6 (t, C-5); 37.0 (t, C-9); 49.4 (d, C-8a); 51.1 (t, C-10); 54.8(t, NCH2); 56.1 (q, OCH3); 56.8 (t, C-12); 88.1 (d, C-4a); 114.1 (d; C-1); 116.4 (d, C-8); 127.1, 127.3 (2 d, C-7, Ph-4); 128.3 (d, Ph-1/2/6); 128.7 (2 d, Ph-3/5); 131.7 (s, C-12a); 138.1 (s, C-12b); 143.9 (s, C-3a); 144.6 (d, C-2); 146.6 (s, C-3); 193.3 (s, C-6)

[0290] (6R)-4a,5,9,10,11,12-Hexahydro-11-acetyl-1-bromo-3-methoxy-6H-benzofuro-[3a,3,2-ef][2]benzazepin-6-ol acetate (48):

[0291] A solution of 300 mg (0.85 mmoles) of 4, 258 mg (2.55 mmoles) of triethylamine in 15 mL of absolute acetone is reacted slowly at 0° C. with 200 mg (2.55 mmoles) of acetyl chloride and subsequently refluxed for 24 hours. The solution is evaporated to dryness, taken up in 2N hydrochloric acid and shaken 3 times with 30 mL of ethyl acetate. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (sodium sulfate), filtered and evaporated to dryness. The crude product, which is contaminated with 59, is obtained by MPLC (60 g silica gel, solvent: chloroform:MeOH=1:1), 190 mg (51% of the theoretical yield) of an oily substance (48) being obtained.

[0292] TLC: chloroform:MeOH=9:1

[0293] 1 H-NMR (CDCl3; δ (ppm)): 1.70 (ddd, 1H H-9); 1.80 (dd, 1H, H-9′); 1.95 (ddd, 1H, H-5); 2.03, 2.12 (2s, 6H, 2 COCH3); 2.02-2.18 (m, 1H, H-5′); 2.68 (ddd, 1H, H-10, J(10,10′)=14.3 Hz); 3.20 (ddd, 1H, H-10′, J(10,10′)=14.3 Hz); 3.85 (s, 3H, OCH3); 4.33 (d, 1H, H-12, J(12,12′)=16.9 Hz); 4.55 (b, 1H, H-6, J(6,8)=4.8 Hz); 5.14 (d, 1H, H-12′, J(12,12′)=16.9 Hz); 5.32 (dd, 1H, H4a, J(4a,5)=J(4a,5′)=5.2 Hz); 5.93 (dd, 1H, H-8, J(7,8)=10.3 Hz, J(6,8)=4.8 Hz); 6.15 (d, 1H, H-7, J(7,8)=10.3 Hz); 6.92 (s, 1H, H-2)

[0294] Alkylation of N-demethylbromogalanthamine (4): (R7,=/, Z=N)

Substance No.	group R6	Name	empirical formula MG
49	83	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-hexyl-6H- benxofuro[3a,3,2,-ef][2]- benzazepin-6ol	C22H30BrNO3 [436.40]
52	84	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11- (cyanomethyl)-6H-benzofuro- [3a,3,2,-ef][2]benzazepin-6-ol	C18H19BrN2O3 [391.27]
51	85	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-6-hydroxy-3-methoxy- 6H-benzofuro[3a,3,2-ef][2]- benzazepin-11-essigsäure- ethylester	C20H24BrNO5 [438.33]
53	86	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-6-hydroxy-3-methoxy- 6H-benzofuro[3a,3,2-ef][2]- benzazepin-11-essigsäureamid	C18H21BrN2O4 [409.29]
55	87	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-[2-(1H- isoindol-1,3(2H)-dion-2-yl)- ethyl]-6H-benzofurol[3a,3,2,- ef][2]benzazepin-6-ol	C26H25BrN2O5 [525.41]
50	88	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-[2- propinyl)-6H-benzofuro[3a,3,2- ef][2]- benzazepin-6-ol	C19H20BrNO3 [390.28]
54	89	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-[2- morpholinoethyl)-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-ol	C22H22BrNOhd 3 l [465.39]
56	90	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-(3- dimethylaminopropyl)-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-ol	C21H29BrN2O3 [437.39]
58	91	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-(3- piperidinopropyl)-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-ol	C24H33BrN2O5 [477.45]
57	92	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-(2- pyrrolidinoethyl)-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-ol	C22H29BrN2O3 [449.40]
42	93	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-(2-propen- yl)-6H-benzofuro[3a,3,2-ef][2]- benzazepin-6-ol	C19H22BrNO3 [392.30]
45	94	(6R)-4a,5,9,10,11,12-Hexahydro- 1-brom-3-methoxy-11-(phenyl- methyl)-6H-benzofuro[3a,3,2- ef][2]-benzazepin-6-ol	C23H24BrNO3 [442.36]

[0295] Method: A mixture of 500 mg (1.42 mmoles) of N-demethylbromogalanthamine (4), 391 mg 2.84 mmoles) of potassium carbonate and 272 mg (1.70 mmoles) of potassium iodide are ground in a mortar and triturated. Subsequently, the mixture in 20 mL of absolute acetone is mixed with 1.2 equivalents of a halide reagent and refluxed. After the reaction is completed (TLC), the reaction mixture is evaporated and the residue taken up in 100 mL of 2N hydrochloric acid, washed with ethyl acetate, made alkaline with concentrated aqueous ammonia and either the precipitate is filtered off with suction or the solution is extracted three times with 30 mL of ethyl acetate. The precipitate is dried at 50° C./50 mbar, the combined organic phases are washed once with saturated, aqueous sodium chloride solution, dried (sodium sulfate, activated charcoal), filtered and evaporated. The product is purified further by column chromatography (15 g of silica gel; solvent: chloroform→chloroform:MeOH=9:1).

[0296] TLC: chloroform:MeOH=9:1

Substance		Reaction		Melting
No.	Reagents	Times	Yield	Point
49	1-Bromhexane	24 h	67% oily	—
			substance
52	Chloroacetonitrile	2 h	89% color-	150-153° C.
			less crystals
51	Ethyl	1 h	quant. oily	—
	chloroacetate		substance
53	Chloroacetamide	1 h	90% color-	164-165° C.
			less crystals
55	N-(2-Bromethyl)-	48 h	quant. yel-	88-89° C.
	phthalimide		low crystals
50	Propargylbromide	4 h	57% oily	—
			substance
54	N-(2-Chlorethyl)-	24 h	98% oily	—
	morpholin * HCl		substance
56	(3-Chlorpropyl)-	72 h	46% oily	—
	dimethylamin * HCl		substance
58	N-(3-Chlorpropyl)-	30 h	85% oily	—
	piperidin * HCl		substance
57	N-(2-Chlorethyl)-	24 h	25% oily	—
	pyrrolidin * HCl		substance
42	Allylbromid		80%
45	Benzylbromid		92%

[0297]

1 H-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
H-
Atom	49	52	51	53	55
H-9	1.55(d)	1.75 (ddd)	1.60 (ddd)	1.65 (ddd)	1.40 (dd)
H-9′	2.05 (ddd)	2.05 (ddd)	1.90-2.05	1.90-2.10	1.90-2.30
H-5	2.00 (dd)	2.55-2.75	1.90-2.05	1.90-2.10	1.90-2.30
H-5′	2.65 (dd)	2.55-2.75	2.20-2.30	2.70 (ddd)	2.65 (ddd)
H-10	3.05 (dd)	3.10 (ddd)	2.65 (dd)	3.10 (ddd)	2.95 (dd)
H-10′	3.30 (ddd)	3.25 (ddd)	3.15 (dd)	3.40 (ddd)	3.25 (dd)
NCH2	2.50 (dd)	3.65 (s)	3.40 (s)	3.20 (d)	1.90-2.30
OCH3	3.85 (s)	3.85 (s)	3.80 (s)	3.85 (s)	3.75 (s)
H-12	3.95 (d)	4.00 (d)	4.12 (d)	4.00 (d)	3.60 (d)
H-12′	4.40 (d)	4.30 (d)	4.45 (d)	4.40 (d)	4.35 (d)
H-6	4.15 (dd)	4.15 (b)	4.16 (s)	4.15 (b)	4.05 (b)
H-4a	4.60 (b)	4.60 (b)	4.60 (b)	4.60 (b)	4.50 (b)
H-8	6.00, 6.10 (AB)	6.05 (b)	6.00 (dd)	6.05 (s)	6.10 (d)
H-7	6.00, 6.10 (AB)	6.05 (b)	6.10 (dd)	6.05 (s)	5.75 (dd)
H-2	6.90 (s)	6.90 (s)	6.90 (s)	6.90 (s)	7.00 (s)
additional	0.90 (t, 3H, ω-	—	1.30 (t, 3H,	5.70, 6.95 (2*	1.90-2.30 (m,
H	CH3); 120-		OCH2CH3);	b, 2* 1H	6H, H-5/9′/
	1.35 (m 6H		4.20 (q, 2H.	replace D2O.	NCH2—CH2):
	γ/δ/ε-CH2);		OCH2CH3)	NH2)	7.80-7.90 (m,
	1.45-1.60 (m,				4H, Ph)
	2H, β-CH2)
J(A,B)	(12, 12′) = 16.9	(9, 9′) = 14.0	(7, 8) = 10.3	(5, 5′) = 16.2	(6, 8) = 4.5
(Hz)		(10, 10′) = 13.6	(9, 9′) = 13.4	(9, 9′) = 16.9	(7, 8) = 9.8
		(12, 12′) = 15.8	(12, 12′) = 16.1	(10, 10′) = 11.6
				(12, 12′) = 16.0

[0298]

H-
Atom	50	54	56	55	57
H-9	1.70 (ddd)	1.48-1.63	1.55 (ddd)	1.45 (d)	1.55 (ddd)
H-9′	1.95-2.01	1.92-2.13	2.00 (ddd)	1.95 (dd)	1.80-2.10
H-5	1.95-2.01	1.92-2.13	1.65-1.83	1.95 (dd)	1.80-2.10
H-5′	2.63 (dd)	2.45-2.95	2.65 (dd)	2.58 (dd)	2.60-2.85
H-10	3.10-3.35	3.12 (ddd)	3.10 (ddd)	3.00 (ddd)	3.15 (ddd)
H-10′	3.10-3.35	3.35 (ddd)	3.30 (ddd)	3.20 (ddd)	3.35 (ddd)
NCH2	3.48 (d)	2.45-2.95	2.50 (dt)	2.45 (t)	2.60-2.85
OCH3	3.83 (s)	3.82 (s)	3.85 (s)	3.80 (s)	3.80 (s)
H-12	3.98 (d)	4.01 (d)	3.95 (d)	3.95 (d)	4.00 (d)
H-12′	4.36 (d)	4.39 (d)	4.45 (d)	4.35 (d)	4.40 (d)
H-6	4.18 (b)	4.12 (dd)	4.15 (dd)	4.13 (b)	4.13 (dd)
H-4a	4.59 (b)	4.59 (b)	4.60 (b)	4.58 (b)	4.60 (d)
H-8	6.02 (dd)	6.02 (dd)	6.10 (d)	6.08 (d)	6.00, 6.08 (AB)
H-7	6.08 (dd)	6.09 (d)	6.00 (dd)	5.98 (dd)	6.00, 6.08 (AB)
H-2	6.92 (s)	6.90 (s)	6.85 (s)	6.90 (s)	6.90 (s)
additional	2.29 (t, 1H,	2.45-2.95 (m,	1.65-1.85 (m,	1.35 (ddd, 2H,	1.80-2.10 (m,
H	≡CH, J(≡CH, NCH2) =	9H, H-	3H, H-5, N—	Pip-4); 1.55	6H, H-5/9′/Pyr-
	2.4 Hz)	5′/NCH2CH2/m	CH2—CH2);	(ddd, 4H, Pip-	3/4); 2.60-
		orph-2/6); 3.72	2.18, 2.22 (2*	3/5); 1.68 (ddd,	2.85 (m, 9H, H-
		(t, 4H, morph-	s, 6H,	2H, N—CH2—	5′/NCH2CH2/
		3/5, J(mo3/5, mo2/6) =	N(CH3)2); 2.30	CH2); 2.28 (dd,	Pyr-2/5)
		4.8 Hz	(t, 2H, CH2-	2H, CH2—NPip);
			NMe2)	2.32 (dd, 2H,). -
J(A,B)	(≡CH, NCH2) =	(mo3/5, mo2/6) =	(12, 12′) = 16.0	(NCH2CH2) =	(9, 9′) = 13.4
(Hz)	2.4	4.8		7.3	(10, 10′) = 12.5
	(6, 8) = 4.5	(10, 10′) = 13.4		(5, 5′) = 10.6	(12, 12′) = 16.0
	(6, 7) = 1.3	(12, 12′) = 16.1		(6, 8) = 4.6
	(7, 8) = 10.0			(7, 8) = 10.4
	(9, 9′) = 13.4			(10, 10′) = 14.3
	(12, 12′) = 15.4			(12, 12′) = 16.0

[0299]

	H-
	Atom	42	45
	H-9	1.58 (ddd)	1.55 (ddd)
	H-9′	1.90-2.10	2.01 (ddd)
	H-5	1.90-2.10	2.60-2.73
	H-5′	2.15-2.25	2.60-2.73
	H-10	2.65 (ddd)	3.50 (ddd)
	H-10′	3.02-3.29	3.27 (ddd)
	NCH2	3.18 (d)	3.70 (s)
	OCH3	3.82 (s)	3.82 (s)
	H-12	3.92 (d)	4.00 (d)
	H-12′	4.35 (d)	4.34 (d)
	H-6	4.11 (b)	4.14 (b)
	H-4a	4.59 (b)	4.64 (b)
	H-8	6.00 (dd)	6.02 (ddd)
	H-7	6.09 (d)	6.14 (dd)
	H-2	6.90 (s)	6.90 (s)
	additional	5.16 (dd, 2H,	7.22-7.35 (m,
	H	═CH2); 5.88	5H, Ph)
		(ddt, 1H, ═CH)
	J(A,B)	(NCH2, ═CH)	(6, 8) = 4.8
	(Hz)	= 7.0	(7, 8) = 10.3
		(9, 9′) = 14.0	(9, 9′) = 13.2
		(12, 12′) = 16.5	(10, 10′) = 13.0
			(12, 12′) = 15.9

[0300]

13 C-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
C-Atom	49	52	51	53	54
C-5	29.7 (t)	29.2 (t)	29.3 (t)	29.4 (t)	(t)
C-9	33.1 (t)	34.5 (t)	33.6 (t)	33.9 (t)	(t)
C-8a	48.8 (s)	48.3 (s)	48.4 (s)	48.3 (s)	(s)
C-10	51.5 (t)	51.6 (t)	51.2 (t)	51.8 (t)	(t)
NCH2	52.5 (t)	53.7 (t)	53.4 (t)	56.3 (t)	(t)
OCH3	55.9 (q)	56.1 (q)	55.7 (q)	55.8 (q)	(q)
C-12	56.0 (t)	57.2 (t)	56.3 (t)	56.9 (t)	(t)
C-6	61.7 (d)	61.6 (d)	61.3 (d)	61.3 (d)	(d)
C-4a	88.6 (d)	88.6 (d)	88.3 (d)	88.3 (d)	(d)
C-1	114.3 (s)	113.9 (s)	113.9 (s)	114.2 (s)	(s)
C-8	115.7 (d)	115.8 (d)	115.4 (d)	115.5 (d)	(d)
C-2	126.7 (d)	126.3 (d)	126.2 (d)	125.6 (d)	(d)
C-7	127.8 (d)	128.5 (d)	127.8 (d)	128.4 (d)	(d)
C-12a	128.1 (s)	130.2 (s)	127.3 (s)	126.5 (s)	(s)
C-12b	134.1 (s)	134.0 (s)	133.7 (s)	133.7 (s)	(s)
C-3a	144.0 (s)	144.5 (s)	143.9 (s)	144.2 (s)	(s)
C-3	145.3 (s)	145.6 (s)	145.2 (s)	145.2 (s)	(s)
additional C	13.9 (q, ω-	115.5 (s, CN)	13.8 (q,	173 (s, CO)
	CH3);		OCH2CH3);
	22.5 (t, ε-CH2);		60.3 (t,
	26.9, 27.4 (2*		OCH2CH3);
	t, γ/δ-CH2);		170.3 (s, CO)
	31.6 (t, β-CH2)

[0301]

C-Atom	56	58	57
C-5	29.4 (t)	29.4 (t)	29.6 (t)	(t)	(t)
C-9	32.8 (t)	32.8 (t)	33.2 (t)	(t)	(t)
C-8a	48.6 (s)	48.5 (s)	48.9 (s)	(s)	(s)
C-10	51.5 (t)	51.1 (t)	52.5 (t)	(t)	(t)
NCH2	55.6 (t)	55.8 (t)	54.7 (t)	(t)	(t)
OCH3	55.7 (q)	55.7 (q)	56.0 (q)	(q)	(q)
C-12	57.3 (t)	56.8 (t)	55.6 (t)	(t)	(t)
C-6	61.4 (d)	61.4 (d)	61.7 (d)	(d)	(d)
C-4a	83.3 (d)	88.3 (d)	88.7 (d)	(d)	(d)
C-1	114.0 (s)	113.9 (s)	114.3 (s)	(s)	(s)
C-8	115.4 (d)	115.4 (d)	115.7 (d)	(d)	(d)
C-2	126.6 (d)	126.4 (d)	126.3 (d)	(d)	(d)
C-7	127.6 (d)	127.6 (d)	128.1 (d)	(d)	(d)
C-12a	127.7 (s)	127.8 (s)	127.6 (s)	(s)	(s)
C-12b	133.8 (s)	133.8 (s)	134.1 (s)	(s)	(s)
C-3a	143.8 (s)	143.7 (s)	144.3 (s)	(s)	(s)
C-3	145.1 (s)	145.1 (s)	145.5 (s)	(s)	(s)
additional	25.3 (t, N—	23.9, 24.2 (2*	23.2 (t, Pyr-
C	CH2CH2); 45.0	t, NCH2CH2,	3/4); 53.7 (t,
	(q, N(CH3)2);	Pip-4); 25.3 (t,	C H2—NPyr); 54.4
	53.4 (t,	Pip-3/5); 50.2	(t, Pyr-2/5)
	C H2-NMe2)	(t, CH2—NPip);
		54.1 (t,)

[0302] Acylation of N-Demethylbromogalanthamine (4): (R7=I, Z=N)

Substance NO.	Group: R6	Name	Empirical formula, MG
59	95	(6R)-4a,5,9,10,11,12-Hexahydro- 1-bromo-3-methoxy-11-acetyl-6H- benzofuro[3z,3,2- ef][2]benzazepin-6-ol	C18H20BrNO4 [394.27]
60	96	Ethyl(6R)-4a,5,9,10,11,12-Hexahydro- 1-bromo-6-hydroxy-3-methoxy- 6H-benzofuro[3a,3,2- ef][2]benzazepin-11-α-oxo- acetate	C20H22BrNO6 [452.31]
62	97	Methyl(6R)-4a,5,9,10,11,12-Hexahydro- 1-bromo-6-hydroxy-3-methoxy- 6H-benzofuro[3a,3,2- ef][2]benzazepin-11-α-oxo- carboxylate	C18H22BrNO5 [410.27]
61	98	(6R)-4a,5,9,10,11,12-Hexahydro- 1-bromo-6-hydroxy-3-methoxy- 6H-benzofuro[3a,3,2- ef][2]benzazepin-11-γ-oxo- butyrate	C21H24BrNO6 [466.34]
64	99	(6R)-4a,5,9,10.11,12-Hexahydro- 1-bromo-3-methoxy-11-(1- oxohexadecyl)-6H-benzofuro- [3a,3,2-ef][2]benzazein-6-ol	C32H48BrNO4 [590.65]

[0303] A solution of 500 mg (1.42 mmoles) of N-demethylbromogalanthamine (4) and 156 mg (1.56 mmoles) of triethylamine in 20 mL of absolute acetone is treated with 0.9 equivalents of acid halide and refluxed. After the reaction is completed (TLC), the reaction mixture is evaporated, the residue taken up in 100 mL of 2N hydrochloric acid, washed with a little acetate, made alkaline with concentrated aqueous ammonia and either the precipitate is filtered off with suction or the solution extracted three times with 30 mL of ethyl acetate. The precipitate is dried at 50° C./50 mbar, the combined organic phases are washed with saturated, aqueous sodium chloride solution, dried (sodium sulfate, activated charcoal), filtered and evaporated. The product is purified further by column chromatography (7 g of silica gel; solvent: chloroform:MeOH=9:1)

[0304] TLC chloroform:MeOH=9:1

Substance		Reaction		Melting
No.	Reagents	Time	Yield	Point
59	Acetyl chloride	3 h	84% yellow	76-78° C.
			crystals
60	Acid chloride of	1.5 h	54% yellow	66-69° C.
	ethyl oxalate		crystals
62	Metyl	1 h	93% color-	158-159° C.
	chloroformate		less crys-
			tals
61	Acid chloride of	1.5 h	35% color-	53-57° C.
	methyl succinate		less crys-
			tals
64	Palmityl chloride		99%

[0305]

1 H-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
H-
Atom	59	60	62*	61	64
H-9	1.79 (ddd)	1.92 (ddd)	1.60-1.90	1.75 (ddd)	1.74 (ddd)
H-9′	1.90 (ddd)	2.03 (ddd)	1.60-1.90	1.94 (ddd)	2.24 (ddd)
H-5	1.97 (dd)	2.25 (ddd)	2.05 (dd)	2.06 (dd)	1.95 (ddd)
H-5′	2.05 (dd)	2.68 (dd)	2.40 (dd)	2.45-2.70	2.45 (ddd)
H-10	2.67 (ddd)	3.38 (ddd)	3.40 (dd)	2.98 (ddd)	2.68 (ddd)
H-10′	3.20 (ddd)	3.63 (ddd)	3.90 (dd)	3.22 (ddd)	3.20 (ddd)
OCH3	3.8 (s)	3.85 (s)	3.75 (s)	3.80 (s)	3.84 (s)
H-12	4.33 (d)	4.25-4.45	4.20 (d)	4.33 (d)	4.31 (d)
H-12′	5.13 (d)	5.20 (d, Conf A),	5.20 (d)	5.22 (d)	5.18 (d)
		5.75 (d, Conf B)
H-6	4.13 (b)	4.10 (b)	4.10 (b)	4.12 (dd)	4.13 (dd)
H-4a	4.60 (b)	4.45 (b, conf A),	4.50 (b)	4.60 (dd)	4.60 (b)
		4.60 (b, Conf B)
H-8	6.03 (dd)	5.90-6.15	5.85 (dd)	6.02 (dd)	6.05 (dd)
H-7	5.90 (d)	5.90-6.15	6.00 (dd)	5.96 (d)	5.91 (d)
H-2	6.94 (s)	6.90 (s)	6.85 (s)	6.90 (s)	6.90 (s)
additional	2.11 (s, 3H,	4.25-4.45 (m,	3.55 (s, 3H,	2.45-2.70 (m,	0.89 (t, ω-CH3);
H	OCH3); 2.30 (b,	3H, H-12ConfA/B/	COOH3)	5H, H-5/	1.18-1.40 (m,
	1H simulates	COOCH2);		COCH2CH2);	22H, CH2(4-14));
	D2O, OH)	1.10 (t, 3H,		3.65 (s, 3H,	1.45-1.67 (m,
		OCH2CH3)		COOCH3)	4H, CH22-3));
					2.18 (t, 2H,
					COCH2)

[0306] 13 C-NMR (DMSO-d6; δ (ppm)): 59: 29.6 (q, COCH3); 30.3, 36.1 (t, C-5Conformer A/B); 37.9, 43.4 (t, C-9Conformer A/B); 46.5, 48.8 (t, C-10Conformer A/B); 48.4 (s, C-8a); 51.4, 55.8 (t, C-12Conformer A/B); 55.9 (q, OCH3); 86.3, 86.5 (d, C-4aConformer A/B); 115.4 (d, C-8); 126.3, 126.4 (d, C-2Conformer A/B); 127.7 (s, C-1); 128.5 (s, C-12a); 128.7 (d, C-7); 133.2, 133.4 (s, C-12bConformer A/B); 144.0, 144.3 (s, C-11aConformer A/B); 146.6, 147.0 (s, C-3Conformer A/B); 168.9, 169.2 (s, COConformer A/B)

[0307] 62: 30.2, 30.5 (t, C-5Conformer A/B); 36.5, 37.3 (t, C-9Conformer A/B); 44.7, 45.0 (t, C-10Conformer A/B); 48.4 (s, C-8a); 49.7, 50.4 (t, C-12Conformer A/B); 52.2 (q, COOCH3); 55.7 (q OCH3); 59.7 (d, C-6); 86.8 (d, C-4a); 111.8, 112.1 (s, C-1Conformer A/B); 115.2 (d, C-8); 125.8, 126.0 (d, C-2Conformer A/B); 128.1, 128.3 (s, C-12aConformer A/B); 128.5, 128.6 (d, C-7Conformer A/B); 133.1 (s, C-12b); 143.9 (s, C-3a); 146.4 (s, C-3); 155.2 (s, CO)

[0308] Rac. N-Boc-Bromogalanthamine (63):

[0309] To a solution of 1.0 g (2.84 mmoles) of rac. N-demethylbromogalanthamine (4) and 620 mg (2.84 mmoles) of di-t-butyl pyrocarbonate in 50 mL of absolute tetrahydrofuran, 286 mg (2.84 mmoles) of triethylamine arc added dropwise and refluxed. After 15 minutes, the tetrahydrofuran is evaporated off in a rotary evaporator and the residue taken up in 50 mL of ethyl acetate. The organic phase is washed once with 2N hydrochloric acid, a saturated aqueous sodium hydrogen carbonate solution and a saturated, aqueous, sodium chloride solution, dried (sodium sulfate) and evaporated, colorless crystals of 63 being obtained quantitatively.

[0310] TLC: EtOAc:MeOH=4:1

[0311] 1 H-NMR (CDCl3; δ (ppm)): 1.45 (s, 9H, t-Bu); 1.60 (dd, 1H, H-9); 2.05 (dd, 1H, H-9′); 2.30 (ddd, 1H, H-5); 2.65 (ddd, 1H, H-5′); 3.30 (ddd; 1H, H-10); 3.85 (s, 3H, OCH3); 4.05-4.30 (r, 2H, H-6/10′); 4.10 (d, 1H, H-12, J(12,12′)=15.1 Hz); 4.60 (dd, 1H, H4a); 5.25 (d, 1H, H-12′, J(12,12′)=15.1 Hz); 5.90 (d, 1H, H-8, J(7,8)=8.9 Hz); 6.00 (dd, 1H, H-7, J(7,8)=8.9 Hz); 6.90 (s, 1H, H-2)

[0312] Modification of N-Substituted Galanthamine Derivatives

Substance No	Educt. No.	R6 Educt	R6 Product	R1	Method
66	61	100	101	Br	A
67	60	102	103	Br	A
71	51	104	105	Br	A
68	51	106	107	Br	B
69	51	108	109	H	C
68	60	110	111	Br	D
70	55	112	113	Br	E
65	59	114	115	H	F

[0313] Method A:

[0314] An approximately 10% solution of the educt in 2N potassium hydroxide is refluxed. After 1 to 3 hours, the reaction is completed and the reaction solution is added dropwise to 2N hydrochloric acid and, in the case of amino acids, neutralized with concentrated aqueous ammonia. The aqueous phase is extracted subsequently three times with chloroform:ethanol 9:1. The organic phase is evaporated and the crude product optionally purified by column chromatography (15 g silica gel G60, solvent: MeOH/methylene chloride mixtures).

[0315] TLC: chloroform:MeOH=9:1

Substance No	Name	SF, MG	Yield	Melting Point
66	(6R)-4a,5,9,10,11,12-	C20H22BrNO6	89% yellow	107-109°	C.
	Hexahydro-1-brom-6-	[452.31]	crystals
	hydroxy-3-methoxy-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-11-γ-oxo-
	butyric acid
67	(6R)-4a,5,9,10,11,12-	C13H18BrNO6	22% red	Decomposition
	Hexahydro-1-brom-6-	[424.26]	crystals	>120°	C.
	hydroxy-3-methoxy-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-11-α-oxo-
	acetic acid
71	(6R)-4a,5,9,10,11,12-	C18H20BrNO5	quant. colorless	Decomposition
	Hexahydro-1-brom-6-	[410.27]	crystals	>200°	C.
	hydroxy-3-methoxy-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-11-acetic acid

[0316] Method B:

[0317] All approximately 5% solution of the educt in absolute tetrahydrofuran is treated at 0° C. with two equivalents of a 10% solution of lithium aluminum hydride in tetroiydrofuran. After 1.5 hours, the reaction solution is hydrolyzed with a 1:1 solution of water in tetrahydrofuran, the tetrahydrofuran is evaporated off in a rotary evaporator and the residue dissolved in 2N hydrochloric acid. After the addition of 2.5 equivalents of tartaric acid, the solution is made alkaline with concentrated aqueous ammonia and extracted with ethyl acetate. The combined organic phases are washed once with a saturated, aqueous sodium chloride solution, dried (sodium sulfate), filtered and evaporated. The crude product is purified by column chromatography (15 g silica gel G60, solvent: chloroform:MeOH=9:1).

[0318] TLC: chloroform:MeOH=9:1

Sub-
stance				Melting
No	Name	SF, MG	Yield	Point
68	(6R)-4a,5,9,10,11,12-	C18H22BrNO4	quanti-	—
	Hexahydro-1-brom-3-	[396.29]	tative
	methoxy-11-(2-		oily sub-
	hydroxyethyl)-6H-		stance
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol

[0319] Method C:

[0320] An approximately 5% solution of the theoretical yield educt in absolute tetrahydrofliran is treated at 0° C. with four equivalents of a 10% solution of lithium aluminum hydride in tetrahydrofuran After 15 minutes, heat to reflux. After 24 hours, the reaction solution is hydrolyzed with a 1:1 solution of water in tetrahydrofuran, the tetrahydrofuran is evaporated off hi a rotary evaporator, and the residue is dissolved in 2N hydrochloric acid. After adding five equivalents of tartaric acid, it is made basic with concentrated hydrous ammonia and extracted with ethyl acetate. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated. The crude product is cleaned by column chromatography (15 g silica gel G60, solvent:

[0321] CHCl3: MeOH=9:1).

[0322] DC: CHCl3: MeOH=9:1

Substance
No.	Name	SF, MG	yield	Smp.
69	(6R)-4a,5,9,10,11,12-	C18H23NO4	81% oily	—
	Hexahydro-3-methoxy-11-	[317.39]	Substance
	(2-hydroxyethyl)-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol

[0323] Method D:

[0324] 0.84 mL 10% lithium aluminum hydride solution (2.20 mmol) is heated in tetrahydrofuran to reflux. 100 mg (0.22 mmol) mt7 are then dissolved in absolute tetrahydrofuran and added dropwise to the boiling solution. After 15 minutes, the reaction mixture is cooled to 0° C. and hydrolyzed with water: tetrahydrofuran 1:1. Subsequently, the tetrahydrofuran is evaporated off in a rotary evaporator, the residue is absorbed in 50 mL 2 N hydrochloric acid, mixed with 0.80 g tartaric acid, made basic with concentrated aqueous ammonia and extracted three times with 30 mL ethyl acetate each. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, whereby 100 mg crude product are obtained, which is cleaned by column chromatography (15 g silica gel, solvent: CHCl3: MeOH=9:1).

[0325] DC: CHCl3: MeOH=9:1

Sub-
stance				Melting
No.	Name	SF, MG	Yield	point
68	(6R-4a,5,9,10,11,12-	C18H22BrNO4	42% oily	—
	Hexahydro-1-brom-3-	[396.29]	Substance
	methoxy-11-(2-hydroxy-
	ethyl)-6H-benzofuro-
	[3a,3,2-ef][2]benzazepin-
	6-ol

[0326] Method E:

[0327] 170 mg (0.32 mmol) st80 and 80 mg (1.60 mmol) are heated to reflux in 10 ml absolute ethanol After 30 minutes the reaction mixture is cooled and after 1 hour the resulting sediment is evaporated in a rotary evaporator. The sediment is washed once with ethanol and the ethanolic phase is subsequently spun in. The crude product is cleaned by column chromatography (15 g silica gel, solvent: CHCl3: MeOH=9:1).

[0328] DC: CHCl3: MeOH=9:1

Sub-
stance				Melt.
No.	Name	SF, MG	Yield	pt.
70	(6R)-4a,5,9,10,11,12-	C18H23BrN2O3	70% color-	116-
	Hexahydro-1-brom-3-	[395.30]	less crys-	117° C.
	methoxy-11-(2-amino-		tals
	ethyl)-6H-benzofuro-
	[3a,3,2-
	ef][2]benzazepin-
	6-ol

[0329] Method F:

[0330] To 2 mL 10% lithium aluminum hydride solution in tetrahydrofuran (5.26 mmol), 50 mg (0.381 mmol)st62 in 1.5 mL absolute tetrahydrofuran are added dropwise. Subsequently, the mixture is heated to reflux for 90 minutes. It is then hydrolyzed at 0° C. with water: tetrahydrofuran=1:1 and the mixture is spun to dry. The residue is then absorbed in 2 N hydrochloric acid, mixed with 1.2 g tartaric acid and made basic with concentrated aqueous ammonia. Following that, it is extracted three times with 40 mL ethyl acetate each, the combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated. The crude product is cleaned by column chromatography (15 g silica gel, solvent: CHCl3: MeOH=9:1).

[0331] DC: CHCl3: MeOH=9:1

Substance				Melt.
No.	Name	SF, MG	Yield	pt.
65	(6R-4a,5,9,10,11,12-	C18H22NO3	76% oily	—
	Hexahydro-1-brom-3-	[300.38]	substance
	methoxy-11-ethyl-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol

[0332]

1 H-NMR (CDDl3 [* in DMSO-d6]; δ (ppm)):
H-
Atom	66	67	71	68	69
H-9	1.70-2.10	1.85-2.35	1.80-2.10	1.60 (ddd)	1.60 (ddd)
H-9′	1.70-2.10	1.85-2.35	1.80-2.10	1.90-2.10	1.90-2.10
H-5	2.40-2.80	1.85-2.35	2.25 (dd)	1.90-2.10	1.90-2.10
H-5′	2.90 (ddd)	3.30-3.70	3.00 (ddd)	2.60-2.75	2.60-2.75
H-10	3.25 (ddd)	3.30-3.70	3.20-3.50	3.10 (ddd)	3.15 (ddd)
H-10′	3.40 (d), 3.60	3.30-3.70	3.20-3.50	3.45 (ddd)	3.40 (ddd)
	(dd)
NCH2	—	—	3.15 (s)	2.60-2.75	2.60-2.75
OCH3	3.80 (s)	3.80 (s)	3.75 (s)	3.80 (s)	3.82 (s)
H-12	4.35 (d)	3.30-3.70	3.60 (d)	4.00 (d)	3.78 (d)
H-12′	5.20 (d)	4.10 (d)	4.20 (d)	4.40 (d)	4.17 (d)
H-6	4.15 (b)	4.60 (b)	4.08 (b)	4.12 (dd)	4.12 (dd)
H-4a	4.60 (b)	4.90 (b)	4.50 (b)	4.60 (b)	4.60 (b)
H-8	5.90 (d)	6.15 (d)	6.10 (d)	5.95-6.10	6.10 (d)
H-7	6.05 (dd)	5.90 (dd)	5.30 (dd)	5.95-6.10	6.00 (dd)
H-2	6.90 (s)	7.15 (s)	6.95 (s)	6.90 (s)	6.55-6.70
additional	2.40-2.80 (m,	9.15 (b, 1H	—	2.45 (b, 2H	2.50 (b, 2H
H	5H, H-5/	replaces D2O		replace D2O,	replace D2O,
	COCH2—	COOH)		OH); 3.55 (t,	OH); 3.55 (t,
	CH2CO)			2H, CH2OH)	2H, CH2OH);
					6.55-6.70 (m,
					2H, H-1/2)
J(A,B)	(4a, 7) = 4.0	—	—	(10, 10′) = 14.3	(9, 9′) = 14.1
(Hz)	(6, 8) = 7.1			(12, 12′) = 16.1	(10, 10′) = 15.1
	(7, 8) = 10.4				(12, 12′) = 15.6
	(12, 12′) = 17.0

[0333]

H-
Atom       70
H-9        1.80-2.15
H-9′       1.80-2.15
H-5        1.80-2.15
H-5′       2.40-2.70
H-10       3.20 (ddd)
H-10′      3.60 (ddd)
NCH2       2.40-2.70
OCH3       3.80 (s)
H-12       3.95 (d)
H-12′      4.50 (d)
H-6        4.10 (dd)
H-4a       4.55 (b)
H-8        5.95-6.05
H-7        5.95-6.05
H-2        6.90 (s)
additional 2.40-2.70 (m,
H          5H, H-5′/
           NCH2CH2)
J(A,B)     —
(Hz)

[0334]

13 C-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
C-Atom	66*	68	69	70	65
C-5	28.8, 30.2 (t)	29.4 (t)	29.7 (t)	(t)	(t)
C-9	36.0, 37.8 (t)	33.2 (t)	33.2 (t)	(t)	(t)
C-8a	48.4 (s)	48.6 (s)	48.2 (s)	(s)	(s)
C-10	43.6, 45.4 (t)	51.7 (t)	51.7 (t)	(t)	(t)
NCH2	—	54.9 (t)	52.0 (t)	(t)	(t)
OCH3	55.8 (q)	55.7 (q)	55.6 (q)	(q)	(q)
C-12	48.8, 50.4 (t)	57.6 (t)	57.6 (t)	(t)	(t)
C-6	59.3 (d)	61.4 (d)	61.7 (d)	(d)	(d)
C-4a	86.4, 86.6 (d)	88.3 (d)	88.4 (d)	(d)	(d)
C-1	111.0, 112.1 (s)	114.3 (s)	121.8 (d)
C-8	115.3 (d)	115.4 (d)	110.9 (d)	(d)	(d)
C-2	128.4, 128.6	121.7 (d)	126.4 (d)	(d)	(d)
	(d)
C-7	126.3 (d)	127.9 (d)	127.5 (d)	(d)	(d)
C-12a	127.4 (s)	127.3 (s)	128.8 (s)	(s)	(s)
C-12b	133.2, 133.4 (s)	133.7 (s)	132.8 (s)	(s)	(s)
C-3a	143.8, 144.2 (s)	144.0 (s)	144.0 (s)	(s)	(s)
C-3	146.5, 146.9 (s)	145.2 (s)	145.7 (s)	(s)	(s)
additional C	27.4 (t, NCO—	56.6 (t,	56.7 (t,
	C H2); 27.9 (t,	CH2OH)	CH2OH)
	C H2COOH);
	170.0, 170.4 (s,
	CON); 173.6,
	173.8 (s, COO)

[0335] General operating rule for splitting off bromine with zinc and calcium chloride:

Substance
No.	Educt	R4	R5	R6	SF, MG
112	4	OH	H	116	C16H19NO3[273.22]
73	52	OH	H	117	C18H20N2O3[312.37]
74	54	OH	H	118	C22H30N2O4[386.50]
43	42	OH	H	119	C19H23NO3[313.40]
46	45	OH	H	120	C23H25NO3[363.46]
72	64	OH	H	121	C32H49NO4[511.75]
47	44	═O	122	C23H23NO3[361.44]

[0336] A solution of 500 mg educt and 1.0 g calcium chloride in 50 mL 50% ethanol is treated with 2.0 g freshly activated zinc powder and heated to reflux. Subsequently, the excess zinc is filtered off, washed with methanol and the residual solution is rotated. The residue is absorbed in 100 mL 1 N hydrochloric acid, made basic with concentrated aqueous ammonia and extracted with three times 50 mL ethyl acetate. The combined organic phases are washed once with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated. The crude product is cleaned by column chromatography (15 g silica gel, solvent: CHCl3: MeOH=9:1).

Sub-		Reac-
stance		tion
No.	Name	time	Yield	Melt. pt.
112	(6R)-4a,5,9,10,11,12-	1.5 h	93% color-	236-240° C.
	Hexahydro-1-brom-3-		less crys-
	methoxy-6H-		tals
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol
73	(6R)-4a,5,9,10,11,12-	3 h	55% color-	68-70° C.
	Hexahydro-3-methoxy-		less crys-
	11-(cyanomethyl)-6H-		tals
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol
74	(6R)-4a,5,9,10,11,12-	3 h	80%
	Hexahydro-3-methoxy-
	11-(2-morpholinoethyl)-
	6H-benzofuro[3a,3,2-
	ef][2]benzazepin-6-ol
72	(6R)-4a,5,9,10,11,12-	3 h	84% color-
	Hexahydro-3-methoxy-		less crys-
	11-(1-oxohexadecyl)-6H-		tals
	benzofuro[3a,3,2-
	ef][2]benzazepin-6-ol
43	(6R)-4a,5,9,10,11,12-	3 h	96%
	Hexahydro-3-methoxy-
	11-(2-propenyl)-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol
46	(6R-4a,5,9,10,11,12-	3 h	52%
	Hexahydro-3-methoxy-
	11-(phenylmethyl)-6H-
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol
47	(6R-4a,5,9,10,11,12-	3.5 h	quantitative	159-162° C.
	Hexahydro-3-methoxy-		orange crys-
	11-(phenylmethyl)-6H-		tals
	benzofuro[3a,3,2-ef][2]-
	benzazepin-6-ol

[0337]

1 H-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
H-
Atom	112	73	74	43	46
H-9	1.70 (dd)	1.71 (ddd)	1.50 (ddd)	1.54 (ddd)	1.54 (ddd)
H-9′	1.70 (dd)	1.92-2.10	1.93-2.12	1.92-2.12	1.94-2.20
H-5	2.05 (ddd)	1.92-2.10	1.93-2.12	1.92-2.12	1.94-2.20
H-5′	2.30 (dd)	2.70 (ddd)	2.66 (ddd)	2.60-2.75	2.71 (ddd)
H-10	3.00-3.20	3.12 (ddd)	3.16 (ddd)	2.60-2.75	3.17 (ddd)
H-10′	3.00-3.20	3.38 (ddd)	3.39 (ddd)	3.25 (ddd)	3.40 (ddd)
NCH2	—	3.58 (s)	2.40-2.66	3.16 (d)	3.68 (s)
OCH3	3.70 (s)	3.85 (s)	3.80 (s)	3.85 (s)	3.87 (s)
H-12	3.75 (d)	3.78 (d)	3.81 (d)	3.80 (d)	3.80 (d)
H-12′	3.90 (d)	4.17 (d)	4.17 (d)	4.08 (d)	4.13 (d9
H-6	4.10 (b)	4.14 (b)	4.12 (b)	4.13 (b)	4.15 (dd)
H-4a	4.45 (dd)	4.60 (b)	4.58 (b)	4.61 (b)	4.66 (b)
H-5	5.80 (dd)	6.00-6.04	5.98 (dd)	6.00 (ddd)	6.01 (ddd)
H-7	6.05 (dd)	6.00-6.04	6.08 (d)	6.10 (dd)	6.12 (dd)
H-1	6.65 (AB)	6.61-6.70	6.62 (AB)	6.64 (AB)	6.66 (AB)
H-2	6.55 (AB)	6.61-6.70	6.58 (AB)	6.57 (AB)	6.50 (AB)
additional	—	—	2.40-2.66 (m,	5.12 (dd, 2H,	7.20-7.39 (m,
H			8H, NCH2CH2/	═CH2); 5.82	5H, Ph)
			Morph-2/6);	(ddt, 1H, ═CH)
			3.68 (t, Morph-
			3/5)
J(A,B)	(5, 5′) = 13.4	(9, 9′) = 12.7	—	(NCH2, ═CH) =	(1, 2) = 8.2
(Hz)	(7, 8) = 9.8	(10, 10′) = 14.0		6.6	(5, 5′) = 15.6
	(12, 12′) = 15.1	(12, 12′) = 15.9		(6, 7) = 1.2	(6, 8) = 4.8
				(6, 8) = 4.5	(7, 8) = 10.2
				(7, 8) = 10.3	(9, 9′) = 13.6
				(12, 12′) = 15.4	(10, 10′) = 14.1
					(12, 12′) = 15.3

[0338]

H-
Atom	72	47
H-9	1.78 (ddd)	1.81 (ddd)
H-9′	2.18 (ddd)	2.16-2.48
H-5	1.95 (ddd)	2.16-2.48
H-5′	2.42 (ddd)	2.77 (dd)
H-10	2.68 (ddd)	3.10-3.42
H-10′	3.18 (ddd)	3.10-3.42
NCH2	—	3.71 (s)
OCH3	3.82 (s)	3.86 (s)
H-12	3.93 (d, KonfA)	3.81 (d)
	4.41 (d, KonfB)
H-12′	4.68 (d, KonfA)	4.13 (d)
	5.28 (d, konfB)
H-6	4.14 (b)	—
H-4a	4.57 (b)	4.79 (b)
H-8	5.93-6.08	7.01 (dd)
H-7	5.93-6.08	6.06 (d)
H-1	6.64-6.70,	6.70 (d)
	6.81-6.88
H-2	6.64-6.70,	6.52 (d)
	6.81-6.88
additional	0.89 (t, ω-CH3); 1.18-1.38 (m,	7.21-7.46 (m, 5H, Ph)
H	22H, CH2(4-14)); 1.48-1.65 (m,
	4H, CH2(2-3)); 2.06 (t, 2H,
	COCH2)
J(A,B)	—	(1, 2) = 8.1
(Hz)		(4a, 5/5′) = 3.8
		(4a, 8) = 1.9
		(5, 5′) = 17.8,
		(7, 8) = 10.4,
		(12, 12′) = 15.6

[0339]

13 C-NMR (CDCl3 [* in DMSO-d6]; δ (ppm)):
	C-Atom	112
	C-5	30.6 (t)	(t)	(t)	(t)	(t)
	C-9	33.5 (t)	(t)	(t)	(t)	(t)
	C-8a	48.1 (s)	(s)	(s)	(s)	(s)
	C-10	46.3 (t)	(t)	(t)	(t)	(t)
	NCH2	—
	OCH3	55.5 (q)	(q)	(q)	(q)	(q)
	C-12	52.8 (t)	(t)	(t)	(t)	(t)
	C-6	59.7 (d)	(d)	(d)	(d)	(d)
	C-4a	86.7 (d)	(d)	(d)	(d)	(d)
	C-8	111.1 (d)	(d)	(d)	(d)	(d)
	C-7	119.5 (d)	(d)	(d)	(d)	(d)
	C-2	121.0 (d)	(d)	(d)	(d)	(d)
	C-1	127.4 (d)	(d)	(d)	(d)	(d)
	C-12a	132.9 (s)	(s)	(s)	(s)	(s)
	C-12b	133.8 (s)	(s)	(s)	(s)	(s)
	C-3a	142.9 (s)	(s)	(s)	(s)	(s)
	C-3	146.3 (s)	(s)	(s)	(s)	(s)
	additional C	—

[0340]

	C-Atom	47
	C-5	(t)	(t)	(t)	(t)	32.5 (t)
	C-9	(t)	(t)	(t)	(t)	36.9 (t)
	C-8a	(s)	(s)	(s)	(s)	48.8 (s)
	C-10	(t)	(t)	(t)	(t)	51.5 (t)
	NCH2					56.4 (s)
	OCH3	(q)	(q)	(c)	(q)	55.6 (q)
	C-6	(d)	(d)	(d)	(d)	194.0 (s)
	C-4a	(d)	(d)	(d)	(d)	87.6 (d)
	C-8	(d)	(d)	(d)	(d)	111.5 (d)
	C-7	(d)	(d)	(d)	(d)	126.8 (d)
	C-2	(d)	(d)	(d)	(d)	144.1 (d)
	C-1	(d)	(d)	(d)	(d)	121.7 (d)
	C-12a	(s)	(s)	(s)	(s)	129.3 (s)
	C-12b	(s)	(s)	(s)	(s)	138.2 (s)
	C-3a	(s)	(s)	(s)	(s)	143.6 (s)
	C-3	(s)	(s)	(s)	(s)	146.6 (s)
	additional C					126.7 (d, Ph-4);
						127.8 (s, Ph-1);
						127.9 (d, Ph-
						2/6); 128.5 (d,
						Ph-3/5)

[0341] O-TOS-Narwedine oxime (75):

[0342] A suspension of 1.05 g (3.51 mmol) narwedine oxime (76,77) in 20 mL absolute pyridine[ep] is treated with 1.33 g (7.03 mmol) p-toluolsulfonic acid chloride and stirred for 20 hours at room temperature. The reaction mixture is subsequently poured over 100 mL water and extracted with 50 mL ethyl acetate. The combined organic phases are washed once with a saturated aqueous sodium chloride solution, dried (Na2SO4, active carbon), filtered and evaporated. The crude product is cleaned by column chromatography (50 g silica gel, solvent CHCl3=>CHCl2: MeOH=9:1), whereby 1.27 g (80% of the theoretical yield.) yellow crystals with a melting point of 78-79° C. are obtained at 75.

[0343] DC: CHCl3: MeOH=9:1

[0344] 1 H-NMR (CDCl3; δ (ppm)): 1.55-1.65, 1.80-1.95 (2* m, 2H H-9/9′ConformerA/B; 2.05-2.25 (m, 1H, H-50ConformerA/B); 2.40, 2.43 (2* s, 6H NCH3, Ph—CH3); 2.50-2.70 (m, 1H, H-5′Conformer A/B); 2.95-3.25 (m, 1H-10Conformer A/B);3.60 3.85 (m, 2H, H-10′/12Conformer A/B); 4.00-4.25 (m, 1H-12′Conformer A/B); 4.55 (b, 1H, H-4aConformer A/B); 6.15, 7.10 (2* d, 1H, H-8Conformer A/B); 6.40, 7.65 (2* d, 1H, H-7Conformer A/B); 6.50-6.70 (m, 2H-1/2Conformer A/B); 7.20-7.35 (m, 2H, Ph-3/5Conformer A/B); 7.75-7.90 (m, 2H, Ph-2/6Conformer A/B)

[0345] 13 C-NMR (DMSO-d6; δ (ppm)): 21.1 (q, Ph—CH3); 23.9 (t, C-5); 31.6 (t, C-9); 40.6 (q, NCH3); 48.7 (s, C-8a); 52.9 (t, C-10); 55.5 (q, OCH3); 59.2 (t, C-12); 84.3 (d, C-4a); 111.9 (d, C-2); 118.6, 121.6 (d, C-8Conformer A/B); 125.5, 128.0 (d, C-7Conformer A/B); 128.4 (d, Ph-2/6); 130.0 (d, Ph-3/5); 131.8 (s, C-12a); 136.1 (s, Ph-1); 137.5 (s, C-12b); 138.7 (d, C-1); 143.1 (s, C-3a); 145.4 (s, C-3); 145.8 (s, Ph-4); 159.8 (s, C-6)

[0346] rac., (−)- and (+)-)-methylnarwedine oxime (78, 79):

[0347] A solution of 300 mg (1.05 mmol) narwedine in 10 mL ethanol is treated with 88 mg (1.05 mmol) O-methylhydroxylamine and 53 mg (0.53 mmol) potassium bicarbonate and heated for 4 hours to reflux. Subsequently, the reaction mixture is evaporated, the residue is absorbed in 50 mL 1 N hydrochloric acid, made basic with concentrated aqueous ammonia and extracted 3 times with 30 mL ethyl acetate each. The combined organic phases are washed once with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, whereby quantitatively viscous substances (with a rotation of aD20[CHCl3]=aD20[CHCl3]=−152° for 78 and/or aD20[CHCl3]=+108° for 79) are obtained at 78/79.

[0348] DC: CHCl3: MeOH=9:1

[0349] 1 H-NMR (CDCl3; δ (ppm)): 1.70 (ddd, 1H, H-9); 2.20 (ddd, 1H, H-9′); 2.30-2.45 (m, 1H, H-5); 2.40 (s, 3H, NCH3); 2.70 (ddd, 1H, H-5′); 3.00-3.35 (m, 2H, H-10/10′); 3.65, 3.70, 4.00, 4.10 (4* d, 2H, H-12Conformer A/B/12′Conformer A/B); 3.80 (s, 3H, OCH3); 3.85, 3.90 (2* s, 3H, N—OCH3 Conformer A/B); 4.60 (b, 1H, H-4a); 6.15, 6.20, 6.75 (s, d, d, 2H, H-7/8Conformer A/B); 6.55-6.70 (m, 2H, H-1/2)

[0350] Narwedine Imine (80):

[0351] A solution of 100 ng (0.35 mmol) narwedine in 10 mL 7 N methanolic ammonia is heated to reflux in a glass autoclave for 10 hours at 100° C. Subsequently, the excess methanol is evaporated off in a rotary evaporator, whereby quantitatively colorless crystals with a melting point of 105-110° C. are obtained at 80.

[0352] DC: CHCl3: MeOH=9:1

[0353] 1 H-NMR (CDCl3 [formation of narwedine and decomposition products during measuring] δ (ppm)): 1.80 (ddd, 1H-9); 2.00-2.35 (m, 2H, H-5/9′); 2.45 (s, 3H, NCH3); 2.80 (ddd, 1H, H-5′); 3.00-3.35 (m, 2H, H-10/10′); 3.70 (d, 1H, H-12); 3.80 (s, 2H, OCH3); 4.05 (d, 1H, H-12′); 4.65 (b, 1H, H4a); 6.15 (d, 1H, H-8); 6.45 (d, 1H, H-7); 6.55-6.70 (m, 2H, H-1/2)

[0354] rac., (+)- or (−)-narwedine oxime (76, 77):

[0355] 1.0 g (3.51 mmol) narwedine, 266 mg (3.86 mmol) hydroxylamine hydrochloride and 193 mg (1.93 mmol) potassium bicarbonate are heated to reflux in 30 mL 96% ethanol. The reaction mixture is spun in after 3 hours, the residue is absorbed in 50 mL 2 N hydrochloric acid and the product is precipitated with concentrated aqueous ammonia. After overnight crystallizing a first fraction of 0.81 g (81% of the theoretical yield.) is obtained. After extraction of the theoretical yield mother fluid with three times 30 mL ethyl acetate a second fraction is obtained, whereby quantitatively colorless crystals with a melting point of 170-171° C. are obtained at 76, 77.

	ap20[CHCl3	ee after CE*
	(−)-Narwedine oxime (77)	−79°	20%
	(+)-Narwedine oxime (76)	+126°	12%

[0356] 1 H-NMR (CDCl3; d(ppm)): 1.70 (dd, 1H, H-9, J(9,9′)=13.4 Hz); 2.20 (ddd, 1H, H-9′, J(9,9′)=13.4 Hz); 2.40 (s, 3H, NCH3); 2.45 (dd, 1H, H-5, J(5,5′)=16.9 Hz); 3.10 (m, 2H, H-5′, J(5,5′)=16.9 Hz); 3.30 (ddd, 1H, H-10, J(10,10)′=14.2 Hz); 3.75 (d, 1H, H-12, J(12,12′)=16.0 Hz); 3.80 (s, 3H, OCH3); 3.85 (dd, 1H, H-10′, J(10,10′)=14.2 Hz); 4.10 (d, 1H, H-12′, J(12,12′)=16.0 Hz); 4.65 (b, 1H, H-4a); 6.20 (b, 2H, H-7/8); 6.55-6.65 (m, 2H, H-1/2)

[0357] 13 C-NMR (DMSO-d6; d(ppm)): 22.3 (t, C-5); 32.8 (t, C-9); 41.2 (q, NCH3); 48.7 (s, C-8a); 53.1 (t, C-10); 55.5 (q, OCH3); 59.5 (t, C-12); 85.9 (d, C4a); 111.6 (d, C-8); 121.1 (d, C-2); 122.5 (d, C-7); 129.5 (s, C-12a); 130.7 (d, C-1); 132.5 (s, C-12b); 143.1 (s, C-3a); 145.8 (s, C-3); 150.1 (s, C-6)

[0358] Conversion of narwedine with hydrazines and hydrazides:

Substance			Empirical
No.	Rest R4R5	Name	formula, MG
81	123	4a,5,9,10,11,12-Hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef][2]benzazepin-6-on 2- Methylhydrazone formic acid-2-	C18H23N3O2 [313.40]
84	124	{4a,5,9,10,11,12-hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef3][2]- benzazepin-6-yliden}hydrazide	C18H21N3O3 [327.39]
83	125	4a,5,9,10,11,12-Hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-on 2-(2- Hydroxyethyl)hydrazone	C19H25N3O3 [343.43]
86	126	4-methylbenzenesulfonic acid-2- {4a,5,9,10,11,12-hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef][2]- benzepin-6-yliden}hydrazide pyrocarbonic acid-t-butylester-2-	C24H27N3O4S [453.56]
85	127	{4a,5,9,10,11,12-hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef][2]- benzazepin-6-yliden}hydrazide pyrocarbonic acid-2-	C22H29N3O4 [399.49]
89	128	{4a,5,9,10,11,12-hexahydro-3- methoxy-11-methyl-6H- beazofuro[3a,3,2-ef3][2]- beazazepin-6-yliden}hydrazide	C19H21N3O5 [371.40]
82	129	4a,5,9,10,11,12-Hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef][2]- benzazepin-6-on 2,2- Dimethylhydrazone	C19H25N3O2 [327.43]
88	130	2-{4a,5,9,10,11,12-Hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-ef3][2]- benzazepin-6-yliden}- hydrazincarboximidamide	C18H23N5O2 [341.42]
90	131	4a,5,9,10,11,12-Hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2- ef][2]benzazepin-6-on Hydrazone carbamic acid-2-	C17H21N3O2 [299.38]
87	132	{4a,5,9,10,11,12-hexahydro-3- methoxy-11-methyl-6H- benzofuro[3a,3,2-eq][2]- benzazepin-6-yliden}hydrazide	C18H22N4O3 [342.40]

[0359] Method: A solution of 500 mg (1.75 mmol) narwedine and 1.1 to 1.2 equivalents N-alkylhydrazone or acid hydrazide, respectively, in 10 mL ethanol is treated with 0.25 equivalents (43 mg, 0.44 mmol) concentrated sulfonic acid and heated to reflux. The reaction mixture is then evaporated, the residue is absorbed in 50 mL 1 N hydrochloric acid, made basic with concentrated aqueous ammonia and the resulting precipitate is evaporated hi a rotary evaporator or the aqueous phase is extracted three times with 30 mL each of ethyl acetate The precipitate is dried at 50° C./50 mbar, the combined organic phases are washed once with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated.

[0360] DC: CHCl3: MeOH=9:1

Substance		Reaction		Melting
No.	Reagent equ. H2SO4	time	Yield	point
81	Methylhydrazin; 0.25	4 h	76% yellow crystals	97-99° C.
84	Ameisensäurehydrazide;	48 h	63% yellow crystals	145-148° C.
	0.0
83	2-Hydrazinoethanol;	30 h	61% yellow crystals	100-105° C.
	0.0
86	p-Toluolsulfon-	6 h	97% colorless	210-212° C.
	säurehydrazid; 0.25		crystals
85	t-Butylcarbazat; 0.25	4 h	quantitative color-	Tranformation at
			less crystals	155-160° C.,
				decomposition >200° C.
89	Oxalsäureethylester-	30 h	64% yellow crystals	189-191° C.
	hydrazide; 0.25
82	N,N-Dimethylhydrazin;	12 h	78% oily substance	—
	0.25
88	Aminoguanidin	20 h	quantitative yellow	112-113° C.
	Hydrogencarbonat; 0.0		crystals
90	10 Äqu.	2 h	94% oily substance	—
	Hydrazinhydrat; 2.5
87	Semicarbazid	4 h	88% colorless	decomposition ab
	Hydrochlorid;		crystals (Lit. [ ] % d.	225° C. (Lit. [ ] Zers.
	0.5 Äqu. KHCO3		Th.)	at ° C.)

[0361]

1 H-NMNR (CDCl3 [* in DMSO-d6]; δ (ppm)):
H
Atom	81	84	83	86	85
H-9	1.75 (ddd)	1.70 (dd)	1.70 (ddd)	1.80 (ddd)	1.70 (ddd)
H-9′	2.10-2.35	2.20 (dd)	2.20 (ddd)	2.15 (ddd)	2.20 (ddd)
H-5	2.10-2.35	2.50 (dd)	2.35 (dd)	2.50 (b)	2.35-2.45
H-5′	2.90-3.30	3.00-3.30	2.70 (ddd)	3.15 (dd)	2.75 (ddd)
H-10	2.90-3.30	3.00-3.30	3.00-3.40	3.25-3.45	3.00-3.35
H-10′	2.90-3.30	3.40 (dd)	3.00-3.40	3.25-3.45	3.00-3.35
NCH3	2.45 (s)	2.45 (s)	6.65 (s)	2.40 (s)	2.40 (s)
OCH3	3.85 (s)	3.85 (s)	3.80 (s)	4.10 (s)	3.80 (s)
H-12	3.70 (d)	3.70 (d)	3.68 (d)	3.58 (d)	3.70 (d)
H-12′	4.10 (d)	4.05 (d)	4.07 (d)	4.30 (d)	4.10 (d)
H-4a	4.70 (b)	4.70 (b)	4.70 (b)	4.60 (b)	4.15 (b)
H-8	5.96 (d)	6.10-6.40	6.16 (d)	6.00 (d)	6.35 (d)
H-7	6.98 (dd)	6.10-6.40	5.98 (dd)	6.32 (d)	6.20 (dd)
H-1/2	6.48-6.68	6.50-6.70	6.55-6.65	6.55-6.78	6.55-6.70
additional	2.50 (s, 3H, N—	8.65 (b 1H,	3.00-3.40 (m,	3.70 (s, 3H,	1.50 (s, 9H,
H	NCH3);	CHO); 10.40	6H, H-10/10′,	PhCH3); 7.36	C(CH3)3); 7.70
	more conform B:	(b, 1H, replaces	N—CH2—CH2—O);	(d, 2H, Ph-3/5);	(b, 1H replaces
	5.80-6.06 (m,	D2O, NH)	more conform B:	7.76(d, 2H,	D2O, NH)
	2H, H-7/8)		4.07, 4.14 (2*	Ph-2/6)
			d, 2H, H-
			12/12′); 6.38
			(dd, 1H, H-8);
			6.70 (dd, 1H,
			H-7)
J(A,B)	(7, 8) = 10.2	(12, 12′) = 14.2	(7, 8) = 14.4;	(7, 8) = 10.2;	(7, 8) = 8.9;
(Hz)			(12, 12′) = 15.2;	(12, 12′) = 16.0	(12, 12′) = 13.4
			(12B, 12B′) = 7.2

[0362]

H-
Atom	89	82	88	90	87
H-9	1.85 (ddd)	1.80 (ddd)	1.65 (dd)	1.70 (dd)	1.65 (dd)
H-9′	2.30 (ddd)	2.20 (ddd)	2.00-2.40	2.15-2.40	2.20 (ddd)
H-5	2.75 (dd)	2.35 2.50	2.00-2.40	2.15-2.40	2.50 (dd)
H-5′	3.05-3.35	2.75 (ddd)	2.75 (ddd)	2.65 (ddd)	2.70 (dd)
H-10	3.05-3.35	3.00-3.35	2.95 (dd)	3.05 (ddd)	2.95-3.20
H-10′	3.05-3.35	3.00-3.35	3.10-3.30	3.25 (ddd)	2.95-3.20
NCH3	2.45 (s)	2.55 (s)	2.25 (s)	2.40 (s)	2.35 (s)
OCH3	3.85 (s)	3.85 (s)	3.70 (s)	3.80 (s)	3.75 (s)
H-12	3.75 (d)	3.70 (d)	3.58 (d)	3.70 (d)	3.55-3.70
H-12′	4.10 (d)	4.10 (d)	4.06 (d)	4.08 (d)	3.95-4.15
H-4a	4.70 (b)	4.65 (b)	4.58 (b)	4.20 (b)	4.60 (b)
H-8	6.05 (d)	6.15-6.40	6.00-6.15	6.05 (d)	5.95 (d)
H-7	6.95 (d)	6.15-6.40	6.00-6.15	6.20 (d)	6.90 (d)
H-1/2	6.60-6.75	6.55-6.75	6.55, 6.68 (AB)	6.55-6.70	6.50-6.65
additional		2.40, 2.50 (2*s,	5.55-5.90 (b,	5.30 (b, 2H	more conform B:
H		6H, N(CH3)2)	4H replace	replace D2O,	3.55-3.70 (m,
			D2O, NH);	NH2);	1H, H-12A/B);
			more conform B:	more conform B:	3.95-4.15 (m,
			6.95 (d, 1H,	6.35 (d, 1H, H-	1H, H-12′A/B);
			H-7)	8); 6.95 (d, 1H,	4.65 (b, 1H, H-
				H-7)	4aB), 6.10 (s,
					1H, H-8B); 6.50-
					6.65 (m, 3H,
					H-1/2/7B)
J(A,B)	(5, 5′) = 17.8;	(12, 12′) = 16.0	(1, 2) = 8.2;	(12, 12′) = 15.1	(5, 5′) = 16.9
(Hz)	(7, 8) = 10.5;		(12, 12′) = 15.3		(7A, 8A) = 9.8
	(9, 9′ = 13.7;
	(12, 12′) = 15.4

[0363] 13 C-NMR (CDCl3 [* in DMSO-d6]; d(ppm)) 86: 24.8 (t, C-5); 31.7 (t, C-9); 41.2 (q, NCH3); 53.0 (t, C-10); 47.8 (s, C-8a); 55.5 (q, OCH3); 58.8 (t, C-12); 85.5 (d, C-4a); 111.9 (d, C-8); 122.3 (d, C-2); 125.0 (d, C-7); 125.2 (s, Ph-1); 127.5 (d, Ph-2/6); 129.5 (d, Ph-3/5); 132.2 (d, C-1); 132.3 (s, C-12a), 136.2 (s, C-12b); 143.3 (s, C-3a); 143.8 (s, Ph-4); 145.8 (s, C-3); 149.8 (s, C-6)

[0364] 85 *: 24.5 (t, C-5); 28.1 (q, C(CH3)3); 32.4 (t, C-9); 41.2 (q, NCH3); 48.2 (s, C-8a); 53.1 (t, C-10); 55.5 (q, OCH3); 59.3 (t, C-12); 79.4 (s, C(CH3)3); 86.0 (d, C-4a); 111.7 (d, C-8); 121.5 (d, C-2); 125.5 (d, C-7); 131.2 (d, C-1); 128.5 (s, C-12a); 132.5 (s, C-12b); 143.3 (s, C-3a); 145.6 (s, C-3); 145.8 (s, C-6); 153.0 (s, CO)

[0365] (−)-Alkyl Galanthamine Halogenide

	Empirical
Product	Formula	Designation	R
	C22H31BrNO3[401.95]	(−)-Pentylgalanthaminium-bromide	133
91	C21H30ClN2O3[358.49]	(−)-Dimethylaminoethylgalanthaminium-chloride	134
92	C23H32ClN2O3[419.97]	(−)-2-Pyrrolidin-N-ethylgalanthaminium-chloride	135
93	C23H32ClN2O4[435.97]	(−)-2-Morpholin-N-ethylgalanthaminium-chloride	136
94	C24H34ClN2O3[434.0]	(−)-2-Piperidin-N-ethylgalanthaminium-chloride	137
95	C25H36ClN2O3[448.03]	(−)-3-Piperidin-N-propylgalanthaminium-chloride	138
	C20H26BrNO3[407.33]	(−)-Allylgalanthaminium-bromide	139

[0366] General Procedure:

[0367] 800 mg (2.78 mmol) (−)-galanthamine and 3.84 g (27.8 mmol) potassium carbonate were presented in 100 mL acetone. After adding 1.5 equivalents of halogenide and a spatula tip of potassium iodide, the reaction mixture was stirred under reflux for 24-36 hours. The potassium carbonate was then evaporated in a rotary evaporator and the filtrate was evaporated. The oily residue was finally cleaned by column chromatography in a mixture of trichloromethane and anionically methanol (9:1).

[0368] DC: CHCl3: MeOH (10% NH3)=9:1

Product	Yield [% d. Th.]	*αD(25° C., c = 1)	Melting Point [° C.]
	71	−83.7°	130-132
91	72	−46.6°	148-150
92	43	−62.5°	120-125
93	94	−52.3°	225-229
94	48	−70.8°	136-140
95	70	−71.5°	126-131
	41	−74.3°	188-192

[0369]

1 H-NMR [DMSO-d6; δ (ppm)]:
Proton		91	92	93
Ha-5	2.10; m	2.10; m	2.00; m	2,00; m
H-1	2.20; m	2.30; m	2.50; m	2.20; m
Hb-5	2.30: m	2.45; m	2.55; m	2.50; m
CH3—N—	3.50; s	2.85; s	2.95; s	3.00; s
Hb-1	2.70; br.d	2.50; m	2.65; m	2.90; m
Hb-6	4.25; m	3.10; m	3.10; m	3.50; m
Ha-6	4.30; m	3.25; m	3.80; m	3.60; m
Hb-8	4.90; br.d	4.50; br.d	4.15; br.d	4.15; br.d
CH3—O—	3.85; s	3.80; s	3.75; s	3.80; s
Ha-8	5.25; br.d	5.05; br.d	5.15; br.d	5.10; br.d
H-12a	4.70; t	4.70; t	4.65; t	4.70; t
H-2	4.20; m	4.10; m	3.90; m	3.90; m
H-3	6.15; dd	5.95; dd	6.00; dd	6.05; dd
H-4	6.45; d	6.20; d	6.15; d	6.20; d
H-9	6.70; d	6.80; d	6.70; d	6.75; d
H-10	7.10; d	6.90; d	6.85; d	6.85; d
diverse H	0.95 (t, 3H, CH3—)	3.35 (s, 6H, 2 ×	1.75 (m, 4H, 2 × CH2*)	2.50-2.60 (m, 6H,
	1.35-1.50 (m, 4H,	CH3—N—)	2.60 (m, 2H, —CH2—N—)	2 × —CH2—N—*)
	2 × —CH2—)	3.40 (t, 2H, —CH2—N—)	3.10 (m, 4H, 2 ×	2.55 (m, 2H, —CH2—N—)
	1.70 (m, 2H, —CH2—)	3.90 (t, 2H, —N—CH2—)	—CH2—N—*)	3.0-3.20 (m, 6H, 3 ×
	2.0 (t, 2H, —N—CH2—)		3.80 (m, 2H, —N—CH2—)	—O—CH2—*)
			*)Pyrrolidin	*)Morpholin
Proton	94	95
Ha-5	2.00; m	1.45; m	2.13; m
Ha-1	2.20; m	2.00; m	2.25; m
Hb-5	2.50; m	2.15; m	2.50; m
CH3—N—	3.15; s	2.85; s	2.75; s
Hb-1	2.65; br.d	2.45; br.d	2.50; m
Hb-6	3.00; m	3.30; m	3.35; m
Ha-6	3.10; m	3.60; m	3.35; m
Hb-8	5.15; br.d	4.45; br.d	4.50; m
CH3—O—	3.85: s	3.80; s	3.75; s
Ha-8	5.40; br.d	5.05; br.d	5.05; br.d
H-12a	4.65; t	4.65; t	4.65; t
H-2	4.15; m	4.10: m	4.15; m
H-3	6.15; dd	5.95; dd	5.90; dd
H-4	6.40; d	6.20; d	6.20; d
H-9	6.70; d	6.75; d	6.85; d
H-10	7.05; d	6.85; d	6.90; d
diverse H	1.40-1.60 (m, 6H, 3 × —CH2—*)	1.50-1.65 (m. 6H, 3 × —CH2—*)	4.35 (d. 2H, —N—CH2—)
	2.40 (m, 4H, 2 × —CH2—N—*)	2.50 (m, 2H, —CH2—CH2—CH2—)	5.70 (d, 2H, —CH═CH2)
	2.95 (m, 2H, —N—CH2—CH2—N—)	3.10-3.45 (m, 6H, 3 × —CH2—N—*)	6.30 (m, 1H, —CH═CH2)
	4.35 (m, 2H, —N—CH2—CH2—N—)	3.75 (t. 2H. —N—CH2—CH2—CH2—)
	*)Piperdin	*)Piperidin

[0370]

13 C-NMR [DMSO-d6; δ (ppm)]:
C-Atom		91	92	93
C-1	27.9; t	31.0; t	30.8	28.0; t
C-5	29.6; t	32.1; t	31.9	30.6; t
CH3—N—	46.2; q	44.5; q	43.6	52.8; q
C-4a	46.2; s	45.9; s	45.9	45.9; s
C-6	60.1; t	51.6; t	49.2	50.2; t
CH3—O	55.7; q	55.6; q	55.6	66.0; q
C-8	60.1; t	60.3; t	60.1	59.7; t
C-2	60.8; d	59.5; d	59.5	59.7; d
C-12a	88.0; d	86.5; d	86.6	86.8; d
C-3	112.0; d	121.1; d	112.0	111.8; d
C-4	124.9; d	123.8; d	123.9	123.8; d
C-9	130.0; d	125.2; d	125.1	124.8; d
C-10	132.3; d	130.1; d	{circumflex over ( )}129.8	130.0; d
C-8a	116.0; s	117.9; s	118.0	117.5; s
C-11b	132.3; s	132.7; s	132.6	132.5; s
C-11a	146.0; s	145.4; s	145.4	145.5; s
C-11	146.1; s	146.4; s	146.3	146.2; s
diverse C	13.5 (q, CH3—)	27.5 (q, CH3—N—)	23.1 (t, C-3* u. C-4*)	51.8 (t, —N—CH2—CH2—)
	21.9 (t, CH3—CH2)	29.5 (q, CH3—N—)	53.4 (t, C-2* u. C-5*)	55.4 (t, 2 × —CH2—N—*)
	21.9 (t, CH3—CH2—CH2—)	49.7 (t, —CH2—N—)	65.0 (t, —CH2—N—)	58.5 (t, —N—CH2—CH2—)
	22.3 (t, —N—CH2—CH2—)	64.9 (t, —N—CH2—)	65.9 (t, —N—CH2—)	60.1 (t, 2 ×—O—CH2—*)
	60.1 (t, —N—CH2—CH2—)		*) Pyrrolidine	*) Morpholine
	C-Atom	94	95
	C-1	25.9; t	30.8; t
	C-5	30.0; t	40.0; t
	CH3—N—	46.6; q	45.9; q
	C-4a	46.6; s	54.8; s
	C-6	53.8; t	55.6; t
	CH3—O—	56.2; q	53.6; q
	C-8	60.8; t	59.6; t
	C-2	61.4; d	59.9; t
	C-12a	88.5; d	86.7; d
	C-3	112.4; d	112.0; d
	C-4	123.4; d	123.9; d
	C-9	125.4; d	125.0; d
	C-10	129.8; d	125.0; d
	C-8a	117.6; s	130.0; s
	C-11b	133.0; s	132.5; s
	C-11a	146.1; s	145.4; s
	C-11	146.4; s	146.4; s
	diverse C	23.1 (t, C-4*)	19.3 (t, N—CH2—CH2—CH2—N—)
		23.9 (t, C-3* u. C-5*)	23.5 (t, C-4*)
		24.7 (t, —N—CH2—CH2—N—)	25.0 (t, C-3* u. C-5*)
		54.5 (t, C-2* u. C-6*)	53.6 (t, C-2* u. C-6*)
		60.8 (t, —N—CH2—CH2—N—)
		*) Piperidin	*) Piperidin

[0371] (+)-Alkyl Galanthamine Halogenide

	Empirical
Product	Formula	Name	R
96	C23H32ClN2O4	(−)-2-Morpholin-N-ethylgalanthaminium-chloride	140
97	C25H26ClN2O3	(−)-3-Piperidin-N-propylgalanthaminium-chloride	141

[0372] General Procedure

[0373] 800 mg (2.78 mmol) (−)-galanthamine and 3.84 g (27.8 mmol) potassium carbonate were presented in 100 mL acetone. After adding 1.5 equivalents of halogenide and a spatula tip of potassium iodide, the reaction mixture was stilled under reflux for 24-36 hours. The potassium carbonate was then evaporated in a rotary evaporator and the filtrate was evaporated. The oily residue was finally cleaned by column chromatography in a mixture of trichloromethane and ammoniacal methanol (9:1).

[0374] DC: CHCl3: MeOH (10% NH3)=9:1

Products	Yield [% d. Th.]	αD(25° C., c = 1)	Melting Point [° C.]
96	44	÷48.6°	185-190
97	65	÷64.0°	118-124

[0375] N-Propargyl-galanthamine Bromide (99)

[0376] IR (KBr): 3439 s br; 3213 s; 3014 w; 2915 s br; 2133 w; 1619 s; 1507 m; 1440 s; 1274 s; 1203 m; 1070 s; 1012 m; 951 m; 865 w; 791 s cm−1

[0377] 1 H-NMR (D2O) δ: 6.95 (m, 2H; 6.12 (m, 2H); 5.08 (d, 1H); 4,70 (m, 2H; 4.46 (m, 2H); 4.29 (m, 2H); 4.11 (m, 1H); 3.80 (s, 3H); 3.69 (m, 1H); 3.00 (s, 3H); 2.41 (m, 2H); 2.20 (m, 2H).

[0378] 13 C-NMR (D2O) δ: 148.1 (s); 147.9 (s); 134.5 (s); 130.2 (d); 127.7 (d); 127.0 (d); 119.4 (q); 114.7 (d); 89.6 (d); 85.0 (d); 72.6 (s); 67.5 (t); 63.3 (t); 62.4 (d); 61.0 (t); 58.1 (q); 48.1 (s); 46.3 (q); 33.5 (t); 31.3 (t).

[0379] N-Acetamido-galanthamine Bromide (100)

[0380] 1 H-NMR (D2O) δ: 6.95 (m, 2H); 6.13 (m, 2H); 5.18 (d, 1H); 4.70-4.28 (m, 7H; 3.83 (s, 3H); 3.08 (s, 3H); 2.50 (d, 1H); 2.39 (d, 1H); 2.18 (m, 2H).

[0381] 13 C-NMR D2O) δ: 168.7 (s); 148.2 (s); 148.0 (s); 134.7 (s); 130.2 (d); 128.2 (d); 127.2 (d); 119.5 (s); 114.8 (d); 89.7 (d); 68.3 (t); 64.0 (t); 62.5 (d); 59.6 (t); 58.2 (q); 48.2 (q); 33.5 (t); 31.3 (t); 18.9 (q).

[0382] (−)-Galanthamine-N-oxide (98):

[0383] 1.5 g (4.08 mmol) (−)-galanthamine hydrobromide are dissolved in 50 mL water, precipitated with concentrated aqueous ammonia and extracted with three times 25 mL trichloromethane. The organic phase is compressed to 30 to 50 mL and treated with 1.4 g (4.08 mmol) 50% metachloroperbenzoic acid. After 30 minutes, the reaction mixture is evaporated and placed on a pan column. The major part of the theoretical yield metachloroperbenzoic acid is then separated with trichloromethane, and the N-oxide is then washed out with trichloromethane:methanol=1:1. The further cleaning of the theoretical yield N-oxide is effected by means of MPLC (60 g SiO2, LM: CHCl3: MeOH=2:1), whereby quantitatively colorless crystals with a melting point of 80-85° C. and a rotation of aD26[MeOH]=−102.9° at 98.

[0384] DC: CHCl3: MeOH=8:2

[0385] 1 H-NMR (DMSO-d6; δ (ppm)): 1.75-1.95 (m, 1H, H-9); 2.00-2.40 (m, 3H, H-5/5′/9′); 2.95 (s, 3H, NCH3); 3.30-3.75 (m, 2H, H-10/10′); 3.75 (s, 3H, OCH3); 4.10 (b, 1H, H-12); 4.35 (d, 1H, H-12′); 4.60 (b, 1H, H-6); 4.95 (breites d, 1H, H-4a); 5.90 (dd, 1H, H-8); 6.15 (b, 1H, H-7); 6.75-6.90 (m, 2H, H-1/2)

[0386] 13 C-NMR (DMSO-d6; δ (ppm)): 31.2 (t, C-5); 34.3 (t, C-9); 45.6 (s, C-8a); 52.5 (q, NCH3); 55.5 (q, OCH3); 59.5 (d, C-6); 69.0 (t, C-10); 73.9 (t, C-12); 86.6 (d, C4a); 112.0 (d, C-8); 120.0 (s, C-12a); 122.9 (d, C-7); 125.1 (d, C-2); 130.3 (d, C-1), 132.0 (s, C-12b); 144.9 (s, C-3a); 146.5 (s, C-3)

[0387] (6R)-4a,5,9,10,11,12-hexahydro-1-bromo-3-methoxy-11-methyl-12-oxo-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol (102)

[0388] A suspension of 450 mg (1.19 mmol) 4a,5,9,10,11,12-hexahydro-1-bromo-3-methoxy-11-methyl-12-oxo-6H-benzofuro[3a,3,2-e]f[2]benza-zepin-6-on (101) in 10 mL absolute tetrahydrofuran is treated at 0° C. with 3.6 mL (3.6 mmol) 1 N L-Selectride solution in tetrahydrofuran. After 30 minutes, it is hydrolyzed with 5 mL water:tetrahydrofuran 1:1. The reaction mixture is then evaporated, the residue is absorbed in 80 mL 2N hydrochloric acid and stilled for 1 hour at room temperature. Subsequently, it is extracted three times with 40 mL each of ethyl acetate. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and condensed by evaporation, whereby a quantitative crude product is obtained, which is cleaned by column chromatography (15 g silica gel, flow agent: CHCl3: MeOH=9:1), whereby quantitative colorless crystals are obtained with a melting point of 188-189° C. at 102.

[0389] DC: CHCl3: MeOH=8:2

[0390] 1 H-NMR (CDCl3; δ (ppm)): 1.73 (ddd, 1H, H-9, J(9,9′)=15.1 Hz); 2.03 (ddd, 1H, H-9′, J(9,9′)=15.1 Hz); 2.27 (ddd, 1H, H-5, J(5,5′)=14.3 Hz); 2.64 (ddd, 1H, H-5′, J(5,5′)=14.3 Hz); 3.18 (s, 3H, NCH3); 3.19 (ddd, 1H, H-10, J(10,10′)=14.8 Hz); 3.75 (ddd, 1H, H-10′, J(10,10′)=14.8 Hz); 3.86 (s, 3H, OCH3); 4.10 (b, 1H, H-6); 4.69 (b, 1H, H-4a); 5.48 (d, 1H, H-8, J(7,8)=10.0 Hz); 5.88 (dd, 1H, H-7, J(7,8)=10.0 Hz); 7.10 (s, 1H, H-2)

[0391] 13 C-NMR (CDCl3; δ (ppm)): 29.8 (t, C-5); 34.1 (q, NCH3); 38.2 (t, C-9); 48.3 (s, C-8a); 48.8 (t, C-10); 56.3 (q, OCH3); 60.9 (d, C-6); 89.9 (d, C-4a); 113.8 (s, C-1); 118.0 (d, C-8); 123.3 (s, C-12a); 126.3 (d, C-7); 130.8 (d, C-2); 132.1 (s, C-12b); 144.8 (s, C-3); 146.2 (s, C-3a); 165.1 (s, C-12)

[0392] Manufacture of Products 105, 107

[0393] Method: A mixture of 500 mg (1.42 mmol) N-demethyl-bromo-galanthamine (4), 391 mg (2.84 mmol) potassium carbonate arid 272 mg (1.70 mmol) potassium iodide is thoroughly ground in a mortar. The mixture is then treated in 20 mL absolute acetone with 1.2 equivalents of halogenide reagent and heated to reflux. After complete conversion (DC), the reaction mixture is condensed by evaporation, the residue is absorbed in 100 mL 2 N hydrochloric acid, washed with ethyl acetate, made basic with concentrated aqueous ammonia and the precipitate is their evaporated in a rotary evaporator or extracted three times with 30 mL each of ethyl acetate. The precipitate is dried at 50° C./50 mbar, the combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4, active carbon), filtered fluid evaporated. Additional cleaning is effected by column chromatography (15 g silica gel, flow agent: CHCl3>>>CHCl3: MeOH=9:1). DC: CHCl3: MeOH=8:2

[0394] 105:

[0395] Educt: (4) and (136). Yield: 62.3% of the theoretical yield, colorless foam.

[0396] 1 H-NMR (CDCl3; δ (ppm)): 2.36-1.36 (m, 12 H); 2.62 (ddd, 1H); 2.89-3.35 (m, 7H); 3.60 (2H, m), 3.80 (s, 3H); 3.85 (d, 1H); 4.10 (dd, 1H); 4.29 (H, b), 4.48 (d, 1H); 4.56 (b, 1H), 5.90-6.05 (m, 2H:); 6.85-6.69 (4H, m), 7.23 (2H, m)

[0397] 107:

[0398] Educt: (4) and (137). Yield: 44.9% of the theoretical yield, colorless foam.

[0399] 1 H-NMR (CDCl3; δ (ppm)): 1.65-1.85 (4H, m), 2.20-1.90 (m, 6 H); 2.60-2.28 (2H, m) 2.62 (ddd, 1H); 2.89-3.35 (m, 5H); 3.60 (2H, m), 3.80 (s, 3H); 3.85 (d, 1H; 4.10 (dd, 1H); 4.20 (H, b), 4.48 (d, 1H); 4.56 (b, 1H), 5.90-6.05 (m, 2H); 6.65-6.30 (4H, m), 7.05-6.83 (2H, m)

[0400] Procedure for Product 109:

[0401] 1.25 g (139) are heated to reflux temperature in 10 mL thionyl chloride, the excess thionyl chloride is distilled off, the residue is absorbed in 40 mL water-free THF arid added dropwise to a solution of 2.0 g (4) in 20 mL THF and stirred for 1 hour at reflux temperature. The reaction mixture is evaporated and the crude product is purified by column chromatography (CHCl3/MeOH, 2-5%): 1.75 g (57% of the theoretical yield.) colorless foam (109).

[0402] 1 H-NMR (CDCl3; δ (ppm)): 1.65-1.85 (m, 4H), 1.98 (ddd, 1H); 2.25 (b, 2H); 2.67-2.58 (m, 3H); 2.75-2.71 (2H, m), 2.87 (H, dd), 3.05-3.35 (m, 5H); 3.55 (2H, m), 3.67-3.74 (2H, d), 3.80 (s, 3H); 3.85 (d, 1H); 4.10 (dd, 1H); 4.40 (d, 1H); 4.56 (b, 1H); 5.90-6.05 (m, 2H); 6.85 (s, H), 7.30 (5H, m)

[0403] Procedure for Product 108:

[0404] 1.0 g (144) are heated for 2 hours to reflux temperature in 10 mL thionyl chloride, the excess thionyl chloride is distilled off, the residue is absorbed in 20 mL water-free THF and added dropwise to a solution of 1.33 g (4) in 20 mL THF and stirred for 1 hour at room temperature. The reaction mixture is evaporated, absorbed in a NaHCO3 solution and extracted with ether (3×40 mL). The ether phase is evaporated and the crude product is purified by column chromatography (CHCl3/MeOH, 5%): 1.22 g (56% of the theoretical yield.) colorless foam (108).

[0405] 1 H-NMR (CDCl3; δ (ppm)): 1.63-1.80 (m, 4H), 1.98 (ddd, 1H); 2.20 (b, 2H); 2.61-2.48 (m, 3H); 2.69-2.74 (2H, m), 2.90 (H, dd), 3.02-3.45 (m, 3H); 3.59 (2H, m), 3.60-3.72 (2H, d), 3.87 (s, 3H); 3.95 (d, 1H); 4.22 (dd, 1H); 4.45 (d, 1H); 4.76 (b, 1H); 5.68-6.00 (m, 2H); 6.95 (s, 1H), 7.10-7.42 (5H, m)

[0406] “Maritidinon-Type” 4,4a-dihydro-7-bromo-9-methoxy-3-oxo (3H,6H) (5,10b) ethanophenanthridine-10-ol (113)

[0407] A solution of 4.70 g (13.4 mmol) N-demethyl-bromonarwedine (15) and 2.35 g calcium chloride are heated to reflux for 3.5 hours in 200 mL 70% ethanol. The reaction mixture is subsequently rotated, the residue is absorbed in 80 mL 1 N hydrochloric acid and the product is precipitated with concentrated aqueous ammonia. After overnight cooling (+4° C.) the precipitate is sucked off and dried at 50° C./ 50 mbar. The aqueous phase is extracted three times with ethyl acetate, the combined organic phases are washed once with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, whereby 4.37 g (93% of the theoretical yield.) colorless crystals of 113 with a melting point of 185-190° C. are obtained.

[0408] DC: EtOAc: MeOH=8:2

[0409] 1 H-NMR (DMSO-d6; δ (ppm)): 1.95 (ddd, 1H, H-11); 2.15 (ddd, 1H, H-11′); 2.30 (dd, 1H, H-4, J(4,4′)=16.0 Hz); 2.65 (dd, 1H, H-4′, J(4,4′)=16.0 Hz); 2.80 (ddd, 1H, H-12, J(17,12′)=15.1 Hz); 3.05 (ddd, 1H, H-12′, J(1,12′)=15.1 Hz); 3.30 (dd, 1H, H-4a); 3.55 (d, 1H, H-6, J(6,6′)=16.9 Hz); 3.75 (s, 3H, O—CH3); 3.90 (d, 1H, H-6′, J(6,6′)=16.9 Hz); 5.80 (d, 1H, H-2, J(1,2)=9.3 Hz); 7.00 (s, 1H, H-8); 7.90 (d, 1H, H-1, J(1,2)=9.3 Hz)

[0410] 13 C-NMR (DMSO-d6; δ (ppm)): 38.0 (t, C-11); 39.8 (t, C4); 42.8 (s, C-10b); 53.1 (t, C-12); 55.9 (t, C-6); 56.0 (q, OCH3); 64.1 (d, C-4a); 109.6 (s, C-7); 113.6 (d, C-2); 123.2 (s, C-6a); 126.6 (d, C-8); 129.1 (s, C-10a); 142.9 (s, C-10); 147.5 (s, C-9); 155.3 (d, C-1); 197.4 (s, C-3)

[0411] 35-4,4a-dihydro-7-bromo-9-methoxy-10-hydroxy (3H,6H) (5,10b) ethanophenanthridine-3-ol (114):

[0412] To a solution of 1.0 g (2.86 mmol) maritidinon-type (113) in 5 mL absolute tetrahydrofuran, 10 mL of a 1 N L-Selectrid-solution in tetrahydrofuran are added dropwise at 0° C.; it is then quickly heated to reflux. After 1.5 hours, hydrolyze at 0° C. with 10 mL tetrahydrofuran:water 1:1 and the tetrahydrofuran is spun off. The residue is absorbed in 80 mL 1 N hydrochloric acid, made basic with concentrated aqueous ammonia and extracted with ethyl acetate. The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, whereby quantitative yellow crystals of 114 with a melting point of 165-167° C. are obtained. DC: CHCl3 : MeOH=9:1.

[0413] 114 and 3R-2,3,4,4a-tetrahydro-7-bromo-9-methoxy-10-hydroxy (1H,6H) (5,10b) ethanophenanthridine-10-ol (116):

[0414] To a solution of 1.0 g (0.29 mmol) maritidinon-type (113) in 1 mL absolute tetrahydrofuran, 1 mL of a 1 N L-Selectrid-solution in tetrahydrofuran is added dropwise and agitated at 0° C. After 1 hour, an additional 1 mL a 1 N L-Selectrid-solution in tetrahydrofuran is added dropwise and agitated for 2.5 hours at 0° C. and for 3.5 hours at room temperature. It is subsequently hydrolyzed with 2 mL of a 1:1 mixture of tetrahydrofuran and water, made basic with concentrated aqueous ammonia after brief agitation and extracted with ethyl acetate. The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated. The two products are separated by column chromatography (7 g silica gel, flow agent: CHCl3: MeOH=8:2), yielding 30 mg (30% of the theoretical yield) colorless crystals of 114 and 20 mg (20% of die theoretical yield) of colorless crystals of 116.

[0415] DC: CHCl3: MeOH=9:1

[0416] 114:

[0417] 1 H-NMR (CDCl3; δ ppm)): 1.50 (ddd, 1H, H-4); 1.80 (ddd, 1H, H-11); 2.20 (ddd, 1H, H-11′); 2.45 (ddd, 1H, H-4′), 2.60-2.80 (n, 2H, H-4a/12); 3.30 (ddd, 1H, H-12′); 3.60 (d, 1H, H-6,J(6,6′)=17.8 Hz); 3.75 (s, 3H, OCH3); 4.00 (d, 1H H-6′, J(6,6′)=17.8 Hz); 4.30 (dd, 1H, H-3); 5.55 (dd, 1H H-2, J(2,3)=9.8 Hz); 6.75 (dd, 1H, H-3, J(2,3)=9.8 Hz); 6.80 (s, 1H, H-8)

[0418] 13 C-NMR (CDCl3; δ ppm)): 26.9 (t, C-11); 35.7 (t, C-4); 37.7 (s, C-10b); 47.7 (t, C-12); 50.7 (t, C-6); 51.0 (q, OCH3); 58.8 (d, C-4a); 62.8 (d, C-3); 105.3 (s, C-7); 107.4 (d, C-2); 118.3 (s, C-6a); 124.8 (d, C-8); 125.5 (s, C-10a); 127.4 (d, C-1); 137.9 (s, C-10); 141.3 (s, C-9)

[0419] 116:

[0420] 1 H-NMR (CDCl3; δ ppm)): 1.55-1.95 (m, 4H, H-1/1′/4/11); 2.15 (m, 1H, H-11′); 2.35 (m, 1H, H-2); 2.60 (dd, 1H, H-4′); 2.75-2.95 (m, 2H, H-4a/12); 3.15 (dd, 1H, H-2′); 3.40 (ddd, 1H, H-12′); 3.70 (d, 1H, H-6, J(6,6′)=6.2 Hz); 3.85 (d, 3H, OCH3); 4.00 (d, 1H, H-6′, J(6,6′)=6.2 Hz); 4.15 (ddd, 1H H-3); 6.90 (s, 1H, H-8)

[0421] 35-4,4a-dihydro-9-methoxy-10-hydroxy (3H,6H) (5,10b) ethanophenanthridine-3-ol (115):

[0422] A solution of 1.0 g (2.84 mmol) maritidinon-type (114) and 2.0 g calcium chloride are treated in 50 mL 50% ethanol with 4.0 g freshly activated zinc powder and heated to reflux for 2 hours. Subsequently, the excess zinc is filtered off, washed with methanol and the residual solution is spun off. The residue is absorbed in 80 mL 1 N hydrochloric acid, made basic with concentrated aqueous ammonia and extracted with three times ethyl acetate. The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried (Na2SO4, active carbon), filtered and evaporated, yielding 450 mg crude product which is cleaned by column chromatography (7 g silica gel, flow agent initially CHCl3 : MeOH=8:2, then CHCl3 : MeOH : NH4OH=49.9 : 49.9 : 0.2), from which 270 mg (35% of the theoretical yield) red crystals of 115 are obtained, with a melting point of 59-60° C. are obtained.

[0423] DC: CHCl3: MeOH=9:1

[0424] 1 H-NMR (DMSO-d6; δ (ppm)): 1.40 (ddd, 1H, H-4); 1.65 (ddd, 1H, H-11); 2.00 (ddd, 1H, H-11′); 2.20 (ddd, 1H, H-4′); 2.65 (dd, 1H H-4a); 3.10 (ddd, 1H, H-12); 3.30-3.50 (m, 1H, H-12′); 3.45 (d, 1H, H-6, J(6,6′)=15.1 Hz); 3.75 (s, 3H, OCH3); 4.05 (d, 1H, H-6′, J(6,6′)=15.1 Hz); 4.20 (dd, 1H, H-3); 5.45 (d, 1H, H-2, J(1,2)=8.9 Hz); 6.40 (d, 1H, H-1, J(1,2)=8.9 Hz); 6.65-6.75 (m, 2H, H-7/8); 8.40 (b, 1H tauscht D2O, Ph—OH)

[0425] 13 C-NMR (DMSO-d6; δ (ppm)): 32.2 (t, C-11); 41.1 (t, C-4); 42.7 (s, C-10b); 52.3 (t, C-12); 54.6 (t, C-6); 55.8 (q, OCH3); 64.1 (d, C-4a); 67.1 (d, C-3); 109.4 (d, C-7); 115.8 (d, C-2); 124.9 (s, C-6a); 129.9 (s, C-10a); 130.2 (d, C-8); 132.5 (d, C-1); 143.7 (s, C-10); 146.0 (s, C-9)

[0426] [4aS-(4aa, 6β, 8aR*)]-4a,5,9,10,11,12-hexahydro=3-methoxy-11-methoxy-11-nitro-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol (117):

[0427] To a solution of 250 mg (0.87 mmol) galanthamine in 10 mL glacial acetic acid, a mixture of 0.5 mL smoking nitric acid and 2 mL glacial acetic acid is added dropwise at 15-20° C. After one hour of agitation at room temperature, additional 0.25 mL smoking nitric acid in 1 mL glacial acetic acid is added dropwise and agitated for 1 additional hour. Subsequently, it is poured on 80 mL water and made basic with a 40% sodium hydroxide solution. The aqueous phase is extracted three times with 30 mL each of ethyl acetate. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, yielding 252 mg (87% of the theoretical yield.) yellow crystals of 117 witl a melting point of 48-50° C.

[0428] DC: CHCl : MeOH=9:1

[0429] 1 H-NMR (CDCl3; δ (ppm)): 1.67 (ddd, 1H, H-9); 1.95-2.30 (m, 2H, H-5/9′); 2.20 (ddd, 1H, H-5′); 2.44 (s, 3H, NCH3); 2.91 (ddd, 1H, H-10); 3.18 (ddd, 1H, H-10′); 3.87 (s, 3H, OCH3); 4.01 (d, 1H, H-12); 4.16 (dd, 1H, H-6); 4.32 (d, 1H, H-12′); 4.68 (b, 1H, H-4a); 6.04 (dd, 1H, H-8); 6.16 (d, 1H, H-7); 7.35 (s, 1H, H-2)

[0430] 13 C-NMR (CDCl3; δ (ppm)): 29.6 (t, C-5); 33.3 (t, C-9); 43.6 (q, NCH3); 48.5 (s, C-8a); 53.4 (t, C-10); 54.4 (t, C-12); 56.1 (q, OCH3); 61.4 (d, C-6); 89.6 (s, C-4a); 108.9 (d, C-8); 126.5 (,); 126.9 (,); 128.3 (d, C-7); 134.8 (,); 143.0 (,); 143.4 (,); 149.8 (,)

[0431] [4aS-(4aa, 6β, 8aR*)]-4a.5,9,10,11,12-Hexahydro-1-amino-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol (118):

[0432] To a solution of 200 mg (0.60 mmol) 117 in 10 mL methanol a solution of 420 mg (2.4 mmol) sodium dithionite in 10 mL water is added dropwise at room temperature and agitated for 1 hour. The methanol is subsequently spun out, the residue is absorbed in 50 mL water, made basic with concentrated aqueous ammonia and extracted five times with 30 mL each of trichloromethane. The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried (Na2SO4), filtered and evaporated, yielding 148 mg (82% of the theoretical yield.) yellow crystals of 118 with a melting point of 151-153° C.

[0433] DC: CHCl3: MeOH=9:1

[0434] 1 H-NMR (CDCl3, δ (ppm)): 1.59 (ddd, 1H, H-9); 1.90-2.10 (m, 2H, H-5/9′); 2.43 (s, 3H, NCH3); 2.62 (ddd, 1H, H-5′); 2.96 (ddd, 1H, H-10); 3.20 (ddd, 1H, H-10′); 3.70 (d, 1H, H-12); 3.79 (s, 3H, OCH3); 4.10 (d, 1H, H-12′); 4.52 (b, 1H, H-4a); 5.98 (dd, 1H, H-8); 6.08 (d, 1H, H-7); 6.16 (s, 1H, H-2)

[0435] New, substituted, bridged-over bases:

142
Substance
No.	J-No.	R23	R23
120		Benzyl	p-Nitro-phenyl-
121		Benzyl	p-Amino-phenyl
122		Benzyl	p-Chlorphenyl
123		Benzyl	p-Hydroxyphenyl
124		Benzyl	o-Nitrophenyl
125		Benzyl	o-Aminophenyl
126		Benzyl	o-Chlorphenyl
127		Benzyl	o-Dimethylaminophenyl
128		p-Ts	Phenyl
129		H	Phenyl
130		p-Ts	p-Methylphenyl
131		H	p-Methylphenyl
132		p-Ts	p-Chlorphenyl
133		H	p-Chlorphenyl
134		p-Ts	p-Fluorphenyl
135		H	p-Fluorphenyl
136		—CH2—CH2—CH2—Cl	Phenyl
137		—CH2—CH2—Cl	p-Fluorphenyl
138		—CH2—CH2—OH	t-BOC
139		—CH2—CH2—OH	Benzyl
140		—CH2—CN	Benzyl
141		—CH2—CH2—NH2	Benzyl
142		—CH2—CH2—CN	Benzyl
143		—(CH2)3—NH2	Benzyl
144		—CH2—COOEt	Benzyl
145		t-BOC	—CH(Ph)2

[0436] 5-Benzyl-2-(4-nitrophenyl)-2,5-diazabicyclo[2.2.1]heptane (120)

[0437] To a solution of 5.30 g 2-benzyl-2,5-diazabicyclo[2.2.1]heptane×2 HBr in 20 mL anhydrous DMSO, 3.97 dried, fine ground K2CO3 and 2.03 g 4-nitrobenzene fluoride were added. It was then agitated magnetically at 80° C. for 3 hours, poured on 100 mL water, the precipitated crystals were sucked off, washed with diisopropyl ether and dried in vacuum: 4.10 g (120) as colorless crystals (92% of the theoretical yield.), melting point 170-173° C. DC: toluene/acetone (1:1) or CHCl3.

[0438] 1 H-NMR (CDCl3): 8.10 (2H, d), 7.35−7.2 (51H, m), 6.45 (2H, d), 4.40 (1H, m), 3.75 (2H, s), 3.65 (1H, b), 3.45(2H, dd), 2.95, 2.30 (2R,dd), 2.10, 1.85(2H, dd)

[0439] 13 C-NMR (CDCl3): 151.14, 139.01, 136.55, 128.26, 126.97, 126.35, 110.42, 60.42, 58.28, 58.191, 53.17, 35.78.

[0440] 5-Benzyl-2-(4-aminophenyl)-2,5-diazabicyclo[2.2.1]heptane (121)

[0441] 4.1 g (120) in 360 mL ethanol and 20 mL water with 5 g NH4Cl and 7 iron powder were heated to reflux temperature under 4 hours of mechanical agitation. The reaction solution is filtered over Celite and active carbon, evaporated, absorbed in 100 mL water, brought to pH 10 with K2CO3 and extracted with ether (4×50 mL). The combined organic phases were dried with Na2SO4, evaporated and distilled in a bulb tube (Kp: 5 mBar; 160-170° C.): 3.0 g (81% of the theoretical yield.) (121) as colorless oil.

[0442] DC: CHCl3/methanol (9:1).

[0443] 1 H-NM (CDCl3): 7.35−7.15 (5H, m), 6.65 (2H, d), 6.45 (2H, d), 4.15 (1H, m), 3.70 (2H, s), 3.50 (H, m) 3.40, 3.30 (2H, dd), 3.20 (2H, b), 2.90, 2.70 (2H, dd), 2.05−1.85 (2H, dd)

[0444] 5-Benzyl-2-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane (122)

[0445] 1.5 g (121) were dissolved in 20 mL concentrated HCl and added dropwise at 0-5° C. to a solution of 0.38 g NaNO2 in 3 mL water, so that the temperature remained under 5° C. The solution was the added dropwise to a solution produced from 1.61 g CuSO3×5 H2O, 0.41 g NaCl, 0.39 g NaHSO3 and 0.23 g NaOH and CuCl in 10 mL HCl and heated for 4 hours to 50° C. It was then poured on 100 mL water, made alkaline with K2CO3 and extracted with ether (5×100 mL). Concentration by evaporation and bulb tube distillation (Kp: 5 mbar; 135° C.) yielded 0.6 g(37% of the theoretical yield.) (122) as a colorless oil.

[0446] DC: CHCl3/methanol (9:1).

[0447] 1 H-NMR (CDCl3): 7.40−7.15 (7H, m), 6.90−6.50 (2H, m), 4.25 (1H, m), 3.70 (2H, s), 3.60−3.45 (H, m), 3.45−3.30 (2H, m), 2.95, 2.70 (2H, dd), 2.10−1.80 (2H, m).

[0448] 5-Benzyl-2-(4-hydroxyphenyl)-2,5-diazabicyclo[2.2.1]heptane (123)

[0449] To a solution of 1.17 g (122) in 17 mL concentrated HCl: 0.35 g NaNO2 in 5 mL water were added slowly dropwise, so that the temperature remained below 5° C. The solution was agitated for 2 hours at 60° C., neutralized with NaHSO3 and extracted with ether (4×50 mL). The combined organic phases were dried with Na2SO4, evaporated and distilled in a bulb tube (Kp: 0.05 mbar; 140° C.): 0.1 g (123) (123) as colorless oil. DC: CHCl3/methanol (9:1).

[0450] 1 H-NMR (CDCl3): 7.50−7.00 (8H, m), 6.85−6.40 (2H, m), 4.25 (1, m), 3.80−3.30 (5H, m), 3.05−2.65 (2H, m), 2.05, 1.90 (2H, dd).

[0451] 5-Benzyl-2-(2-nitrophenyl)-2,5-diazabicyclo[2.2.1]heptane (124)

[0452] To a solution of 22.3 g 2-benzyl-2,5-diazabicyclo[2.2.1]heptane×2 HBr in 110 mL anhydrous DMSO, 17.6 g dried, finely ground K2CO3 and 9.0 g 2-nitrobenzene fluoride were added. It was then agitated magnetically at 80° C. for 3 hours, poured on 300 mL water, the precipitated crystals were sucked off, washed with diisopropyl ether and dried in vacuum: 19.1 g (124) as colorless crystals (96.9% of the theoretical yield.), melting point 107-108° C.

[0453] DC: toulene/acetone (1:1) or CHCl3.

[0454] 1 H-NMR (CDCl3): 7.75 (H, d), 7.35 (H, d), 7.30−7.15 (5H, m), 6.85−6.70 (2H, m), 4.30 (H, m), 3.65 (2H, s), 3.55 (2H, m), 2.90 (2H, dd), 2.85 (H, m), 2.00 (2H, dd).

[0455] 5-Benzyl-2-(2-aminophenyl)-2,5-diazabicyclo[2.2.1]heptane (125)

[0456] 5.0 g (124) in 360 mL ethanol and 20 mL water with 4 g NH4Cl and 6.7 iron powder were heated to reflux temperature under 4 hours of mechanical agitation. The reaction solution is filtered over Celite and active carbon, evaporated, absorbed in 100 mL water, brought to pH 10 by means of K2CO3 and extracted with ether (4×50 mL). The combined organic phases were dried with Na2SO4, evaporated and distilled in a bulb tube (Kp: 5 mbar; 160-170° C.): 2.20 g (48.8% of the theoretical yield.) (125) as colorless oil. DC: CHCl3/methanol (9:1).

[0457] 1 H-NMR (CDCl3): 7.45−7.20 (5H, m), 7.05−6.65 (4H, m), 3.95−3.65 (5H, m), 3.60−3.40 (2H, m), 3.20−3.00 (H, m), 2.95−2.75 (2H, m), 2.00−1.85 (2H, m).

[0458] 5-Benzyl-2-(2-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane (126)

[0459] Procedure analogous to (122).

[0460] Yield after bulb tube distillation (Kp: 5 mbar, 135° C.): 0.60 g (37.5% of the theoretical yield.) (126) as colorless oil. DC: CHCl3/Methanol (9:1).

[0461] 1 H-NMR (CDCl3): 7.50−7.20 (6H, m), 6.85−6.55 (3H, m), 4.25 (H, m), 3.85−3.70 (2H, s), 3.65−3.50 (H, b), 3.45−3.30 (2H, m), 3.00, 2.75 (2H, dd), 2.15−1.80 (2H, m)

[0462] 5-Benzyl-2-(2-dimethylaminophenyl)-2,5-diazabicyclo[2.2.1]heptane (127)

[0463] 5-Benzyl-2-(2-methylaminophenyl)-2,5-diazabicyclo[2.2.1]heptane (127a)

[0464] 0.95 g (125) with 0.5 g PO(OMe)3 were heated for 3 hours to 160-180° C., cooled, hydrolyzed with 5 mL 30% NaOH, 10 mL water were added, and them extracted with ether (3×10 mL). Concentration by evaporation and color chromatography (CHCl3/Methanol 3%) yielded 0.15 g colorless oil (127-a) (15.6% of the theoretical yield.) and 0.09 g colorless oil (107) (8.5% of the theoretical yield.).

[0465] 1 H-NMR (CDCl3) (127-b): 7.45−7.20 (5H, m), 7.10−6.95 (2H, t), 6.80−6.00 (2H, dd), 3.90−3.65 (4H, m), 3.65−3.40 (2H, dd), 3.50−2.60 (6H, m), 2.0−1.80 (2H, m)

[0466] 1 H-NMR (CDCl3) (127): 7.40−7.20 (5H, m), 6.70−6.55 (3H, m), 6.40 (H, m), 3.75 (2H, s) −3.30−3.65 (H, m), 3.60−3.55 (2H, dd), 3.45−3.20 (3H, m), 2.90−2.75 (6H, s,s), 2.30−2.15 (2H, dd).

[0467] Production of phenyl-substituted 2.5-diazabicyclo[2.2.1]heptane:

		Melting Point/
No.	Yield	Kp	DC	Method
128	62.5%	139-143° C.	Petrolether/EtOAc (7:3)	A
129	71%	0.05 mbar/	DC: CHCl3/Methanol (9:1)	B
		120-130°
130	46%	149-151° C.	DC: Petrolether/EtOAc (7:3)	A
131	65%	0.05 mbar/	DC: CHCl3/Methanol (9:1)	B
		130-140° C.
132	69%	214-217° C.	DC: Petrolether/EtOAc (7:3)	A
133	56%	0.05 mbar/	DC: CHCl3/Methanol (9:1)	B
		120-130° C.
134	55%	Melting	DC: Petrolether/EtOAc (7:3)	A
		Point:
		180-184° C.
135	74%	0.05 mbar/	DC: CHCl3/Methanol (9:1)	B
		120-130° C.

[0468] Method (A) for Cyclization of tritosyl-4-hydroxyprolinol:

[0469] 20 g (35 mmol) tritosyl-4-hydroxyprolinol with 75 mL toluene, 9.8 g (100 mmol) triethylamine and 35 mmol of the theoretical yielde appropriately substituted aniline (freshly distilled or uncrystallized) are heated in a steel autoclave for 3 hours to 160-170° C. After cooling and opening of the theoretical yielde autoclave, the product is rinsed out from the autoclave with 100 mL toluene, shaken once with 100 m; NaCl solution and once with 100 NaHCO3, and the organic phase is dried by means of Na2SO4 and evaporated. The crystalline product is digested with isopropyl, filtered and dried.

[0470] Method (B) for Splitting Off the p-Ts Protective Group

[0471] 2.5 g educt in 40 mL glacial acetic acid and 20 mL concentrated sulfuric acid are agitated for 2 hours at 80° C. Subsequently, it is poured on 200 mL ice/water, extracted with EtOAc (2 times 100 mL) (EtOAc phase is discarded), the aqueous phase is treated with 30% NaOH to ph 12 and extracted with EtOAc (6×50 mL). The Ethyl acetate phase is evaporated and bulb-tube distilled: colorless oil.

[0472] NMR Spectra:

[0473] 5-Phenyl-2-p-tosyl-2,5-diazabicyclo[2.2.1]heptane (128)

[0474] 1 H-NMR (CDCl3): 7.68 (2H, d), 7.29 (2H, d), 7.18 (2H, m), 6.72 (H, t), 6.4 (2H, dd), 4.51 (H, b), 4.32 (H, b), 3.52 (2H, dd), 3.24 (2H, dd), 2.42 (3H, s), 1.86 (H, d), 1.40 (H, d).

[0475] 13 C-NMR (CDCl3): 146.18, 143.49, 135.27, 129.66, 129.10, 127.18, 116.84, 112.39, 59.98, 56.91, 56.52, 52.25, 36.50, 21.37.

[0476] 2-Phenyl-2,5-diazabicyclo[2.2.1]heptane (129)

[0477] 1 H-NMR (CDCl3): 7.23 (2H, m), 6.71 (3H, m), 4.30 (H, b), 3.78 (H, b), 3.66 (H, dd), 3.18−2.89 (3H, m), 2.06−1.78 (3H, m).

[0478] 13 C-NMR (CDCl3): 146.92, 129.09, 116.08, 112.41, 59.78, 56.62, 56.22, 49.65, 37.18

[0479] 5-(4-Methylphenyl)-2-p-tosyl-2,5-diazabicyclo[2.2.1]heptane (130)

[0480] 1 H-NMR (CDCl3): 7.68 (2H, d), 7.27 (2H, d), 7.00 (2H, d), 6.36 (2H, d), 4.49 (H, s) 4.25 (H, s), 3.53 (H, d), 3.46 (H, dd), 3.26 (H, dd), 3.17 (H, d), 2.41 (3H, s), 2.24 (3H, s), 1.83 (H, d), 1.38 (H, d).

[0481] 13 C-NMR (CDCl3): 144.09, 143.44, 135,35, 129.63, 127.30, 125.96, 112.55, 60.02, 57.06, 56.73, 51.99, 36.46, 21.36, 20.16.

[0482] 2-(4-Methylphenyl)-2,5-diazabicyclo[2.2.1]heptane (131)

[0483] 1 H-NMR (CDCl3): 7.05 (2H, d), 6.48 (2H, d), 4.25 (H, s), 3.77 (H, s), 3.68 (H,dd), 3.16 (H, dd) 3.02 (1H, dd), 2.92 (H, dd), 2.24 (3H, s), 1.95 (H, d), 1.82 (H, b), 1.80, (H,d).

[0484] 5-(4-Chlorophenyl)-2-p-tosyl-2,5-diazabicyclo[2.2.1]heptane (132)

[0485] 1 H-NMR (CDCl3): 7.52 (2H, d), 7.13 (2H, d), 6.96 (2H, d), 6.22 (2H, d), 4.38 (H, s), 4.12 (H, s), 3.40−3.29 (2H, m), 3.12 (H, dd), 3.03 (H, dd), 2.30 (3H, s), 1.73 (H, d), 1.28 (H, d).

[0486] 13 C-NMR (CDCl3/DMSO): 144.70, 143.30, 134.58, 129.44, 128.40, 126.77, 120.58, 113.34, 59.60, 56.73, 56.44, 51.81, 36.09, 21.00

[0487] 2-(4-Chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane (133)

[0488] 1 H-NMR (CDCl3): 7.14 (2H, d), 6.45 (2H, d), 4.23 (H, s), 3.76 (H, s), 3.62 (H, d), 3.08 (H, d), 3.00 (H, d), 2.89 (H, d), 1.92 (H, d), 1.81 (H, d), 1.56 (H, b).

[0489] 13 C-NMR (CDCl3): 145.53, 128.78, 120.56, 113.44, 59.77, 56.83, 56.19, 49.50, 37.26

[0490] 5-(4-fluorophenyl)-2-p-tosyl-2,5-diazabicyclo[2.2.1]heptane (134)

[0491] 1 H-NMR (CDCl3): 7.68 (2H, d), 7.27 (2H, d), 6.82-6.95 (2H, m), 6.40−6.29 (2H, m), 4.49 (H, s), 4.23 (H, s), 3.52 (H, d), 3.46 (H, dd), 3.25 (H, dd), 3.13 (H, d) 2.41 (3H, s), 1.86 (H, d), 1.41 (H, d).

[0492] 13 C-NMR (CDCl3): 157.63, 152.96, 143.56, 142.80, 142.77, 135.21, 129.65, 127.17, 115.73, 115.29, 113.20, 113.05, 59.97, 57.35, 56.93, 51.79, 36.60, 21.34.

[0493] 5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptane (135)

[0494] 1 H-NMR (CDCl3): 7.05−6.83 (2H, m), 6.52−6.28 (2H, m ), 4.20 (H, s), 3.76 (H, s), 3.64 (H, dd), 3.10 (H, d), 3.00 (H, dd), 2.88 (H, d), 1.96 (H, d), 1.81 (H, d), 1.76 (H, b).

[0495] 13 C-NMR (CDCl3): 157.27, 152.63, 143.61, 115.67, 115.32, 113.13, 112.98, 60.21, 57.04, 56.27, 49.21, 37.29.

[0496] 5(3-Chloropropyl)-2-phenyl-2,5-diazabicyclo[2.2.1]heptane (136):

[0497] 129 (1.0 g, 5.7 mmoles), 0.23 g (5.7 mmoles) of sodium amide and 20 mL of toluene are refluxed for 1 hour. After that, 0.93 g (5.7 mmoles) of 1-bromo-3-chloropropane in 10 mL of toluene are added dropwise over a period of 20 minutes and refluxed for 2 hours. After cooling, the reaction mixture is extracted with 2N HCl (2−50 mL) and the aqueous phase made alkaline with 30% sodium hydroxide and extracted with toluene (3−40 mL). Evaporation and bulb tube evaporation (boiling point at 0.05 mbar: 120°-130° C.) resulted in 0.97 g (70.4% of the theoretical yield) of 136 as a colorless oil.

[0498] TLC: chloroform: MeOH=9:1

[0499] 1 H-NMR (CDCl3): 7.19 (2H, m), 6.69 (3H, m), 4.27 (H, b), 3.68 (H, b), 3.60 (H, dd), 3.18−2.89 (5H, m), 2.36−1.36 (7H, m).

[0500] 5-(2-Chloroethyl)-2-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptane (137):

[0501] 135 (1.0 g, 5.2 mmoles), 0.21 g (5.3 mmoles) of sodium amide and 20 mL of toluene are refluxed for 1 hour. After that, 0.77 g (5.2 mmoles) of 1-bromo-3-chloroethane in 10 mL of toluene are added dropwise over a period of 20 minutes and refluxed for 2 hours. After cooling, the reaction mixture is extracted with 2N HCl (2×50 mL) and the aqueous phase made alkaline with 30% sodium hydroxide and extracted with toluene (3−40 mL). Evaporation and bulb tube evaporation (boiling point at 0.05 mbar: 100°-120° C.) resulted in 0.76 g (56.7% of the theoretical yield) of 137 as a colorless oil.

[0502] TLC: chloroform: MeOH=9:1

[0503] 1 H-NMR (CDCl3): 1H-NMR (CDCl3): 7.05−6.83 (2H, m), 6.52−6.28 (2H, m), 4.20 (H, s), 3.76 (H, s), 3.64 (H, dd), 3.10 (H, d), 3.00 (H, dd), 2.88 (H, d), 2.66−2.28 (2H, m), 2.20−1.90 (2H, m) 1.96 (H, d), 1.81 (H, d), 1.76 (H, b).

[0504] 2-t-Boc-5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptane (138):

[0505] Gaseous ethylene oxide is introduced slowly for 1.5 hours at 20° C. and with stirring into a solution of 2.5 g of 2-t-Boc-2,5-diazabicyclo[2.2.1]heptane in 50 mL of methanol, the temperature increasing to 35° C. The solution was evaporated and the oily crude product distilled using a bulb tube (boiling point 0.05 mbar, 90°-100° C.); 1.60 g of 138 as a colorless oil (52.5% of the theoretical yield).

[0506] 1 H-NMR (CDCl3): 4.31 (H, d), 3.54 (2H, t), 3.40 (H, d), 3.18 (H, dd), 2.92 (H, dd), 2.73 (2H, m), 2.56 (H, d), 1.84 (H, d), 1.72 (H, d), 1.54 (9H, s)

[0507] 13 C-NMR (CDCl3): 157.80, 79.21, 61.76, 61.24, 59.82, 59.68, 56.40, 56.09, 55.73, 55.43, 49.95, 49.21, 36.01, 35.36, 28.27

[0508] 2-Benzyl-5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptane (139):

[0509] Procedure: See 138

[0510] Yield: 83.3% of the theoretical yield of 139, as a colorless oil with a boiling point of 120°-130° C. at 0.005 mbar.

[0511] 1 H-NMR (CDCl3): 7.30 (5H, m), 3.67-3.74 (2H, d), 3.55 (2H, m), 3.30 (2H, b), 3.20 (H, b), 2.87 (H, dd), 2.75 (H, dd), 2.71 (H, t), 2.67 (2H, m), 1.78 (H, m), 1.68 (H, m).

[0512] 13 C-NMR (CDCl3): 139.63, 128.29, 128.09, 126.65, 62.49, 61.16, 59.80, 58.19, 56.45, 56.26, 56.19, 33.64

[0513] 2-Benzyl-5-cyanomethyl-2,5-diazabicyclo[2.2.1]heptane (140)

[0514] Finely ground potassium carbonate, as well as 1.3 mL of freshly distilled chloroacetonitrile were added to a solution of 3 g of 2-benzyl-2,5-diazabicyclo[2.2.1]heptane in 40 mL of anhydrous toluene and refluxed for 10 hours with vigorous stirring. The solution was cooled, filtered and evaporated. Bulb tube distillation (boiling point: 110°-120° C. at 0.01 mbar) resulted in 3.57 g of 140 as a colorless oil (97% of the theoretical yield).

[0515] 1 H-NMR (CDCl3): 7.41−7.18 (5H, m), 3.65, 3.75 (2R d), 3.53, 3.46 (2H, d), 3.45 (H, b), 3.37 (H, b), 3.04 (H, d), 2.73 (H, d), 2.71(H, dd), 2.68 (H, d), 1.82 (H, d), 1.77 (H, d).

[0516] 13 C-NMR (CDCl3): 139.41, 128.08, 127.92, 126.51, 117.03, 62.47, 61.39, 57.97, 57.09, 55.97, 41.23, 33.00.

[0517] 2-Benzyl-5-(2-aminoethyl)-2,5-diazabicyclo[2.2.1]heptane (141)

[0518] A solution of 5.74 g (25.3 mmoles) of 140 and 50 mL of NH3 were hydrogenated with 2 g of Raney nickel in a steel autoclave at 100 bar H2 and 100° C. for 2 hours. The catalyst was filtered off with suction and the solution was evaporated and distilled using a bulb tube (boiling point: 135°-145° C. at 0.01 mbar): 5.02 g of 141 as a colorless oil (87% of the theoretical yield).

[0519] 1 H-NMR (CDCl3): 7.18 (5H, m), 3.70 (2H, d), 3.23 (2H, b), 2.69−2.42 (8H, m), 1.71 (H, ddd), 1.65 (H, ddd), 1.70 (2H, b).

[0520] 13 C-NMR (CDCl3): 139.62, 127.92, 127.65, 126.19, 62.15, 61.15, 57.92, 57.30, 56.19, 55.91, 40.80, 33.32

[0521] 2-Benzyl-5-cyanoethyl-2,5-diazabicyclo[2.2.1]heptane (142)

[0522] Freshly distilled acrylonitrile (2.5 g) is added to a solution of 3 g of 2-benzyl-2,5-diazabicyclo[2.2.1]heptane in 40 mL of anhydrous toluene and refluxed with vigorous stirring. The solution was cooled, filtered and evaporated. Bulb tube distillation (boiling point: 120°-130° C. at 0.01 mbar) resulted in 3.43 g of 142 as a colorless oil (88% of the theoretical yield).

[0523] 1 H-NMR (CDCl3): 7.39−7.17 (5H, m), 3.70 (2H, d), 3.30 (H, b), 3.26 (H, b), 2.88−2.59 (4H, m), 2.74 (H, d) 2.63 (H, dd), 2.42 (2H, t), 1.75 (H, dd), 1.64 (H, dd).

[0524] 13 C-NMR (CDCl3): 139.50, 128.17, 127.99, 126.57, 118.64, 62.40, 61.15, 58.68, 56.59, 55.91, 49.77, 33.66, 18.21

[0525] 2-Benzyl-5-(2-aminopropyl)-2,5-diazabicyclo[2.2.1]heptane (143) Analog: Similar to 141

[0526] Yield: 83.7% of the theoretical, colorless oil, boiling point: 120°-130° C. at 0.01 mbar

[0527] 1 H-NMR (CDCl3): 7.18 (5H, m), 3.70 (2H, d), 3.31 (H, b), 3.16 (H, b), 2.91−2.48 (8H, m), 2.22 (2H, b), 1.71 (2H, m), 162 (H, d), 1.49 (H, d)

[0528] 13 C-NMR (CDCl3): 139.46, 127.76, 127.54, 126.03, 61.55, 60.90, 57.76, 56.08, 55.32, 51.58, 39.99, 33.05, 31.97

[0529] Ethyl 2-(5-benzyl-2,5-diazabicyclo[2.2.1]heptane)-acetate (144)

[0530] Ethyl bromoacetate (2.5 g) and 3 g of dried, finely ground potassium carbonate are added to a solution of 3 g of 2-benzyl-2,5-diazabicyclo[2.2.1]heptane in 40 mL of toluene and refluxed for 8 hours with vigorous stirring. The solution was cooled, filtered and concentrated. Bulb tube distillation (boiling point: 125°-130° C. at 0.01 mbar) resulted in 1.79 g of 144 as a colorless oil (40% of the theoretical yield).

[0531] 13 C-NMR (CDCl3): 170.96, 139.44, 128.14, 128.03, 126.62, 62.31, 61.64, 60.36, 58.06, 56.90, 55.47, 55.33, 33.74, 14.03

[0532] 2-tBoc-5-diphenylmethyl-2,5-diazabicyclo[2.2.1]heptane (145)

[0533] Triethylamine (0.8 g) and 1.55 g of diphenylmethyl chloride are added to a solution of 1.5 g of 2-tBoc-2,5-diazabicyclo[2.2.1]heptane in anhydrous THF and refluxed with stirring for 4 hours. The THF was then evaporated off, taken up in 50 mL of saturated sodium hydrogen carbonate solution and extracted 3 times with 30 mL of ether. Evaporation resulted in 2.2 g of yellowish crystals of 145 (78% of the theoretical yield).

[0534] 1 H-NMR (CDCl3): 7.43−7.11 (10H, m), 4.81 (H, b), 4.31 (H, d), 3.40 (H, d), 3.18 (H, dd), 2.92 (H, dd), 2.56 (H, d), 1.84 (H, d), 1.72 (H, d), 1.54 (9H, s)

[0535] Literature List

[0536] (1) S. Y. Han, J. E. Sweeney, E. S. Bachman, E. J. Schweiger, J. T. Coyle, B. M. Davis, M. M. Joullie, Eur. J. Med. Chem. 27, 673-687 (1992)

[0537] (2) T. Kametani, K. Yamaki, S. Yaki, K. Fukumoto, J. Chem. Soc. (C), 2602 (1969)

[0538] (3) T. Kametani, K. Shishido, E. Hayashi, J. Org. Chem., 36, 1259 (1971)

[0539] (4) T. Kametani, C. Seino, K. Yamaki, S. Shibuya, K. Fukumoto, J. Chem. Soc., 1043-1047 (1971)

[0540] (5) T. Kametani, K. Yamaki, T. Terui, S. Shibuya, K. Fukumoto, J. Chem. Soc. Perkin I, 1513-1516 (1972)

[0541] (6) T. Kametani, K. Yamaki, T. Terui, J. Het. Chem. 10, 35-37 (1973)

[0542] (7) J. Szewczyk, A. Lewin, F. I. Caroll, J. Het. Chem 25, 1809-1811 (1988)

[0543] (8) R. Vlahov, D. Krikorian, G. Spassov, M. Chinova, I. Vlahov, G. Parushev, G. Snatzke, L. Ernst, K. Kieslich, W. Abraham, W. Shedrick, Tetrahedron 45, 3329 (1989)

[0544] (9) P. Strehlke, G. A. Hoyer, E. Schröder, E. Arch. Pharm. 388 (2), 94-109 (1975)

[0545] (10) M. Ishizaki, K. Ozaki, A. Kanematsu, T. Isoda, O. Hoshino, J. Org. Chem. 58, 3877-3885 (1993)

[0546] (11) C. Nogueiras, W. Döpke, G. Lehmann, tetrahedron Letters 35,3249-3250 (1971)

[0547] (12) H. H. Wassermann, R. J. Gambale, Tertrahedron 48 (35), 7059-7070 (1992)

[0548] (13) J. M. Pons, A. Pommier, J. Lerpiniere, P. Kocienski, J. Chem. Soc., Perkin Trans I 14, 1549-1551 (1993)

[0549] (14) T. Kioshi, Yakugaku Zhassi, 104, 1009 (1984)

[0550] (15) B. M. Davsis, Pat WO 88/08708 A1 (1988)

[0551] (16) Stichting Biomed. Res., Pat NL 88000350 A1 (1989)

[0552] (17) J. Bastida; F. Viladomat; J. M. Llabres, S. Quiroga, C. Codina, M. Rubiralta, Planta Med. 56, 123, 1990

[0553] (18) S. J. Han, S. C. Mayer, E. J. Schweiger, B. M. Davis, M. M. Joullie, Boorg. Med. Chem. Lett. 1, 579, 1991

[0554] (19) D. Albrigt, N. Goldman, Pat. 64219 (1968)

[0555] (20) H. G. Boit, W. Döpke, A. W. Beitner, Chem. Ber. 90, 2197 (1957)

[0556] (21) R. Matusch, M. Kreh, U. Müller, Helv. Chim. Acta 77, 1611 (1994)

[0557] (22) H. M. Fales, L. D. Gioffrida, W. C. Wildman, J.Am. Chem. Soc. 78, 4145 (1956)

[0558] (23) S. Kobayashi, K. Satoh, S. Numata.; T. Hingu, M. Kihara, Phytochemistry 30, 675 (1991)

[0559] (24) R. W. Kosley, L. Davis, V. Taberna, Pat. EP 653427 A1 (1995), U.S. Pat. No. 93-137,440

[0560] (25) R. W. Kosley, L. Davis, V. Taberna, Pat. EP 649346 A1 (1995), U.S. Pat. No. 93-137,444

[0561] (26) R. W. Kosley, L. Davis, V. Taberna, Pat. EP 648771 A1 (1995), U.S. Pat. No. 93-137,443

[0562] (27) W. S. K. Kaisha, EP 393400 (1990), JP 82321 (1989), JP 238064 (1989)

[0563] (28) D. L. Romero e.y., Pat WO 91-09849 (1991), U.S. Pat. No. 90-07390 (1990)

[0564] (29) J. E. Arrowsmith, Pat. EP 324543 (1989), GB 8800694 (1988)

[0565] (30) D. G. Hutchinson, Pat. WO 9323384 (1993), U.S. Pat. No. 92-880,432 (1992)

[0566] (31) P. S. Portoghese, A. A. Mikhail, J. Org. Chem. 31, 1059 (1966)

[0567] (32) T. F. Braish, D. E. Fox, J. Org. Chem., 55, 1684-1687 (1990)

[0568] (33) S. Ziklova, K. Ninov, Tr. Nauchniozsled. Khim. Farm. Inst. 12, 35-46 (1982)

[0569] (34) K. Fujii, K. Tomino, H. Watanabe, J. Pharm. Soc. Japan 74, 1049-51 (1954)

[0570] (35) H. G. Morren, R. Danayer, R. Linz, J. Mathieu, H. Strubbe, S. Trolin, Ind. Chim. Belge 22, 409-416 (1957)

[0571] (36) D. C. Jones, M. A. Winter, K. S. Hirsch, N. Stamm, H. M. Taylor, J. Med. Chem. 33 (1), 416-429 (1990)

[0572] (37) G. L. Regnier, C. G. Guillonneau, J. L. Duhault, F. P. Tisserand, G. Saint-Romas, S. M. Holstorp, Eur. J. Med. Chem 22, 243-250 (1987)

[0573] (38) G. E. Martin e.a., J. Med. Chem. 32, 1056 (1989)

[0574] (39) Z. Budai, Hpat. HU 61737 (1991)

[0575] (40) D. W. Smith, Pat. EP 345808 (1988), U.S. Pat. No. 204,845 (1988), U.S. Pat. No 338,253 (1989)

[0576] (41) J. P. Yevich, EP 400661 (1990), U.S. Pat. No. 360,657 (1989), U.S. Pat. No. 503,197 (1990)

[0577] (42) T. F. Braish, Pat. EP 397351 (1990), U.S. Pat. No. 350,423 (1989), U.S. Pat. No. 423,063 (1989)

[0578] (43) am 15. Oktober 1995 bekanntgemachte österr. Patentanmeldung 1980/94 vom 21. Oktober 1994

[0579] (44) G. L. Ellman K. D. Courtney, V. Andres, R. M. Featherstone, Biochem. Pharmacol 7, 88(1961). Sanochemia Ltd. 1996.04.19 vertreten durch:

Claims

1. Compounds of the general formula (II)

2. Compounds having the general formula (III):

3. A compound of claim 2 having the formula:

4. A compound of claim 2 having the formula:

5. A composition consisting essentially of a compound according to claim 2, in admixture with a pharmaceutically acceptable excipient.

6. A method for the treatment of Alzheimer's disease, comprising administering to a human patient in need thereof a pharmaceutically acceptable amount of a compound as claimed in claim 2.

7. A method for the treatment of trisomy 21, comprising administering to a human patient in need thereof a pharmaceutically acceptable amount of a compound as claimed in claim 2.